BioMedLib Search Engine
[ goto HOMEPAGE ]
Search the biomedical literature, for the most relevant articles.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
aids associated lymphomas 2005:2010[pubdate] *count=100
235 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
aids associated lymphomas
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 235
1.
Bortolin MT, Zanussi S, Talamini R, Simonelli C, Pratesi C, Tedeschi R, Abbruzzese L, Manuele R, Rupolo M, Tirelli U, De Paoli P:
Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).
AIDS Res Hum Retroviruses
; 2010 Feb;26(2):245-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Predictive value of
HIV
type 1 DNA levels on overall survival in
HIV
-
related lymphoma
Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).
The kinetics and predictive value of
HIV
-1 DNA (
HIV
DNA) levels in relapsed or refractory
HIV lymphoma
patients, treated with high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT), were investigated.
HIV
DNA was measured by real-time PCR in the peripheral blood mononuclear cells (PBMCs) of 22 patients observed for a median follow-up of 31.0 months.
At baseline,
HIV
DNA was found to be correlated with
HIV
-1 RNA (
HIV
RNA) (r = 0.56), but not with CD4(+) counts (r = -0.10).
HIV
RNA load was under control for the entire follow-up, while
HIV
DNA levels were almost always detectable (baseline levels vs. 1 year from ASCT levels, p > 0.05).
Baseline
HIV
DNA levels were significantly different between alive and deceased patients (p = 0.03), and the overall survival (OS) analysis showed that for patients with higher
HIV
DNA levels at baseline there was a higher and nearly significant risk of death if compared to patients with lower levels (HR, 8.33, 95% CI, 0.99-70.06, p = 0.05).
Our study demonstrated that high
HIV
DNA levels at baseline could predict overall survival after ASCT in one of the largest cohorts of
HIV lymphoma
patients treated with salvage therapy.
[MeSH-major]
Antineoplastic Agents / therapeutic use. DNA, Viral / blood.
HIV
-1 / isolation & purification.
Lymphoma
,
AIDS
-
Related
/ mortality. Stem Cell Transplantation. Viral Load
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
HIV InSite.
treatment guidelines - Palliative Care of Patients with HIV
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20156109.001).
[ISSN]
1931-8405
[Journal-full-title]
AIDS research and human retroviruses
[ISO-abbreviation]
AIDS Res. Hum. Retroviruses
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / DNA, Viral
2.
Tarantul VZ:
Virus-associated lymphomagenesis.
Int J Biomed Sci
; 2006 Jun;2(2):101-13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Virus-
associated
lymphomagenesis.
Lymphomas
are one of the best studied cancer types closely
associated
with a small but definite range of viruses.
Numerous data show a close interrelation between lymphomagenesis and infection by such viruses as Kaposi's sarcoma herpesvirus (KSHV), Epstein-Barr virus (EBV), hepatitis C virus (HCV), human T-cell leukemia virus (HTLV), and human immunodeficiency virus (
HIV
).
For instance, experiments on monkeys artificially infected with viruses and data on anti-cancer effect of specific antiviral preparations strongly suggest the involvement of viruses in
lymphoma
development.
The present review is devoted to the association of different viruses with human
lymphomas
and to viral genes potentially involved in the neoplastic process.
The recognition of virus involvement in lymphomagenesis may facilitate new strategies for cancer therapy, diagnosis and screening and can lead to a reduction in the number of individuals at risk of
disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 23674972.001).
[ISSN]
1550-9702
[Journal-full-title]
International journal of biomedical science : IJBS
[ISO-abbreviation]
Int J Biomed Sci
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC3614592
[Keywords]
NOTNLM ; HIV / HIV virus HIV / epstein-barr virus / epstein-barrvirus / hepatitis b virus / hepatitis cvirus / herpesvirus / lymphoma / oncogenicity / virus
3.
Folk GS, Abbondanzo SL, Childers EL, Foss RD:
Plasmablastic lymphoma: a clinicopathologic correlation.
Ann Diagn Pathol
; 2006 Feb;10(1):8-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasmablastic
lymphoma
: a clinicopathologic correlation.
Plasmablastic
lymphoma
(PBL) is an uncommon, recently described B-cell-derived
lymphoma
that displays distinctive affinity for extranodal presentation in the oral cavity.
Plasmablastic
lymphoma
is strongly
associated
with human immunodeficiency virus (
HIV
) infection, but has been reported in
HIV
-negative individuals.
Plasmablastic
lymphoma
may be poorly recognized by pathologists, which is partly attributable to its relatively rare occurrence and unusual immunophenotype.
Five cases of oral cavity
lymphomas
conforming to the current World Health Organization morphological criteria for PBL were retrieved from the consultation files at the Armed Forces Institute of Pathology.
Follow-up revealed only 1 patient alive with no evidence of
disease
.
Our cases show that PBL is an aggressive type of B-cell
lymphoma
predominantly found in the oral cavity.
Plasmablastic
lymphoma
is often
associated
with
HIV
infection.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
, B-Cell / pathology. Mouth / pathology. Mouth Neoplasms / pathology. Plasma Cells / pathology
MedlinePlus Health Information.
consumer health - Oral Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16414538.001).
[ISSN]
1092-9134
[Journal-full-title]
Annals of diagnostic pathology
[ISO-abbreviation]
Ann Diagn Pathol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 3.2.2.5 / Antigens, CD38
Advertisement
4.
Hassan A, Kreisel F, Gardner L, Lewis JS Jr, El-Mofty SK:
Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status.
Head Neck Pathol
; 2007 Dec;1(2):150-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasmablastic
lymphoma
of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status.
Plasmablastic
lymphoma
(PBL) is a rare acquired immunodeficiency syndrome-
associated
non-Hodgkin'
s lymphoma
(
AIDS
-NHL), with predilection for the mucosa of oral cavity.
It usually has a plasmablastic morphology, expressing plasma cell-
associated
antigens with weak or absent expression of B-cell-
associated
markers.
To further define the immunophenotypic and molecular genetics of these tumors, we investigated two cases of plasmablastic
lymphomas
of the head and neck for c-myc gene rearrangement and immunoglobulin heavy chain (IgV(H)) hypermutation status.
For the first time we report a case of
AIDS
-
related
PBL that, by fluorescence in situ hybridization (FISH), shows a c-myc gene rearrangement.
Although current literature suggests that most cases of c-myc gene rearranged
AIDS
-NHL are Burkitt'
s lymphoma
, our case has an immunophenotype characteristic for PBL.
The concurrent B-cell immunophenotype of BCL-6(-)/CD138(+)/MUM-1(+) also suggests a post-germinal center B-cell origin of this
lymphoma
.
[MeSH-major]
Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics.
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
, Large-Cell, Immunoblastic / pathology. Mouth Neoplasms / pathology. Proto-Oncogene Proteins c-myc / genetics
MedlinePlus Health Information.
consumer health - Oral Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leuk Lymphoma. 2005 Jan;46(1):77-81
[
15621784.001
]
[Cites]
Mod Pathol. 2005 Jun;18(6):806-15
[
15578069.001
]
[Cites]
Cancer. 2005 Jun 25;105(3):139-44
[
15803491.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206
[
16037778.001
]
[Cites]
Am J Surg Pathol. 2005 Dec;29(12):1633-41
[
16327436.001
]
[Cites]
Ann Diagn Pathol. 2006 Feb;10(1):8-12
[
16414538.001
]
[Cites]
Oral Oncol. 2002 Jan;38(1):96-102
[
11755827.001
]
[Cites]
Hum Pathol. 2002 Apr;33(4):392-404
[
12055673.001
]
[Cites]
Br J Haematol. 2002 Dec;119(3):622-8
[
12437635.001
]
[Cites]
Histopathology. 2003 Jun;42(6):605-9
[
12786898.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):3928-32
[
14581416.001
]
[Cites]
Am J Surg Pathol. 2004 Jun;28(6):736-47
[
15166665.001
]
[Cites]
J Natl Cancer Inst Monogr. 1998;(23):95-100
[
9709310.001
]
[Cites]
Blood. 1999 Sep 15;94(6):1848-54
[
10477713.001
]
[Cites]
Blood. 1993 Jan 1;81(1):166-76
[
8380252.001
]
[Cites]
Blood. 1993 Jul 15;82(2):552-63
[
8392399.001
]
[Cites]
Blood. 1997 Feb 15;89(4):1413-20
[
9028965.001
]
[Cites]
Semin Diagn Pathol. 1997 Feb;14(1):67-82
[
9044511.001
]
(PMID = 20614267.001).
[ISSN]
1936-0568
[Journal-full-title]
Head and neck pathology
[ISO-abbreviation]
Head Neck Pathol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
[Other-IDs]
NLM/ PMC2807524
[Keywords]
NOTNLM ; Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma / Immunoglobulin variable heavy chain hypermutation status / Plasmablastic lymphoma / c-myc gene rearrangement
5.
Marimo C:
Epidemiology of oral Kaposi's sarcoma in Zimbabwe 1988-1997: a population-based study.
Cent Afr J Med
; 2008 Jan-Apr;54(1-4):15-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: Sub-Saharan Africa has the highest number of
HIV
/
AIDS
cases globally which contrasts with the lack of population-based studies of oral Kaposi's sarcoma (OKS); one of the clinical cardinal signs of
HIV
/
AIDS
.
To date, no study has investigated the incidence of OKS in African populations affected by the
HIV
/
AIDS
epidemic.
Among
AIDS
-
associated
malignancies, OKS accounted for 98% while the balance comprised Burkitt'
s lymphoma
, Hodgkin's and Non-Hodgkin's
lymphomas
, haemangiosarcoma and
lymphoma
not specified.
These findings are attributable to the high human immunodeficiency virus infection (
HIV
) rates recorded for
MedlinePlus Health Information.
consumer health - Kaposi's Sarcoma
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21644423.001).
[ISSN]
0008-9176
[Journal-full-title]
The Central African journal of medicine
[ISO-abbreviation]
Cent Afr J Med
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Zimbabwe
6.
Ho SF, Fink C, Murray PI:
Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.
Ocul Immunol Inflamm
; 2005 Dec;13(6):471-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for
AIDS
-
associated
lymphoma
.
We report an
HIV
-positive patient who developed a unilateral retinitis and subsequent intracranial lesions.
The
finding
of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS non-Hodgkin'
s lymphoma
, which was subsequently confirmed on brain biopsy.
[MeSH-major]
DNA, Viral / genetics. Herpesvirus 4, Human / genetics.
Lymphoma
,
AIDS
-
Related
/ diagnosis
Genetic Alliance.
consumer health - AIDS-HIV
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Ophthalmic Manifestations of HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16321894.001).
[ISSN]
0927-3948
[Journal-full-title]
Ocular immunology and inflammation
[ISO-abbreviation]
Ocul. Immunol. Inflamm.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / DNA, Viral
7.
Sirianni MC, Campagna M, Scaramuzzi D, Carbonari M, Toschi E, Bacigalupo I, Monini P, Ensoli B:
Control of human herpes virus type 8-associated diseases by NK cells.
Ann N Y Acad Sci
; 2007 Jan;1096:37-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Control of human herpes virus type 8-
associated
diseases by NK cells.
NK cell activity is reduced during
disease
progression in human immunodeficiency virus (
HIV
) infection, and in individuals with
AIDS
-
associated
tumors linked with infection by the oncogenic human herpes virus type-8 (HHV8), including Kaposi's sarcoma (KS) and primary effusion
lymphomas
(PEL).
We have demonstrated that
AIDS
-
related
KS (
AIDS
-KS) is characterized by an increased expression of inhibitory receptors by T lymphocytes, and that
HIV
-non-infected patients with KS (classic KS, C-KS) have a substantial number of NK cells bearing these same receptors.
However, the cytotoxic activity of NK cells is reduced in patients with C-KS,
AIDS
-KS, or PEL patients, who are all infected by the HHV8, and this correlates with
disease
severity.
Since PEL cells express the same HHV8 latency program as KS cells, these data point to MHC-I downregulation by HHV8 as a primary immune evasion mechanism against CTL responses, further reinforced by upregulation of inhibitory receptors on T and NK cells in the setting of
HIV
and/or HHV8 infection.
Thus, studies on killing receptor regulation and signaling in T and NK cells may shed light on the pathogenesis of HHV8-
associated
tumors both in
HIV
-infected or -noninfected patients.
[MeSH-minor]
Cytotoxicity, Immunologic.
HIV
Infections / complications.
HIV
Infections / therapy. Histocompatibility Antigens Class I / metabolism. Humans. Immune System. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / virology. Signal Transduction. T-Lymphocytes / metabolism. T-Lymphocytes, Cytotoxic / metabolism
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17405914.001).
[ISSN]
0077-8923
[Journal-full-title]
Annals of the New York Academy of Sciences
[ISO-abbreviation]
Ann. N. Y. Acad. Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Histocompatibility Antigens Class I
8.
Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR:
Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus.
J Virol
; 2010 Nov;84(22):11670-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
LCL formation serves as a model for lymphomagenesis, and LCLs are phenotypically similar to EBV-positive diffuse large B-cell
lymphomas
(DLBCLs), which represent a common
AIDS
-
associated
malignancy.
B-cell infection by EBV induces the expression of several cellular microRNAs (miRNAs), most notably miR-155, which is overexpressed in many tumors and can induce B-cell
lymphomas
when overexpressed in animals.
In contrast, three other B-cell
lymphoma
lines, including two EBV-positive Burkitt'
s lymphoma
cell lines, grew normally in the absence of miR-155 function.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Virol. 2006 Jun;80(11):5321-6
[
16699012.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9
[
16641092.001
]
[Cites]
J Gen Virol. 2006 Oct;87(Pt 10):2885-90
[
16963746.001
]
[Cites]
Science. 2007 Apr 27;316(5824):604-8
[
17463289.001
]
[Cites]
Science. 2007 Apr 27;316(5824):608-11
[
17463290.001
]
[Cites]
Nucleic Acids Res. 2007;35(10):e73
[
17478510.001
]
[Cites]
Int J Cancer. 2007 Sep 1;121(5):1156-61
[
17487835.001
]
[Cites]
Nat Methods. 2007 Sep;4(9):721-6
[
17694064.001
]
[Cites]
J Virol. 2007 Dec;81(23):12836-45
[
17881434.001
]
[Cites]
Nature. 2007 Dec 13;450(7172):1096-9
[
18075594.001
]
[Cites]
Immunity. 2007 Dec;27(6):847-59
[
18055230.001
]
[Cites]
Cancer Genet Cytogenet. 2008 Feb;181(1):8-15
[
18262046.001
]
[Cites]
J Pathol. 2008 May;215(1):13-20
[
18348159.001
]
[Cites]
Oncogene. 2008 Apr 3;27(15):2128-36
[
17968323.001
]
[Cites]
Nat Biotechnol. 2008 Apr;26(4):407-15
[
18392026.001
]
[Cites]
J Virol. 2008 Jun;82(11):5295-306
[
18367535.001
]
[Cites]
Immunity. 2008 May;28(5):621-9
[
18450484.001
]
[Cites]
Immunity. 2008 May;28(5):630-8
[
18455451.001
]
[Cites]
Oncogene. 2008 Jul 17;27(31):4373-9
[
18372920.001
]
[Cites]
Nature. 2008 Aug 7;454(7205):780-3
[
18596690.001
]
[Cites]
Cancer Res. 2008 Oct 1;68(19):8164-72
[
18829576.001
]
[Cites]
J Virol. 2008 Nov;82(21):10436-43
[
18753206.001
]
[Cites]
Biochem Biophys Res Commun. 2008 Dec 12;377(2):579-83
[
18926796.001
]
[Cites]
Nucleic Acids Res. 2008 Nov;36(20):6608-19
[
18940871.001
]
[Cites]
J Virol. 2008 Dec;82(24):12213-20
[
18842708.001
]
[Cites]
Virology. 2008 Dec 20;382(2):257-66
[
18950829.001
]
[Cites]
J Virol. 2009 Jan;83(1):489-92
[
18945769.001
]
[Cites]
Blood. 2009 Feb 5;113(6):1213-24
[
18955561.001
]
[Cites]
J Virol. 2009 Apr;83(7):3333-41
[
19144710.001
]
[Cites]
Leukemia. 2009 Apr;23(4):807-10
[
18987659.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7113-8
[
19359473.001
]
[Cites]
Genes Dev. 2009 May 15;23(10):1151-64
[
19451215.001
]
[Cites]
J Virol. 2009 Dec;83(23):12009-17
[
19759154.001
]
[Cites]
RNA Biol. 2009 Nov-Dec;6(5):541-5
[
19901530.001
]
[Cites]
J Virol. 2010 Jan;84(2):695-703
[
19889781.001
]
[Cites]
EMBO Mol Med. 2009 Aug;1(5):288-95
[
19890474.001
]
[Cites]
Science. 2010 Jan 8;327(5962):198-201
[
19965718.001
]
[Cites]
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3111-6
[
20133617.001
]
[Cites]
Cell. 2010 Apr 2;141(1):129-41
[
20371350.001
]
[Cites]
J Virol. 2010 May;84(10):5229-37
[
20219912.001
]
[Cites]
J Virol. 2010 Jul;84(13):6318-27
[
20427544.001
]
[Cites]
Mol Cell. 2002 Jun;9(6):1327-33
[
12086629.001
]
[Cites]
Cell. 2004 Jan 23;116(2):281-97
[
14744438.001
]
[Cites]
Science. 2004 Apr 30;304(5671):734-6
[
15118162.001
]
[Cites]
Nature. 1988 Sep 8;335(6186):181-3
[
3412474.001
]
[Cites]
Mol Cell Biol. 1989 Jun;9(6):2657-64
[
2548084.001
]
[Cites]
J Virol. 1998 Nov;72(11):8463-71
[
9765382.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32
[
15738415.001
]
[Cites]
J Pathol. 2005 Oct;207(2):243-9
[
16041695.001
]
[Cites]
Genes Chromosomes Cancer. 2006 Jan;45(1):103-6
[
16175574.001
]
[Cites]
Genes Chromosomes Cancer. 2006 Feb;45(2):147-53
[
16235244.001
]
[Cites]
RNA. 2006 May;12(5):733-50
[
16540699.001
]
[Cites]
PLoS Pathog. 2006 Mar;2(3):e23
[
16557291.001
]
(PMID = 20844043.001).
[ISSN]
1098-5514
[Journal-full-title]
Journal of virology
[ISO-abbreviation]
J. Virol.
[Language]
ENG
[Grant]
United States / NIAID NIH HHS / AI / T32 AI007392; United States / NIAID NIH HHS / AI / P30-AI045008; United States / NIAID NIH HHS / AI / R01-AI067968; United States / NIAID NIH HHS / AI / R01 AI067968; United States / NCI NIH HHS / CA / T32-CA0009111; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NCI NIH HHS / CA / T32 CA009111; United States / NIAID NIH HHS / AI / T32-AI007392; United States / NCI NIH HHS / CA / K99 CA137860-01A1; United States / NCI NIH HHS / CA / K99 CA137860; United States / NCI NIH HHS / CA / K99-CA137860
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / MIRN155 microRNA, human; 0 / MicroRNAs
[Other-IDs]
NLM/ PMC2977875
9.
Navarro WH, Kaplan LD:
AIDS-related lymphoproliferative disease.
Blood
; 2006 Jan 1;107(1):13-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
-
related
lymphoproliferative
disease
.
Not long after the recognition of
HIV
as the causative agent of
AIDS
, it was evident that individuals infected with
HIV
developed
lymphoma
at a greater rate than the population at large.
Approximately two thirds of
AIDS
-
related lymphoma
(ARL) cases are categorized as diffuse large B-cell type, with Burkitt
lymphomas
comprising 25% and other histologies a much smaller proportion.
Typically, these individuals have presented with advanced extranodal
disease
and CD4+ lymphocyte counts of less than 200/mm3.
Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-
associated
herpesvirus have led to the genesis of previously rare or unrecognized
lymphoma
subtypes such as plasmablastic and primary effusion
lymphomas
.
Significant progress has been made in the understanding and management of ARL but outcomes still remain inferior compared to those achieved in
HIV
- individuals.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ therapy
Genetic Alliance.
consumer health - AIDS-HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16099881.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
100
10.
Corti M, Villafañe MF, Trione N, Schtirbu R, Narbaitz M:
Primary pulmonary AIDS-related lymphoma.
Rev Inst Med Trop Sao Paulo
; 2005 Jul-Aug;47(4):231-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary pulmonary
AIDS
-
related lymphoma
.
Extranodal involvement is common in
lymphomas associated
with human immunodeficiency virus infection (
HIV
) and acquired immunodeficiency syndrome (
AIDS
).
However, primary pulmonary
AIDS
-
related
non-Hodgkin'
s lymphoma
is very rare and only few reports were published in the medical literature.
Primary pulmonary
lymphoma
associated
with
AIDS
is generally a high-grade B-cell non-Hodgkin
lymphoma
and Epstein-Barr virus is strongly
associated
with the pathogenesis of these tumors.
We report a patient with
AIDS
and primary pulmonary
lymphoma
which clinical presentation was a total atelectasis of the left lung.
[MeSH-major]
Lung Neoplasms / diagnosis.
Lymphoma
,
AIDS
-
Related
/ diagnosis. Pulmonary Atelectasis / etiology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - Collapsed Lung
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16138208.001).
[ISSN]
0036-4665
[Journal-full-title]
Revista do Instituto de Medicina Tropical de São Paulo
[ISO-abbreviation]
Rev. Inst. Med. Trop. Sao Paulo
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Brazil
11.
Stevenson GT:
CD38 as a therapeutic target.
Mol Med
; 2006 Nov-Dec;12(11-12):345-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma,
AIDS
-
associated lymphomas
, and post-transplant lymphoproliferations.
[MeSH-minor]
Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Humans. Leukemia / immunology.
Lymphoma
, B-Cell / immunology. Mice. Mice, SCID. Multiple Myeloma / immunology. Transplantation, Heterologous
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leuk Res. 2001 Jan;25(1):1-12
[
11137554.001
]
[Cites]
Mol Cancer Ther. 2004 Mar;3(3):345-52
[
15026555.001
]
[Cites]
Scand J Immunol. 1978 Apr;7(4):297-306
[
418499.001
]
[Cites]
Am J Hematol. 1990 Feb;33(2):101-9
[
2301368.001
]
[Cites]
Blood. 1991 Mar 1;77(5):1071-9
[
1995092.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):352-6
[
8380497.001
]
[Cites]
Blood. 1994 Sep 1;84(5):1442-9
[
7520771.001
]
[Cites]
Blood. 1994 Nov 1;84(9):3017-25
[
7524764.001
]
[Cites]
Blood. 2005 Sep 1;106(5):1762-9
[
15905193.001
]
[Cites]
Leuk Res. 2007 Apr;31(4):455-63
[
16920192.001
]
(PMID = 17380203.001).
[ISSN]
1076-1551
[Journal-full-title]
Molecular medicine (Cambridge, Mass.)
[ISO-abbreviation]
Mol. Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.2.2.5 / Antigens, CD38
[Other-IDs]
NLM/ PMC1829201
12.
Mwakigonja AR, Kaaya EE, Mgaya EM:
Malignant lymphomas (ML) and HIV infection in Tanzania.
J Exp Clin Cancer Res
; 2008;27:9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignant
lymphomas
(ML) and
HIV
infection in Tanzania.
BACKGROUND:
HIV
infection is reported to be
associated
with some malignant
lymphomas
(ML) so called
AIDS
-
related
lymphomas
(ARL), with an aggressive behavior and poor prognosis.
The ML frequency, pathogenicity, clinical patterns and possible association with
AIDS
in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.
Available sera from 38 ML patients were screened (ELISA) for
HIV
antibodies.
RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin'
s disease
(HD).
The ML tumors frequency increased from 0.42% (1997) to 0.70% (2001) and 23.7% of tested sera from these patients were
HIV
positive.
Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell
lymphomas
however, no clear cases of primary effusion
lymphoma
(PEL) and primary central nervous system
lymphoma
(PCNSL) were diagnosed.
CONCLUSION: Malignant
lymphomas
apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young,
HIV
infected and
AIDS
patients.
The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the
HIV
serology indicate a pathogenic association with
AIDS
.
Therefore, routine
HIV
screening of all malignant
lymphoma
patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
[MeSH-major]
HIV
Infections / complications.
Lymphoma
,
AIDS
-
Related
/ epidemiology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Burkitt
Lymphoma
/ epidemiology. Burkitt
Lymphoma
/ etiology. Burkitt
Lymphoma
/ virology. Child. Child, Preschool. Female.
HIV
Seropositivity. Hodgkin
Disease
/ epidemiology. Hodgkin
Disease
/ etiology. Hodgkin
Disease
/ virology. Humans. Immunohistochemistry.
Lymphoma
, Non-Hodgkin / epidemiology.
Lymphoma
, Non-Hodgkin / etiology.
Lymphoma
, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Med Clin (Barc). 2000 Jan 15;114(1):19-21
[
10782456.001
]
[Cites]
Trop Doct. 2008 Jan;38(1):7-11
[
18302850.001
]
[Cites]
Med Trop (Mars). 1999;59(4 Pt 2):499-502
[
10901854.001
]
[Cites]
Leukemia. 2000 Jul;14(7):1301-9
[
10914556.001
]
[Cites]
Curr Opin Oncol. 2000 Sep;12(5):383-94
[
10975544.001
]
[Cites]
Med Oncol. 2001;18(1):15-22
[
11778965.001
]
[Cites]
AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):383-90
[
11897040.001
]
[Cites]
East Afr Med J. 2000 Aug;77(8):435-9
[
12862069.001
]
[Cites]
Oncogene. 2004 Aug 23;23(38):6524-34
[
15322522.001
]
[Cites]
East Afr Med J. 1966 Jul;43(7):274-83
[
5911333.001
]
[Cites]
Br Med Bull. 1971 Jan;27(1):14-20
[
5100946.001
]
[Cites]
Cancer. 1980 Jul 1;46(1):186-9
[
6893012.001
]
[Cites]
Acta Pathol Microbiol Scand A. 1981 Nov;89(6):417-24
[
6278823.001
]
[Cites]
East Afr Med J. 1982 Apr;59(4):256-60
[
7140611.001
]
[Cites]
Ann Trop Paediatr. 1984 Jun;4(2):83-5
[
6083750.001
]
[Cites]
IARC Sci Publ. 1985;(60):155-64
[
4065944.001
]
[Cites]
Cancer. 1991 Apr 1;67(7):1865-73
[
2004300.001
]
[Cites]
Lancet. 1991 Apr 6;337(8745):805-9
[
1672911.001
]
[Cites]
Int J Cancer. 1993 Jun 19;54(4):594-606
[
8514451.001
]
[Cites]
Curr Opin Oncol. 1994 Sep;6(5):489-91
[
7827151.001
]
[Cites]
Semin Diagn Pathol. 1997 Feb;14(1):48-53
[
9044509.001
]
[Cites]
Int J Cancer. 1997 Nov 27;73(5):645-50
[
9398040.001
]
[Cites]
Immunol Rev. 1998 Apr;162:293-8
[
9602372.001
]
[Cites]
Hum Pathol. 1998 Nov;29(11):1285-9
[
9824108.001
]
[Cites]
Blood. 1999 Feb 15;93(4):1364-71
[
9949180.001
]
[Cites]
Bull Cancer. 1999 Jun;86(6):529-36
[
10417426.001
]
[Cites]
J Pak Med Assoc. 1999 Jan;49(1):11-5
[
10463009.001
]
[Cites]
Int J Cancer. 1999 Nov 12;83(4):481-5
[
10508483.001
]
[Cites]
East Afr Med J. 2004 Aug;(8 Suppl):S63-7
[
15622604.001
]
[Cites]
East Afr Med J. 2004 Aug;(8 Suppl):S90-6
[
15622607.001
]
[Cites]
East Afr Med J. 2004 Aug;81(8):384-7
[
15622930.001
]
[Cites]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[
15761078.001
]
[Cites]
J Clin Oncol. 2005 Jul 1;23(19):4430-8
[
15883411.001
]
[Cites]
CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264
[
16020424.001
]
[Cites]
Blood. 2005 Aug 1;106(3):1031-6
[
15840698.001
]
[Cites]
Curr HIV/AIDS Rep. 2005 Aug;2(3):146-53
[
16091262.001
]
[Cites]
Indian Pediatr. 2006 Feb;43(2):141-7
[
16528110.001
]
[Cites]
Herpes. 2006 May;13(1):12-6
[
16732997.001
]
[Cites]
Afr Health Sci. 2006 Jun;6(2):69-75
[
16916294.001
]
[Cites]
Oncol Rep. 2007 Jun;17(6):1291-9
[
17487381.001
]
[Cites]
Int J Cancer. 2007 Oct 15;121(8):1806-12
[
17557295.001
]
[Cites]
Cancer Sci. 2008 Feb;99(2):345-9
[
18201268.001
]
[Cites]
Malays J Pathol. 1999 Jun;21(1):45-50
[
10879278.001
]
(PMID = 18577266.001).
[ISSN]
1756-9966
[Journal-full-title]
Journal of experimental & clinical cancer research : CR
[ISO-abbreviation]
J. Exp. Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Other-IDs]
NLM/ PMC2438337
13.
Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC:
Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.
J Acquir Immune Defic Syndr
; 2010 May 1;54(1):18-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Recurrent chromosomal alterations in molecularly classified
AIDS
-
related
lymphomas
: an integrated analysis of DNA copy number and gene expression.
HIV
-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin
Lymphoma
relative to
HIV
(-) persons.
Due to their aggressive nature,
AIDS
-
related
lymphomas
(ARL) can also be more difficult to classify.
Genetic abnormalities are known to play a significant role in
HIV
(-) lymphomagenesis.
Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt
lymphoma
and diffuse large B-cell
lymphoma
, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell
lymphoma
.
These data demonstrate the ability to molecularly classify B-ARL
lymphomas
by gene expression and identified DNA copy number alterations targeted in B-ARL.
[MeSH-major]
Chromosome Aberrations. Gene Dosage. Gene Expression.
HIV
Infections / complications.
Lymphoma
,
AIDS
-
Related
/ diagnosis.
Lymphoma
,
AIDS
-
Related
/ pathology
[MeSH-minor]
Adult. Burkitt
Lymphoma
/ diagnosis. Burkitt
Lymphoma
/ pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans.
Lymphoma
, Large B-Cell, Diffuse / diagnosis.
Lymphoma
, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
SciCrunch.
ArrayExpress: Data: Microarray
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20216076.001).
[ISSN]
1944-7884
[Journal-full-title]
Journal of acquired immune deficiency syndromes (1999)
[ISO-abbreviation]
J. Acquir. Immune Defic. Syndr.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
14.
Gotoh M, Kitahara T, Iguchi T, Izumi M, Mukai K, Ohyashiki K:
[HIV-related multiple non-Hodgkin lymphomas].
Rinsho Ketsueki
; 2008 Nov;49(11):1552-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
HIV
-
related
multiple non-Hodgkin
lymphomas
].
He was
HIV
-positive, and had gastric diffuse large B-cell
lymphoma
and renal T-cell anaplastic large cell
lymphoma
(T-ALCL).
We diagnosed double
lymphomas
related
to
AIDS
.
The patient received anti-retroviral therapy, and started the CHOP regimen for the double
lymphomas
, resulting in transient improvement.
Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple
lymphomas
.
This case suggested that cancer generation was promoted by low immunity, although it is known that ambivalent tumors such as non-Hodgkin
lymphomas
can occur frequently.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ diagnosis.
Lymphoma
, B-Cell / diagnosis.
Lymphoma
, Large B-Cell, Diffuse / diagnosis.
Lymphoma
, Large-Cell, Anaplastic / diagnosis.
Lymphoma
, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISOLONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19047787.001).
[ISSN]
0485-1439
[Journal-full-title]
[Rinshō ketsueki] The Japanese journal of clinical hematology
[ISO-abbreviation]
Rinsho Ketsueki
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
15.
Lim ST, Levine AM:
Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.
CA Cancer J Clin
; 2005 Jul-Aug;55(4):229-41; 260-1, 264
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Recent advances in acquired immunodeficiency syndrome (
AIDS
)-
related lymphoma
.
Human immunodeficiency virus-infected patients are at an increased risk for developing both Hodgkin and non-Hodgkin
lymphoma
when compared with the general population.
With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-
related lymphoma
(ARL) is now the second most common cancer
associated
with human immunodeficiency virus after Kaposi sarcoma.
Over the last few years, advances in our understanding of the molecular biology of this heterogeneous group of
lymphomas
have led to the adoption of new classification systems.
Apart from the contribution of HAART, this improvement in prognosis can also be attributed to new initiatives in treatment of these patients, such as the use of effective infusional regimens, the feasibility of high-dose therapy with peripheral stem cell rescue for relapsed or refractory
disease
, and better supportive care.
Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-
related
Burkitt
lymphoma
.
[MeSH-major]
Antiretroviral Therapy, Highly Active.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
AIDS
-
Related
/ physiopathology
[MeSH-minor]
AIDS
-
Related
Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16020424.001).
[ISSN]
0007-9235
[Journal-full-title]
CA: a cancer journal for clinicians
[ISO-abbreviation]
CA Cancer J Clin
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
52
16.
Epeldegui M, Widney DP, Martínez-Maza O:
Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions.
Curr Opin Oncol
; 2006 Sep;18(5):444-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pathogenesis of
AIDS
lymphoma
: role of oncogenic viruses and B cell activation-
associated
molecular lesions.
PURPOSE OF REVIEW: We discuss recently published studies that elucidate the pathogenesis of
AIDS
-
associated
lymphoma
.
RECENT FINDINGS: Several recent reports have provided valuable new information on the role of gamma-herpesviruses in the pathogenesis of
AIDS
-
associated
lymphoma
.
In addition to this, significant new information has become available on how B cell activation-
associated
DNA-modifying events, involving activation-induced cytidine deaminase and DNA polymerase-eta, contribute to the molecular lesions that result in
AIDS
-
associated
lymphoma
.
In particular, new evidence that oncogenic viruses can directly induce activation-induced cytidine deaminase expression and oncogene mutation in human B cells is of central relevance to better understanding the pathogenesis of
AIDS
-
associated
lymphoma
.
SUMMARY: New information provides insights into the contributions of immune dysfunction and oncogenic virus infection to pathogenesis of
AIDS
-
associated
lymphoma
, and may lead to new potential targets for therapeutic intervention in these cancers.
[MeSH-major]
HIV
Infections / complications.
Lymphoma
,
AIDS
-
Related
/ genetics.
Lymphoma
,
AIDS
-
Related
/ virology.
Lymphoma
, B-Cell / genetics. Oncogenic Viruses / pathogenicity
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16894291.001).
[ISSN]
1040-8746
[Journal-full-title]
Current opinion in oncology
[ISO-abbreviation]
Curr Opin Oncol
[Language]
eng
[Grant]
United States / NIAID NIH HHS / AI / AI35040; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA70080; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein; EC 3.5.4.5 / Cytidine Deaminase
[Number-of-references]
28
17.
Yamanaka K, Fuhlbrigge RC, Mizutani H, Kupper TS:
Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma.
Arch Dermatol Res
; 2010 Aug;302(6):453-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell
lymphoma
.
In advanced stages, cutaneous T cell
lymphomas
(CTCL) are
associated
with increased mortality from infections and also increased susceptibility to skin malignancies.
Genetic Alliance.
consumer health - Cutaneous T-Cell Lymphoma
.
Genetic Alliance.
consumer health - Peripheral T-cell lymphoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Dermatol. 2003 Feb;42(2):116-22
[
12708999.001
]
[Cites]
AIDS. 2003 May 2;17(7):947-54
[
12700443.001
]
[Cites]
Blood. 2003 Dec 1;102(12):4059-66
[
12829591.001
]
[Cites]
N Engl J Med. 2004 Feb 19;350(8):757-66
[
14973217.001
]
[Cites]
J Am Acad Dermatol. 2004 May;50(5):701-5
[
15097953.001
]
[Cites]
J Exp Med. 2004 Sep 20;200(6):749-59
[
15365096.001
]
[Cites]
J Am Acad Dermatol. 1981 Feb;4(2):176-80
[
7217388.001
]
[Cites]
J Dermatol. 1990 Aug;17(8):477-81
[
2229651.001
]
[Cites]
JAMA. 1992 Mar 11;267(10):1354-8
[
1740857.001
]
[Cites]
J Invest Dermatol. 1992 Jul;99(1):90-4
[
1607682.001
]
[Cites]
Blood. 1996 Aug 15;88(4):1383-9
[
8695857.001
]
[Cites]
Arch Dermatol Res. 1996 Dec;289(1):9-13
[
9017129.001
]
[Cites]
Pediatr Res. 1998 Mar;43(3):396-402
[
9505280.001
]
[Cites]
Blood. 2005 Feb 15;105(4):1640-7
[
15514008.001
]
[Cites]
J Clin Invest. 2005 Apr;115(4):798-812
[
15841167.001
]
[Cites]
Clin Cancer Res. 2005 Aug 15;11(16):5748-55
[
16115912.001
]
[Cites]
Clin Cancer Res. 2006 Jan 15;12(2):376-82
[
16428475.001
]
[Cites]
Blood. 2006 Mar 15;107(6):2440-5
[
16322477.001
]
[Cites]
Infection. 2008 Mar;36(2):120-9
[
18379725.001
]
[Cites]
Clin Lymphoma Myeloma. 2008 Apr;8(2):100-5
[
18501103.001
]
[Cites]
Semin Immunol. 2008 Jun;20(3):196-203
[
18757210.001
]
[Cites]
J Am Acad Dermatol. 2008 Dec;59(6):949-52
[
18835065.001
]
[Cites]
Blood. 2000 Jan 1;95(1):352-9
[
10607724.001
]
[Cites]
Nat Biotechnol. 2000 Jul;18(7):729-34
[
10888839.001
]
[Cites]
Nat Immunol. 2000 Aug;1(2):132-7
[
11248805.001
]
[Cites]
J Am Acad Dermatol. 2001 Aug;45(2):208-16
[
11464181.001
]
[Cites]
Blood. 2001 Aug 15;98(4):1116-21
[
11493459.001
]
[Cites]
Hum Immunol. 2002 Jan;63(1):51-60
[
11916170.001
]
[Cites]
Clin Exp Immunol. 2003 Apr;132(1):105-12
[
12653844.001
]
[Cites]
Arch Dermatol. 2003 Jul;139(7):909-13
[
12873887.001
]
(PMID = 20111968.001).
[ISSN]
1432-069X
[Journal-full-title]
Archives of dermatological research
[ISO-abbreviation]
Arch. Dermatol. Res.
[Language]
ENG
[Grant]
United States / NIAID NIH HHS / AI / AI041707-12; United States / NCI NIH HHS / CA / P50 CA093683-07; United States / NIAID NIH HHS / AI / R01 AI041707-12; United States / NCI NIH HHS / CA / P50 CA093683; United States / NIAID NIH HHS / AI / R01 AI041707
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
Germany
[Chemical-registry-number]
0 / Diphtheria Toxin; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Receptors, Antigen, T-Cell; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
[Other-IDs]
NLM/ NIHMS190229; NLM/ PMC2892560
18.
Tanaka PY, Calore EE:
P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
Pathol Res Pract
; 2007;203(1):1-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
P-glycoprotein expression in non-Hodgkin's
lymphomas
of human immunodeficiency virus infected patients.
It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin'
s lymphoma
treatment response, but a poor outcome has been reported in patients with positive P-gp expression.
AIDS
-
related
lymphomas
have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin'
s lymphoma HIV
-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.
In patients having achieved complete remission, the median
disease
-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.
Our results show that P-gp is expressed before treatment of non-Hodgkin'
s lymphoma
of
HIV
patients, and is
related
to poor response to treatment and overall survival.
[MeSH-major]
Acquired Immunodeficiency Syndrome.
Lymphoma
,
AIDS
-
Related
/ metabolism. P-Glycoprotein / biosynthesis
[MeSH-minor]
Adolescent. Adult. Anti-
HIV
Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use.
Disease
-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Pathol Res Pract. 2007;203(10):763
(PMID = 17157997.001).
[ISSN]
0344-0338
[Journal-full-title]
Pathology, research and practice
[ISO-abbreviation]
Pathol. Res. Pract.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
19.
Martini M, Capello D, Serraino D, Navarra A, Pierconti F, Cenci T, Gaidano G, Larocca LM:
Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas.
J Infect
; 2007 Mar;54(3):298-306
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Characterization of variants in the promoter of EBV gene BZLF1 in normal donors,
HIV
-positive patients and in
AIDS
-
related
lymphomas
.
OBJECTIVE: The aim of this study was to determine the occurrence of polymorphic variants of EBV BamHI fragment Z (BZLF1) promoter zone Zp in tumor and non-tumor-
associated
EBV.
We characterized the Zp region in type A and type B EBV, infecting
AIDS
-
related
non-Hodgkin's
lymphomas
(
AIDS
-NHL) and non-malignant lymphoid tissues derived from
HIV
-positive patients and from healthy individuals.
METHODS: The Zp region was directly sequenced in 133 EBV-positive DNA samples: 63
AIDS
-NHL (32 systemic
AIDS
-NHL and 31
AIDS
-primary central nervous system
lymphoma
[
AIDS
-PCNSL]), 30 lymphoid tissues derived from
HIV
-positive individuals and 40 lymphoid samples derived from healthy individuals.
Zp-V3 was significantly
associated
with
AIDS
-PCNSL (P<0.001) and with systemic
AIDS
-NHL (P=0.007), in particular with
AIDS
-
related
immunoblastic
lymphoma
(P<0.001).
Moreover, in malignant samples, this variant was also significantly
associated
with type B EBV (P<0.001).
Finally, the new identified Zp-PV variant was isolated in 7
AIDS
-PCNSL.
CONCLUSIONS: The frequency of polymorphisms in the regulatory zone of BZLF1 is different between malignant and non-malignant samples in
AIDS
patients and may identify EBV subtypes with different transforming activities, including those
associated
to the pathogenesis of B cell
lymphoma
.
[MeSH-major]
Acquired Immunodeficiency Syndrome / virology. DNA-Binding Proteins / genetics. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics.
Lymphoma
/ virology. Promoter Regions, Genetic. Trans-Activators / genetics. Viral Proteins / genetics
[MeSH-minor]
DNA, Viral / genetics. Humans. Lymphoid Tissue / virology.
Lymphoma
,
AIDS
-
Related
/ virology. Polymorphism, Genetic. Sequence Analysis, DNA. Statistics as Topic
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16784778.001).
[ISSN]
1532-2742
[Journal-full-title]
The Journal of infection
[ISO-abbreviation]
J. Infect.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Trans-Activators; 0 / Viral Proteins
20.
Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF:
Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
HIV Med
; 2005 Jan;6(1):21-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin'
s lymphoma
in
AIDS
patients.
BACKGROUND: Neurological disorders are common in
HIV
-infected patients.
Central nervous system (CNS)
lymphoma
should always be considered because it is an important cause of morbidity and mortality.
OBJECTIVES: To investigate the clinical utility of flow cytometry immunophenotyping (FCI) in diagnosing or discarding leptomeningeal involvement in
HIV
-infected patients and to compare its sensitivity with that of conventional cytological methods.
METHODS: Fifty-six cerebrospinal fluid (CSF) samples from 29
HIV
-infected patients were independently evaluated by flow cytometry and cytology.
RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS
lymphoma
.
This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin'
s lymphoma
should be strongly considered.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ diagnosis. Meningeal Neoplasms / diagnosis
[MeSH-minor]
Adult. Burkitt
Lymphoma
/ cerebrospinal fluid. Burkitt
Lymphoma
/ diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity
Genetic Alliance.
consumer health - AIDS-HIV
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15670248.001).
[ISSN]
1464-2662
[Journal-full-title]
HIV medicine
[ISO-abbreviation]
HIV Med.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
England
21.
Nyagol J, De Falco G, Lazzi S, Luzzi A, Cerino G, Shaheen S, Palummo N, Bellan C, Spina D, Leoncini L:
HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.
J Hematop
; 2008 Jul;1(1):3-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HIV
-1 Tat mimetic of VEGF correlates with increased microvessels density in
AIDS
-
related
diffuse large B-cell and Burkitt
lymphomas
.
In some subtypes of non-Hodgkin's
lymphomas
, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density.
Several studies have indicated that VEGF receptors are also targeted by Tat protein from the
HIV
-1-infected cells.
We evaluated the role of
HIV
-1 Tat in regulating the level of VEGF expression and microvessel density in the
AIDS
-
related
diffuse large B-cell (DLBCL) and Burkitt
lymphomas
(BL).
Reduced VEGF protein expression in primary
HIV
-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines.
Microvascular density assessed by CD34 expression was, however, higher in
HIV
-1 positive than in
HIV
-1 negative tumors.
Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the
AIDS
-
associated
tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the
AIDS
-
associated
non-Hodgkin's
lymphomas
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Med. 1996 Dec;2(12):1371-5
[
8946838.001
]
[Cites]
Oncogene. 2000 Jan 20;19(3):373-9
[
10656684.001
]
[Cites]
Oncogene. 1996 Jan 18;12(2):289-97
[
8570206.001
]
[Cites]
Nature. 1995 Jul 6;376(6535):66-70
[
7596436.001
]
[Cites]
Leuk Lymphoma. 2007 Oct;48(10):2014-21
[
17917969.001
]
[Cites]
Br J Cancer. 2007 Jul 16;97(2):223-30
[
17595666.001
]
[Cites]
Exp Cell Res. 2007 May 1;313(8):1561-74
[
17382929.001
]
[Cites]
Am J Pathol. 2007 Apr;170(4):1362-9
[
17392174.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52
[
17360578.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9
[
17320821.001
]
[Cites]
Nat Struct Mol Biol. 2007 Mar;14(3):249-50
[
17293873.001
]
[Cites]
J Cell Biochem. 2007 Feb 15;100(3):727-37
[
17115409.001
]
[Cites]
Curr Med Chem. 2006;13(16):1845-57
[
16842197.001
]
[Cites]
FEBS J. 2005 Nov;272(22):5723-41
[
16279938.001
]
[Cites]
Folia Histochem Cytobiol. 2004;42(4):241-3
[
15704651.001
]
[Cites]
Biochem Pharmacol. 2004 Dec 15;68(12):2359-66
[
15548382.001
]
[Cites]
Circulation. 1997 Dec 2;96(11):4083-94
[
9403634.001
]
[Cites]
J Biol Chem. 1998 Nov 20;273(47):31119-24
[
9813014.001
]
[Cites]
Science. 1998 Dec 4;282(5395):1837-9
[
9874635.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6
[
9520456.001
]
[Cites]
J Clin Pathol. 1997 Jun;50(6):481-4
[
9378813.001
]
[Cites]
Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5
[
7542074.001
]
[Cites]
Cancer Res. 1995 Sep 15;55(18):3964-8
[
7664263.001
]
[Cites]
Nature. 1994 Oct 20;371(6499):674-80
[
7935812.001
]
[Cites]
Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80
[
12750926.001
]
[Cites]
Angiogenesis. 2002;5(3):141-51
[
12831055.001
]
[Cites]
Cell Prolif. 2003 Jun;36(3):131-49
[
12814430.001
]
[Cites]
Nat Rev Cancer. 2003 Jun;3(6):401-10
[
12778130.001
]
[Cites]
Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28
[
12769789.001
]
[Cites]
J Rheumatol. 2003 Feb;30(2):260-8
[
12563678.001
]
[Cites]
J Clin Oncol. 2002 Nov 1;20(21):4368-80
[
12409337.001
]
[Cites]
Hum Pathol. 2002 Jul;33(7):723-31
[
12196924.001
]
[Cites]
Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44
[
11965229.001
]
[Cites]
Clin Microbiol Rev. 2002 Apr;15(2):310-26
[
11932235.001
]
[Cites]
Am J Clin Pathol. 2001 Dec;116(6):838-45
[
11764072.001
]
[Cites]
Biochem J. 2001 Feb 1;353(Pt 3):569-78
[
11171054.001
]
[Cites]
Cancer Res. 2001 Jan 15;61(2):462-8
[
11212232.001
]
[Cites]
Curr Opin Oncol. 2000 Sep;12(5):445-9
[
10975552.001
]
[Cites]
Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71
[
10873597.001
]
[Cites]
Oncologist. 2000;5 Suppl 1:3-10
[
10804084.001
]
[Cites]
Am J Pathol. 1996 Apr;148(4):1065-74
[
8644848.001
]
(PMID = 19669199.001).
[ISSN]
1868-9256
[Journal-full-title]
Journal of hematopathology
[ISO-abbreviation]
J Hematop
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC2712328
22.
Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF:
HIV-associated lymphomas and gamma-herpesviruses.
Blood
; 2009 Feb 5;113(6):1213-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HIV
-
associated lymphomas
and gamma-herpesviruses.
Among the most common
HIV
-
associated lymphomas
are Burkitt
lymphoma
(BL) and diffuse large B-cell
lymphoma
(DLBCL) with immunoblastic-plasmacytoid differentiation (also involving the central nervous system).
Lymphomas
occurring specifically in
HIV
-positive patients include primary effusion
lymphoma
(PEL) and its solid variants, plasmablastic
lymphoma
of the oral cavity type and large B-cell
lymphoma
arising in Kaposi sarcoma herpesvirus (KSHV)-
associated
multicentric Castleman
disease
.
These
lymphomas
together with BL and DLBCL with immunoblastic-plasmacytoid differentiation frequently carry EBV infection and display a phenotype
related
to plasma cells.
EBV infection occurs at different rates in different
lymphoma
types, whereas KSHV is specifically
associated
with PEL, which usually occurs in the setting of profound immunosuppression.
The current knowledge about
HIV
-
associated lymphomas
can be summarized in the following key points:.
(1)
lymphomas
specifically occurring in patients with
HIV
infection are closely linked to other viral diseases;.
(2)
AIDS lymphomas
fall in a spectrum of B-cell differentiation where those
associated
with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with
lymphomas
and concomitant
HIV
infection could be improved using better combined chemotherapy protocols incorporating anticancer treatments and antiretroviral drugs.
[MeSH-major]
Gammaherpesvirinae / pathogenicity.
HIV
-1 / pathogenicity. Herpesviridae Infections / virology.
Lymphoma
,
AIDS
-
Related
/ virology
Genetic Alliance.
consumer health - HIV
.
HIV InSite.
treatment guidelines - Palliative Care of Patients with HIV
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18955561.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Antiviral Agents
[Number-of-references]
162
23.
Fakhari FD, Jeong JH, Kanan Y, Dittmer DP:
The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.
J Clin Invest
; 2006 Mar;116(3):735-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The latency-
associated
nuclear antigen of Kaposi sarcoma-
associated
herpesvirus induces B cell hyperplasia and
lymphoma
.
Kaposi sarcoma-
associated
herpesvirus (KSHV) is a human lymphotropic herpesvirus.
It is implicated in B cell neoplasias such as primary effusion
lymphoma
and multicentric Castleman
disease
in
AIDS
patients.
The KSHV latency-
associated
nuclear antigen (LANA) is consistently expressed in all KSHV-
associated
tumor cells and was shown to bind the tumor suppressor proteins p53 and pRb.
We also observed
lymphomas
, implying that LANA can activate B cells and provide the first step toward lymphomagenesis.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
Marmoset Gene list: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Cell. 2003 Jan;3(1):23-36
[
12559173.001
]
[Cites]
J Virol. 2002 Nov;76(21):11024-32
[
12368345.001
]
[Cites]
Cancer Res. 2003 May 1;63(9):2010-5
[
12727810.001
]
[Cites]
Blood. 2003 May 15;101(10):4115-21
[
12531789.001
]
[Cites]
J Virol. 2003 Jun;77(11):6474-81
[
12743304.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404
[
12925741.001
]
[Cites]
J Clin Invest. 2004 Jan;113(1):124-36
[
14702116.001
]
[Cites]
Cancer Res. 2004 Jan 15;64(2):581-9
[
14744772.001
]
[Cites]
Br J Cancer. 2004 Jun 1;90(11):2145-8
[
15150582.001
]
[Cites]
Cancer Res. 2004 Jul 15;64(14):4790-9
[
15256448.001
]
[Cites]
Am J Surg Pathol. 2004 Nov;28(11):1401-16
[
15489644.001
]
[Cites]
Methods Mol Biol. 2005;292:449-80
[
15507725.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 Jun;87(12):4781-4
[
2352948.001
]
[Cites]
EMBO J. 1992 May;11(5):1891-9
[
1582417.001
]
[Cites]
Eur J Immunol. 1992 Nov;22(11):3001-11
[
1425924.001
]
[Cites]
Lancet. 1995 Sep 23;346(8978):799-802
[
7674745.001
]
[Cites]
J Exp Med. 1996 Jul 1;184(1):283-8
[
8691144.001
]
[Cites]
N Engl J Med. 1998 Apr 2;338(14):948-54
[
9521982.001
]
[Cites]
J Virol. 1998 Oct;72(10):8309-15
[
9733875.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51
[
10200299.001
]
[Cites]
Science. 1999 Apr 23;284(5414):641-4
[
10213686.001
]
[Cites]
J Virol. 2005 Jan;79(2):1244-51
[
15613351.001
]
[Cites]
J Mol Diagn. 2005 Feb;7(1):17-27
[
15681470.001
]
[Cites]
J Biol Chem. 2005 Feb 4;280(5):3862-74
[
15525642.001
]
[Cites]
Cancer Res. 2005 Apr 1;65(7):2626-35
[
15805259.001
]
[Cites]
Leukemia. 2005 May;19(5):851-5
[
15744337.001
]
[Cites]
Cancer Cell. 2005 May;7(5):445-55
[
15894265.001
]
[Cites]
Cancer Res. 2005 Jul 1;65(13):5925-34
[
15994971.001
]
[Cites]
Virology. 1999 Nov 25;264(2):254-64
[
10562490.001
]
[Cites]
J Exp Med. 1999 Dec 20;190(12):1857-68
[
10601360.001
]
[Cites]
Nature. 1999 Dec 23-30;402(6764):889-94
[
10622254.001
]
[Cites]
Mod Pathol. 2000 Jan;13(1):77-85
[
10658913.001
]
[Cites]
J Immunol. 2000 Feb 15;164(4):1961-70
[
10657646.001
]
[Cites]
Nat Med. 2000 Oct;6(10):1121-7
[
11017143.001
]
[Cites]
J Virol. 2001 Jan;75(1):458-68
[
11119614.001
]
[Cites]
Blood. 2001 Feb 1;97(3):744-51
[
11157493.001
]
[Cites]
J Virol. 2001 Feb;75(4):1798-807
[
11160678.001
]
[Cites]
Blood. 2001 Apr 1;97(7):2130-6
[
11264181.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24
[
11274437.001
]
[Cites]
J Biol Chem. 2001 Jun 22;276(25):22971-8
[
11313352.001
]
[Cites]
J Virol. 2001 Sep;75(17):7882-92
[
11483733.001
]
[Cites]
J Virol. 2002 Jun;76(12):6213-23
[
12021355.001
]
[Cites]
Blood. 2002 Jul 1;100(1):246-58
[
12070034.001
]
[Cites]
Clin Microbiol Rev. 2002 Jul;15(3):439-64
[
12097251.001
]
[Cites]
Nat Med. 2003 Mar;9(3):300-6
[
12592400.001
]
(PMID = 16498502.001).
[ISSN]
0021-9738
[Journal-full-title]
The Journal of clinical investigation
[ISO-abbreviation]
J. Clin. Invest.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / CA109232
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
[Other-IDs]
NLM/ PMC1378187
24.
Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R:
Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.
Microbes Infect
; 2008 Jun;10(7):748-56
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Epstein-Barr virus (EBV) causes EBV-
associated
lymphoproliferative diseases in patients with profound immune suppression.
Most of these diseases are life-threatening and the prognosis of
AIDS
-
associated lymphomas
is extremely unfavorable.
We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-
associated
lymphoproliferative diseases.
These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-
associated
lymphoproliferative diseases.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18538617.001).
[ISSN]
1286-4579
[Journal-full-title]
Microbes and infection
[ISO-abbreviation]
Microbes Infect.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
France
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin
25.
Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Fachiroh J, Paramita DK, Tan IB, Haryana SM, Middeldorp JM:
Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.
J Clin Microbiol
; 2005 Jul;43(7):3066-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia and is strongly
associated
with Epstein-Barr virus (EBV).
The presence of circulating tumor cells was assessed by amplification of BamHI-A rightward frame 1 (BARF1) mRNA, a viral oncogene abundantly expressed in EBV-carrying carcinomas but virtually absent from EBV-
associated lymphomas
.
Genetic Alliance.
consumer health - Nasopharyngeal carcinoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 1999 Nov 1;59(21):5452-5
[
10554016.001
]
[Cites]
Clin Cancer Res. 2000 Mar;6(3):1046-51
[
10741733.001
]
[Cites]
Cancer Res. 2000 May 15;60(10):2745-8
[
10825150.001
]
[Cites]
J Virol. 2000 Oct;74(19):9078-82
[
10982353.001
]
[Cites]
Klin Padiatr. 2000 Jul-Aug;212(4):206-10
[
10994552.001
]
[Cites]
J Gen Virol. 2000 Oct;81(Pt 10):2417-23
[
10993929.001
]
[Cites]
Cancer Res. 2000 Oct 1;60(19):5584-8
[
11034107.001
]
[Cites]
J Virol. 2000 Nov;74(22):10681-9
[
11044112.001
]
[Cites]
Protein Expr Purif. 2000 Nov;20(2):324-33
[
11049756.001
]
[Cites]
J Virol Methods. 2000 Nov;90(2):193-204
[
11064119.001
]
[Cites]
Mol Pathol. 2000 Oct;53(5):248-54
[
11091848.001
]
[Cites]
Blood. 2000 Dec 15;96(13):4055-63
[
11110673.001
]
[Cites]
J Mol Diagn. 2001 Feb;3(1):1-10
[
11227065.001
]
[Cites]
J Mol Diagn. 2000 Nov;2(4):191-201
[
11232109.001
]
[Cites]
Blood. 2001 Mar 1;97(5):1165-71
[
11222357.001
]
[Cites]
J Clin Microbiol. 2001 Apr;39(4):1211-6
[
11283029.001
]
[Cites]
J Clin Oncol. 2001 May 15;19(10):2607-15
[
11352952.001
]
[Cites]
Clin Cancer Res. 2002 Feb;8(2):433-7
[
11839660.001
]
[Cites]
Cancer. 2002 Feb 1;94(3):723-9
[
11857305.001
]
[Cites]
Mol Biotechnol. 2002 Feb;20(2):163-79
[
11876473.001
]
[Cites]
Nat Rev Immunol. 2001 Oct;1(1):75-82
[
11905817.001
]
[Cites]
AIDS. 2002 May 3;16(7):993-1001
[
11953465.001
]
[Cites]
Leuk Lymphoma. 2002 Apr;43(4):831-40
[
12153173.001
]
[Cites]
Clin Cancer Res. 2002 Aug;8(8):2612-9
[
12171892.001
]
[Cites]
J Clin Microbiol. 2002 Nov;40(11):3986-92
[
12409363.001
]
[Cites]
J Clin Microbiol. 2002 Nov;40(11):4105-13
[
12409382.001
]
[Cites]
J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9
[
12419787.001
]
[Cites]
Semin Cancer Biol. 2002 Dec;12(6):431-41
[
12450729.001
]
[Cites]
Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36
[
12482570.001
]
[Cites]
J Clin Virol. 2003 Oct;28(2):155-64
[
12957185.001
]
[Cites]
Clin Cancer Res. 2003 Aug 15;9(9):3254-9
[
12960110.001
]
[Cites]
Clin Cancer Res. 2003 Aug 15;9(9):3431-4
[
12960133.001
]
[Cites]
J Clin Microbiol. 2003 Nov;41(11):5245-9
[
14605174.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44
[
14688409.001
]
[Cites]
Cancer. 2004 Mar 15;100(6):1162-70
[
15022282.001
]
[Cites]
Cancer. 2004 Apr 1;100(7):1429-37
[
15042677.001
]
[Cites]
Cancer Sci. 2004 Jun;95(6):508-13
[
15182432.001
]
[Cites]
N Engl J Med. 2004 Jun 10;350(24):2461-70
[
15190138.001
]
[Cites]
J Infect Dis. 2004 Jul 1;190(1):53-62
[
15195243.001
]
[Cites]
Oncogene. 2004 Jun 17;23(28):4938-44
[
15064715.001
]
[Cites]
Methods Mol Biol. 2005;292:15-26
[
15507698.001
]
[Cites]
Int J Cancer. 1976 Jan 15;17(1):1-7
[
175020.001
]
[Cites]
Int J Cancer. 1977 Nov 15;20(5):655-62
[
200568.001
]
[Cites]
J Gen Virol. 1985 Sep;66 ( Pt 9):1931-40
[
2993484.001
]
[Cites]
J Virol. 1987 Dec;61(12):3870-8
[
2824821.001
]
[Cites]
Nature. 1989 May 18;339(6221):237-8
[
2716852.001
]
[Cites]
EMBO J. 1989 Oct;8(10):2897-903
[
2555151.001
]
[Cites]
J Clin Microbiol. 1990 Mar;28(3):495-503
[
1691208.001
]
[Cites]
Oncogene. 1993 Jun;8(6):1575-83
[
8389032.001
]
[Cites]
J Clin Microbiol. 1997 Jun;35(6):1612-5
[
9163497.001
]
[Cites]
Oncogene. 1997 Jun 26;14(25):3073-81
[
9223671.001
]
[Cites]
J Virol Methods. 1997 Sep;67(2):199-207
[
9300385.001
]
[Cites]
Clin Chem. 1997 Oct;43(10):1843-9
[
9342002.001
]
[Cites]
Clin Cancer Res. 1998 Mar;4(3):665-9
[
9533535.001
]
[Cites]
J Med Virol. 1998 Jul;55(3):227-33
[
9624611.001
]
[Cites]
J Virol Methods. 1998 Jun;72(2):175-84
[
9694325.001
]
[Cites]
IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492
[
9705682.001
]
[Cites]
J Clin Microbiol. 1998 Nov;36(11):3164-9
[
9774558.001
]
[Cites]
J Clin Microbiol. 1999 Sep;37(9):2852-7
[
10449464.001
]
[Cites]
Mol Pathol. 1999 Apr;52(2):97-103
[
10474689.001
]
[Cites]
Transpl Infect Dis. 2001 Jun;3(2):79-87
[
11395973.001
]
[Cites]
Clin Cancer Res. 2003 Mar;9(3):1033-8
[
12631603.001
]
[Cites]
Cell Death Differ. 2003 Jan;10(1):108-16
[
12655299.001
]
[Cites]
Cancer Res. 2003 May 1;63(9):2028-32
[
12727814.001
]
[Cites]
Int J Cancer. 2003 Jul 10;105(5):706-9
[
12740922.001
]
[Cites]
Cancer. 2003 Jul 15;98(2):288-91
[
12872347.001
]
(PMID = 16002393.001).
[ISSN]
0095-1137
[Journal-full-title]
Journal of clinical microbiology
[ISO-abbreviation]
J. Clin. Microbiol.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / RNA, Messenger
[Other-IDs]
NLM/ PMC1169169
26.
Gujral S, Gandhi JS, Valsangkar S, Shet TM, Epari S, Subramanian PG:
Study of the morphological patterns and association of Epstein-Barr virus and human herpes virus 8 in acquired immunodeficiency deficiency syndrome-related reactive lymphadenopathy.
Indian J Pathol Microbiol
; 2010 Oct-Dec;53(4):723-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Study of the morphological patterns and association of Epstein-Barr virus and human herpes virus 8 in acquired immunodeficiency deficiency syndrome-
related
reactive lymphadenopathy.
AIMS: Study of the morphological patterns of acquired immunodeficiency syndrome (
AIDS
)-
related
lymphadenopathy.
SETTINGS AND DESIGN: We retrospectively selected cases of
AIDS
-
related
benign lymphadenopathy.
Cases with
lymphomas
, frank granulomas and necrosis were excluded.
We analyzed different morphological patterns and correlated these with immunophenotypic markers along with viral markers human herpesvirus 8-latency-
associated
nuclear antigen (HHV8-LANA), and Epstein-Barr virus-encoded ribonucleic acid (EBER) studies via in situ hybridization (EBER-ISH).
MATERIALS AND METHODS: We present the morphological patterns of 13 cases of human immunodeficiency virus (
HIV
)-reactive lymph nodes and their clinical, hematological, biochemical and radiological parameters with special emphasis on the presence or absence of viral markers, including HHV8 and EBV.
Two cases of multicentric Castleman'
s disease
expressed EBER; however, they did not express HHV8.
CONCLUSION: The wide spectrum of histological changes in
HIV
-
associated
lymphadenopathy requires recognition.
The histological changes can mimic those of other infective lymphadenitis, follicular
lymphoma
, Castleman'
s disease
, progressive transformation of germinal center, Hodgkin'
s disease
and spindle cell neoplasms.
[MeSH-major]
AIDS
-
Related
Opportunistic Infections / pathology. Epstein-Barr Virus Infections / pathology.
HIV
Infections / complications. Herpesviridae Infections / pathology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Lymphatic Diseases / pathology
Genetic Alliance.
consumer health - MYH9 related thrombocytopenia
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS and Infections
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - Lymphatic Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21045401.001).
[ISSN]
0974-5130
[Journal-full-title]
Indian journal of pathology & microbiology
[ISO-abbreviation]
Indian J Pathol Microbiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Chemical-registry-number]
0 / Biomarkers
27.
Epeldegui M, Vendrame E, Martínez-Maza O:
HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.
Immunol Res
; 2010 Dec;48(1-3):72-83
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HIV
-
associated
immune dysfunction and viral infection: role in the pathogenesis of
AIDS
-
related lymphoma
.
HIV
infection is
associated
with a much higher risk for the development of non-Hodgkin
lymphoma
(
AIDS
-NHL).
The principal causes of lymphomagenesis in
HIV
-infected individuals are thought to be the loss of immune function seen in
HIV
infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as
HIV
infection-
associated
immune dysregulation, including chronic B-cell activation.
In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in
HIV
-infected individuals.
[MeSH-major]
AIDS
-
Related
Opportunistic Infections / immunology. Acquired Immunodeficiency Syndrome / immunology. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / immunology.
HIV
/ immunology.
Lymphoma
,
AIDS
-
Related
/ immunology.
Lymphoma
, Non-Hodgkin / immunology
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS and Infections
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Semin Oncol. 2000 Aug;27(4):431-41
[
10950370.001
]
[Cites]
Immunity. 2000 Oct;13(4):485-95
[
11070167.001
]
[Cites]
J Virol. 2001 Jul;75(13):6173-82
[
11390619.001
]
[Cites]
AIDS. 2001 May 25;15(8):957-64
[
11399977.001
]
[Cites]
Blood. 2001 Jul 1;98(1):146-55
[
11418474.001
]
[Cites]
Eur J Immunol. 2001 May;31(5):1544-9
[
11465112.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5
[
12665622.001
]
[Cites]
Tumour Biol. 2003 Mar-Apr;24(2):82-93
[
12853703.001
]
[Cites]
Nat Rev Immunol. 2003 Aug;3(8):609-20
[
12974476.001
]
[Cites]
Clin Immunol. 2003 Nov;109(2):119-29
[
14597210.001
]
[Cites]
J Immunol. 2003 Nov 15;171(10):5215-24
[
14607922.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7
[
14999097.001
]
[Cites]
Blood. 2004 Oct 1;104(7):1952-60
[
15213097.001
]
[Cites]
Proc Natl Acad Sci U S A. 1983 Jun;80(11):3456-60
[
6222380.001
]
[Cites]
Science. 1986 Sep 5;233(4768):1084-6
[
3016902.001
]
[Cites]
J Immunol. 1987 Jun 1;138(11):3720-4
[
2953790.001
]
[Cites]
Immunol Today. 1989 May;10(5):153-7
[
2525911.001
]
[Cites]
J Exp Med. 1989 Dec 1;170(6):2081-95
[
2531194.001
]
[Cites]
Immunology. 1989 Dec;68(4):526-31
[
2481643.001
]
[Cites]
AIDS. 1992 Oct;6(10):1105-16
[
1466841.001
]
[Cites]
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
[
1361652.001
]
[Cites]
J Clin Oncol. 1993 Jun;11(6):1099-107
[
8099121.001
]
[Cites]
Blood. 1993 Dec 1;82(11):3430-6
[
8241510.001
]
[Cites]
Eur J Immunol. 1994 Aug;24(8):1869-73
[
8056045.001
]
[Cites]
Immunol Today. 1994 Sep;15(9):418-22
[
7524519.001
]
[Cites]
J Immunol. 1995 Mar 15;154(6):2533-44
[
7533177.001
]
[Cites]
Blood. 1995 Apr 1;85(7):1843-9
[
7703491.001
]
[Cites]
Mol Med. 1995 Jul;1(5):495-505
[
8529116.001
]
[Cites]
Ann Intern Med. 1997 Sep 15;127(6):423-8
[
9312998.001
]
[Cites]
Leuk Lymphoma. 1998 Jul;30(3-4):257-67
[
9713958.001
]
[Cites]
Clin Immunol. 1999 Feb;90(2):157-64
[
10080826.001
]
[Cites]
Blood. 1999 Jul 1;94(1):275-82
[
10381523.001
]
[Cites]
Clin Immunol. 1999 Sep;92(3):293-9
[
10479534.001
]
[Cites]
Clin Immunol. 1999 Nov;93(2):114-23
[
10527687.001
]
[Cites]
J Immunol. 2005 Jun 15;174(12):7912-9
[
15944297.001
]
[Cites]
Blood. 2005 Aug 1;106(3):1031-6
[
15840698.001
]
[Cites]
AIDS. 2005 Oct 14;19(15):1711-2
[
16184051.001
]
[Cites]
J Interferon Cytokine Res. 2005 Nov;25(11):702-6
[
16318584.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18093-8
[
16330748.001
]
[Cites]
J Immunol. 2006 Apr 1;176(7):3931-41
[
16547227.001
]
[Cites]
RNA. 2006 May;12(5):733-50
[
16540699.001
]
[Cites]
Tumour Biol. 2006;27(4):187-94
[
16651853.001
]
[Cites]
PLoS Pathog. 2006 Mar;2(3):e23
[
16557291.001
]
[Cites]
Mol Immunol. 2007 Jan;44(4):494-505
[
16574227.001
]
[Cites]
Mol Immunol. 2007 Feb;44(5):934-42
[
16730063.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3859-64
[
16882707.001
]
[Cites]
Ann Rheum Dis. 2007 Jan;66(1):23-7
[
16569685.001
]
[Cites]
JAMA. 2006 Dec 20;296(23):2823-31
[
17179459.001
]
[Cites]
Nat Med. 2007 Feb;13(2):139-45
[
17290272.001
]
[Cites]
Blood. 2007 Mar 15;109(6):2545-52
[
17132718.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12
[
17360630.001
]
[Cites]
Transl Res. 2007 Apr;149(4):231-5
[
17383597.001
]
[Cites]
J Virol. 2007 Jun;81(11):5872-81
[
17392362.001
]
[Cites]
J Immunol. 2007 Jun 1;178(11):6730-3
[
17513719.001
]
[Cites]
Nucleic Acids Res. 2007;35(10):e73
[
17478510.001
]
[Cites]
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
[
17565153.001
]
[Cites]
Lancet. 2007 Jul 7;370(9581):59-67
[
17617273.001
]
[Cites]
J Immunol. 2007 Sep 1;179(5):3153-60
[
17709530.001
]
[Cites]
AIDS. 2007 Nov 12;21(17):2265-70
[
18090274.001
]
[Cites]
Nat Genet. 2008 Jan;40(1):108-12
[
18066064.001
]
[Cites]
Cancer Res. 2008 Mar 1;68(5):1436-42
[
18316607.001
]
[Cites]
Blood. 2008 Apr 15;111(8):4029-38
[
18263783.001
]
[Cites]
J Immunol. 2008 Jul 1;181(1):186-9
[
18566383.001
]
[Cites]
Blood. 2008 Dec 1;112(12):4401-10
[
18780835.001
]
[Cites]
Ann Rheum Dis. 2009 Jan;68(1):89-93
[
18375535.001
]
[Cites]
Blood. 2009 Feb 5;113(6):1213-24
[
18955561.001
]
[Cites]
Int J Cancer. 2009 Apr 15;124(8):1745-55
[
19165855.001
]
[Cites]
J Clin Oncol. 2009 Feb 20;27(6):967-73
[
19114696.001
]
[Cites]
J Infect Dis. 2009 Jul 1;200(1):79-87
[
19476437.001
]
[Cites]
Clin Cancer Res. 2009 Oct 1;15(19):5968-73
[
19773382.001
]
[Cites]
Biochem Biophys Res Commun. 2009 Dec 11;390(2):269-72
[
19799865.001
]
[Cites]
Mol Immunol. 2009 Nov;47(1):3-7
[
19193443.001
]
[Cites]
Mol Cell. 2009 Nov 25;36(4):631-41
[
19941823.001
]
[Cites]
Semin Cancer Biol. 2009 Dec;19(6):351-65
[
19619654.001
]
[Cites]
Semin Cancer Biol. 2009 Dec;19(6):401-6
[
19619656.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22421-6
[
20080792.001
]
[Cites]
Int J Cancer. 2010 Mar 15;126(6):1316-26
[
19530237.001
]
[Cites]
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9
[
19654554.001
]
[Cites]
J Clin Oncol. 2010 Feb 10;28(5):773-9
[
20048176.001
]
[Cites]
Cytokine. 2010 Apr;50(1):58-68
[
20060740.001
]
[Cites]
J Leukoc Biol. 2010 Apr;87(4):627-32
[
20042471.001
]
[Cites]
AIDS. 2010 Apr 24;24(7):1025-33
[
20299965.001
]
[Cites]
J Acquir Immune Defic Syndr. 2010 May 1;54(1):18-26
[
20216076.001
]
[Cites]
Cancer Immunol Immunother. 2010 Jul;59(7):979-87
[
20352428.001
]
[Cites]
Br J Haematol. 2010 May;149(4):484-97
[
20346013.001
]
[Cites]
Biochem Biophys Res Commun. 2010 May 21;396(1):67-73
[
20494113.001
]
[Cites]
PLoS One. 2010;5(7):e11448
[
20625427.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84
[
10566552.001
]
[Cites]
Inflamm Bowel Dis. 1999 Nov;5(4):285-94
[
10579123.001
]
[Cites]
Clin Immunol. 1999 Dec;93(3):239-44
[
10600334.001
]
[Cites]
J Allergy Clin Immunol. 2000 May;105(5):975-82
[
10808179.001
]
[Cites]
AIDS. 2000 Jul 7;14(10):1460-1
[
10930167.001
]
(PMID = 20717742.001).
[ISSN]
1559-0755
[Journal-full-title]
Immunologic research
[ISO-abbreviation]
Immunol. Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA073475
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS461037; NLM/ PMC3640300
28.
Shackelford J, Pagano JS:
Role of the ubiquitin system and tumor viruses in AIDS-related cancer.
BMC Biochem
; 2007;8 Suppl 1:S8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Role of the ubiquitin system and tumor viruses in
AIDS
-
related
cancer.
This review focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset of viral malignancies; those
associated
with
AIDS
.
The viruses include Kaposi's sarcoma herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's sarcoma, certain B-cell
lymphomas
and cervical cancer, respectively.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.
com
).
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Curr HIV Res. 2004 Oct;2(4):343-9
[
15544455.001
]
[Cites]
Cell Cycle. 2004 Nov;3(11):1345-7
[
15492505.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62
[
11087859.001
]
[Cites]
Acta Virol. 2000 Jun-Aug;44(3):211-26
[
11155368.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23
[
11158620.001
]
[Cites]
Eur J Cancer. 2001 Jul;37(10):1227-35
[
11423255.001
]
[Cites]
J Virol. 2001 Aug;75(16):7583-91
[
11462030.001
]
[Cites]
Oncogene. 2001 Aug 2;20(34):4740-9
[
11498796.001
]
[Cites]
Chem Biol. 2001 Aug;8(8):739-58
[
11514224.001
]
[Cites]
Am J Clin Pathol. 2001 Nov;116(5):637-46
[
11710679.001
]
[Cites]
J Cell Biol. 2001 Dec 24;155(7):1265-73
[
11756476.001
]
[Cites]
J Biol Chem. 2002 Feb 22;277(8):6124-30
[
11751860.001
]
[Cites]
Nat Med. 2002 Apr;8(4):338-40
[
11927937.001
]
[Cites]
EMBO J. 2002 May 15;21(10):2418-29
[
12006494.001
]
[Cites]
Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70
[
12108891.001
]
[Cites]
Oral Dis. 2002;8 Suppl 2:161-8
[
12164651.001
]
[Cites]
Curr Top Microbiol Immunol. 2002;269:23-36
[
12224511.001
]
[Cites]
Cancer Lett. 2002 Dec 15;188(1-2):15-24
[
12406543.001
]
[Cites]
Virus Res. 2002 Nov;89(2):213-28
[
12445661.001
]
[Cites]
Semin Cancer Biol. 2002 Dec;12(6):431-41
[
12450729.001
]
[Cites]
Semin Cancer Biol. 2003 Feb;13(1):59-67
[
12507557.001
]
[Cites]
Semin Cancer Biol. 2003 Feb;13(1):69-76
[
12507558.001
]
[Cites]
J Pathol. 2003 Feb;199(2):140-5
[
12533825.001
]
[Cites]
Carcinogenesis. 2003 Feb;24(2):159-69
[
12584163.001
]
[Cites]
Hum Mutat. 2003 Mar;21(3):307-12
[
12619117.001
]
[Cites]
Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents
[
12794189.001
]
[Cites]
Med Sci (Paris). 2003 Jan;19(1):100-6
[
12836198.001
]
[Cites]
Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi
[
12852651.001
]
[Cites]
Virology. 2004 Jun 20;324(1):17-27
[
15183049.001
]
[Cites]
Isr Med Assoc J. 2004 Jul;6(7):420-4
[
15274534.001
]
[Cites]
Trends Immunol. 2004 Aug;25(8):422-6
[
15275641.001
]
[Cites]
Cancer Chemother Biol Response Modif. 2003;21:717-46
[
15338771.001
]
[Cites]
Semin Cancer Biol. 2004 Dec;14(6):453-71
[
15489139.001
]
[Cites]
Nat Rev Cancer. 2004 Oct;4(10):757-68
[
15510157.001
]
[Cites]
Science. 1989 Feb 17;243(4893):934-7
[
2537532.001
]
[Cites]
EMBO J. 1989 Dec 20;8(13):4099-105
[
2556261.001
]
[Cites]
J Clin Oncol. 2005 Jan 20;23(3):630-9
[
15659509.001
]
[Cites]
Annu Rev Med. 2005;56:29-44
[
15660500.001
]
[Cites]
Immunity. 2005 Jan;22(1):59-70
[
15664159.001
]
[Cites]
Viral Immunol. 2004;17(4):473-80
[
15671745.001
]
[Cites]
Cleve Clin J Med. 2005 Jan;72(1):73-8
[
15691060.001
]
[Cites]
Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65
[
15718150.001
]
[Cites]
Curr Med Chem. 2005;12(3):357-74
[
15723624.001
]
[Cites]
Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19
[
15757400.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 2005;45:465-76
[
15822185.001
]
[Cites]
J Virol. 2005 May;79(9):5705-12
[
15827185.001
]
[Cites]
Am J Clin Pathol. 2005 Feb;123(2):222-8
[
15842046.001
]
[Cites]
Anticancer Drugs. 2005 Jun;16(5):475-81
[
15846112.001
]
[Cites]
Cell Cycle. 2005 Feb;4(2):290-6
[
15655370.001
]
[Cites]
Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12
[
15867955.001
]
[Cites]
AIDS Rev. 2005 Jan-Mar;7(1):56-61
[
15875661.001
]
[Cites]
Oncologist. 2005 Jun-Jul;10(6):412-26
[
15967835.001
]
[Cites]
Science. 2005 Jul 1;309(5731):127-30
[
15994556.001
]
[Cites]
J Antimicrob Chemother. 2005 Aug;56(2):277-81
[
16006448.001
]
[Cites]
EMBO J. 2006 Apr 19;25(8):1635-45
[
16601694.001
]
[Cites]
Adv Dent Res. 2006;19(1):99-105
[
16672559.001
]
[Cites]
Lancet. 2006 May 6;367(9521):1495-502
[
16679162.001
]
[Cites]
Curr Mol Med. 2006 May;6(3):291-308
[
16712476.001
]
[Cites]
Front Biosci. 2006;11:2672-713
[
16720343.001
]
[Cites]
Cancer Treat Rev. 2006 Oct;32(6):445-55
[
16860939.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9870-7
[
17047048.001
]
[Cites]
Mol Cell Biol. 2007 Apr;27(8):2910-8
[
17296724.001
]
[Cites]
Adv Cancer Res. 2000;78:1-29
[
10547667.001
]
[Cites]
Oncogene. 1999 Dec 13;18(53):7690-700
[
10618709.001
]
[Cites]
Virology. 2000 Mar 1;268(1):178-91
[
10683340.001
]
[Cites]
Semin Cancer Biol. 1999 Dec;9(6):387-95
[
10712885.001
]
[Cites]
Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45
[
12852653.001
]
[Cites]
Anticancer Res. 2003 May-Jun;23(3A):2133-8
[
12894587.001
]
[Cites]
Oncogene. 2003 Aug 11;22(33):5108-21
[
12910248.001
]
[Cites]
Oncogene. 2003 Aug 11;22(33):5122-30
[
12910249.001
]
[Cites]
Oncogene. 2003 Sep 29;22(42):6639-45
[
14528289.001
]
[Cites]
Ann Med. 2003;35(6):404-12
[
14572164.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6
[
14663138.001
]
[Cites]
AIDS Rev. 2003 Oct-Dec;5(4):222-9
[
15012001.001
]
[Cites]
Oncogene. 2004 Mar 15;23(11):2107-15
[
15021898.001
]
[Cites]
Nat Rev Cancer. 2004 May;4(5):349-60
[
15122206.001
]
[Cites]
Mol Cell Biol. 2004 Jun;24(12):5089-93
[
15169876.001
]
[Cites]
Curr Protein Pept Sci. 2004 Jun;5(3):153-61
[
15180520.001
]
[Cites]
Oncologist. 2005 Aug;10(7):528-38
[
16079320.001
]
[Cites]
Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11
[
16091217.001
]
[Cites]
Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67
[
15979320.001
]
[Cites]
Antivir Ther. 2005;10(6):745-51
[
16218174.001
]
[Cites]
Essays Biochem. 2005;41:139-56
[
16250903.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6
[
16344472.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18562-6
[
16352731.001
]
[Cites]
Curr Opin Infect Dis. 2006 Feb;19(1):14-9
[
16374212.001
]
[Cites]
Ann Pharm Fr. 2005 Sep;63(5):343-9
[
16385784.001
]
[Cites]
Ann N Y Acad Sci. 2005 Nov;1056:328-43
[
16387699.001
]
[Cites]
Annu Rev Med. 2006;57:33-47
[
16409135.001
]
[Cites]
Expert Opin Investig Drugs. 2006 Feb;15(2):117-30
[
16433592.001
]
[Cites]
Yonsei Med J. 2006 Feb 28;47(1):1-14
[
16502480.001
]
[Cites]
Cancer Gene Ther. 2006 May;13(5):445-50
[
16341140.001
]
[Cites]
Curr Med Chem. 2006;13(7):745-54
[
16611064.001
]
[Cites]
Nihon Rinsho. 2006 Mar;64 Suppl 3:635-8
[
16615550.001
]
[Cites]
Int J Oncol. 2000 May;16(5):853-70
[
10762621.001
]
[Cites]
J Natl Cancer Inst. 2000 May 3;92(9):690-8
[
10793105.001
]
[Cites]
Bioessays. 2000 May;22(5):442-51
[
10797484.001
]
[Cites]
Clin Lab Med. 2000 Jun;20(2):383-406
[
10863646.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6
[
10859362.001
]
[Cites]
Semin Oncol. 2000 Aug;27(4):390-401
[
10950365.001
]
[Cites]
Adv Pharmacol. 2000;49:479-514
[
11013772.001
]
[Cites]
Mol Cell Biol. 2000 Nov;20(22):8526-35
[
11046148.001
]
[Cites]
Cell. 1990 Dec 21;63(6):1129-36
[
2175676.001
]
[Cites]
Hum Cell. 1992 Mar;5(1):25-41
[
1329931.001
]
[Cites]
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
[
1361652.001
]
[Cites]
Princess Takamatsu Symp. 1991;22:239-48
[
1668886.001
]
[Cites]
Int J Cancer. 1993 Sep 9;55(2):208-12
[
8370617.001
]
[Cites]
Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60
[
8814120.001
]
[Cites]
Mol Med Today. 1997 Jun;3(6):246-53
[
9211415.001
]
[Cites]
Semin Cancer Biol. 1996 Dec;7(6):317-26
[
9284524.001
]
[Cites]
J Biol Chem. 1997 Nov 28;272(48):30135-40
[
9374493.001
]
[Cites]
FEBS Lett. 1997 Dec 22;420(1):25-7
[
9450543.001
]
[Cites]
J Biol Chem. 1998 Mar 13;273(11):6439-45
[
9497376.001
]
[Cites]
Lancet. 1998 Jun 20;351(9119):1833-9
[
9652666.001
]
[Cites]
Nature. 1998 Aug 6;394(6693):588-92
[
9707121.001
]
[Cites]
Trends Microbiol. 1998 Jul;6(7):276-82
[
9717216.001
]
[Cites]
Oncogene. 1998 Dec 10;17(23):2943-54
[
9881696.001
]
[Cites]
Front Biosci. 1999 May 15;4:D468-75
[
10331991.001
]
(PMID = 18047745.001).
[ISSN]
1471-2091
[Journal-full-title]
BMC biochemistry
[ISO-abbreviation]
BMC Biochem.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Ubiquitin
[Number-of-references]
119
[Other-IDs]
NLM/ PMC2106372
29.
Kelemen K, Cao W, Peterson LC, Evens AM, Variakojis D:
Primary mediastinal large B-cell lymphoma in HIV: report of two cases.
J Hematop
; 2009 Mar;2(1):45-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal large B-cell
lymphoma
in
HIV
: report of two cases.
Primary mediastinal large B cell
lymphoma
(PMLBCL) is a subtype of diffuse large B cell
lymphoma
arising in the mediastinum with distinctive clinical and morphological features.
Though diffuse large B cell
lymphoma
is one of the most common non-Hodgkin
lymphoma
associated
with
AIDS
, there are no data available regarding the association of
HIV
and PMLBCL.
We report here two cases of PMLBCL arising in
AIDS
patients.
One of the two patients, a 25-year-old woman who had localized
disease
and evidence of Epstein-Barr virus in
lymphoma
cells, did not respond to chemotherapy and died of
disease
progression 5 months after diagnosis.
The second patient, a 38-year-old male with disseminated
disease
, responded to therapy and is
disease
-free after 9 months of follow-up.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):44-54
[
8465656.001
]
[Cites]
J Pathol. 1992 Aug;167(4):381-4
[
1328576.001
]
[Cites]
Blood. 1991 Aug 1;78(3):780-8
[
1713514.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
J Clin Oncol. 2001 Apr 15;19(8):2171-8
[
11304769.001
]
[Cites]
J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97
[
8350362.001
]
[Cites]
Blood. 2007 Aug 1;110(3):972-8
[
17400912.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3786-91
[
16917006.001
]
[Cites]
Am J Med Sci. 2005 Mar;329(3):136-8
[
15767818.001
]
[Cites]
Hematol Oncol Clin North Am. 1996 Oct;10(5):1135-48
[
8880201.001
]
[Cites]
Br J Haematol. 1995 Jun;90(2):235-43
[
7794745.001
]
[Cites]
Blood. 2000 Oct 15;96(8):2730-4
[
11023505.001
]
(PMID = 19669223.001).
[ISSN]
1868-9256
[Journal-full-title]
Journal of hematopathology
[ISO-abbreviation]
J Hematop
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC2713493
30.
Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA:
Cutaneous malignancy and human immunodeficiency virus disease.
J Am Acad Dermatol
; 2006 Feb;54(2):189-206; quiz 207-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cutaneous malignancy and human immunodeficiency virus
disease
.
Certain skin cancers occur with increased frequency or altered course in patients infected with
HIV
.
Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with
HIV
.
The incidence of
HIV
-
associated
Kapsosi's sarcoma has markedly decreased since the advent of
HIV
antiretroviral therapy.
Cutaneous T-cell
lymphoma
(CTCL) is rare in this population.
Other types of cutaneous
lymphoma
and
HIV
-
associated
pseudo-CTCL are discussed.
LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with
HIV
.
[MeSH-major]
HIV
Infections / epidemiology. Skin Neoplasms / epidemiology
[MeSH-minor]
Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry.
Lymphoma
, Large-Cell, Anaplastic / epidemiology.
Lymphoma
, T-Cell, Cutaneous / epidemiology.
Lymphoma
, T-Cell, Cutaneous / immunology.
Lymphoma
, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16443048.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-Retroviral Agents
[Number-of-references]
274
31.
Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, Würdinger T, Middeldorp JM:
Functional delivery of viral miRNAs via exosomes.
Proc Natl Acad Sci U S A
; 2010 Apr 6;107(14):6328-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
These EBV-miRNAs are functional because internalization of exosomes by MoDC results in a dose-dependent, miRNA-mediated repression of confirmed EBV target genes, including CXCL11/ITAC, an immunoregulatory gene down-regulated in primary EBV-
associated lymphomas
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Rev Immunol. 2001 Oct;1(1):75-82
[
11905817.001
]
[Cites]
Nat Cell Biol. 2009 Sep;11(9):1143-9
[
19684575.001
]
[Cites]
J Exp Med. 2003 Dec 1;198(11):1653-63
[
14657218.001
]
[Cites]
Cell. 2004 Jan 23;116(2):281-97
[
14744438.001
]
[Cites]
Science. 2004 Apr 30;304(5671):734-6
[
15118162.001
]
[Cites]
J Exp Med. 1996 Mar 1;183(3):1161-72
[
8642258.001
]
[Cites]
Immunity. 1998 Sep;9(3):395-404
[
9768759.001
]
[Cites]
Blood. 2004 Nov 15;104(10):3257-66
[
15284116.001
]
[Cites]
J Immunol. 2005 Jun 1;174(11):6599-607
[
15905498.001
]
[Cites]
Nat Rev Cancer. 2006 Apr;6(4):259-69
[
16557279.001
]
[Cites]
PLoS Pathog. 2006 Mar;2(3):e23
[
16557291.001
]
[Cites]
Blood. 2007 Feb 1;109(3):1043-50
[
17018863.001
]
[Cites]
Nat Cell Biol. 2007 Jun;9(6):654-9
[
17486113.001
]
[Cites]
Science. 2007 Jul 20;317(5836):376-81
[
17641203.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9
[
17911266.001
]
[Cites]
J Virol. 2007 Dec;81(24):13771-82
[
17942535.001
]
[Cites]
Nat Biotechnol. 2007 Dec;25(12):1457-67
[
18026085.001
]
[Cites]
AIDS. 2007 Oct 18;21(16):2141-9
[
18090040.001
]
[Cites]
Nat Rev Immunol. 2008 Feb;8(2):120-30
[
18204468.001
]
[Cites]
J Immunol. 2008 Mar 1;180(5):3081-90
[
18292531.001
]
[Cites]
Cancer Res. 2008 Mar 1;68(5):1436-42
[
18316607.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
[
18663219.001
]
[Cites]
PLoS One. 2008;3(11):e3694
[
19002258.001
]
[Cites]
Virology. 2008 Dec 20;382(2):257-66
[
18950829.001
]
[Cites]
Nat Cell Biol. 2008 Dec;10(12):1470-6
[
19011622.001
]
[Cites]
Semin Cancer Biol. 2008 Dec;18(6):388-96
[
19013244.001
]
[Cites]
J Cell Biol. 2008 Dec 29;183(7):1187-91
[
19103810.001
]
[Cites]
Nature. 2009 Jan 22;457(7228):421-5
[
19158788.001
]
[Cites]
J Virol. 2009 Mar;83(5):2357-67
[
19091858.001
]
[Cites]
Cell. 2009 Feb 20;136(4):592-7
[
19239880.001
]
[Cites]
Virology. 2009 Apr 10;386(2):387-97
[
19217135.001
]
[Cites]
Nat Rev Immunol. 2009 Aug;9(8):581-93
[
19498381.001
]
[Cites]
Genes Dev. 2009 Aug 15;23(16):1971-9
[
19684116.001
]
[Cites]
Nat Cell Biol. 2009 Sep;11(9):1150-6
[
19684574.001
]
[Cites]
J Biol Chem. 2003 Mar 28;278(13):10963-72
[
12519789.001
]
(PMID = 20304794.001).
[ISSN]
1091-6490
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA065883
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / MicroRNAs; 0 / RNA, Viral
[Other-IDs]
NLM/ PMC2851954
32.
Lawson JS, Heng B:
Viruses and breast cancer.
Cancers (Basel)
; 2010;2(2):752-72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Viruses are the accepted cause of many important cancers including cancers of the cervix and anogenital area, the liver, some
lymphomas
, head and neck cancers and indirectly human immunodeficiency virus
associated
cancers.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 24281093.001).
[ISSN]
2072-6694
[Journal-full-title]
Cancers
[ISO-abbreviation]
Cancers (Basel)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
[Other-IDs]
NLM/ PMC3835103
33.
Shankar SK, Mahadevan A, Satishchandra P, Kumar RU, Yasha TC, Santosh V, Chandramuki A, Ravi V, Nath A:
Neuropathology of HIV/AIDS with an overview of the Indian scene.
Indian J Med Res
; 2005 Apr;121(4):468-88
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Neuropathology of
HIV
/
AIDS
with an overview of the Indian scene.
Neurological manifestations of
HIV
infection and
AIDS
are being recognized with a frequency that parallels the increasing number of
AIDS
cases.
Next to sub-Saharan Africa, India has the second largest burden of
HIV related
pathology, essentially caused by
HIV
-1 clade C in both the geographic locales, in contrast to USA and Europe.
But the true prevalence of
HIV related
neuroinfections and pathology is not available due to inadequate medical facilities, social stigma and ignorance that lead to underdiagnosis.
Inspite of heavy burden of
HIV
/
AIDS
,
HIV
associated
neoplasia is infrequent, including primary CNS
lymphomas
.
HIV
encephalitis and
HIV
associated
dementia are considered infrequent, though systematic studies have just been initiated in various centres.
Till now the
AIDS
cases in India were drug naive but a new cohort of cases following initiation of HAART therapy as a national policy is soon emerging, altering the biology and evolution of
HIV
/
AIDS
in India.
Lacunae in the epidemiology, diagnosis and study of biology of
HIV
/
AIDS
are outlined for future research.
[MeSH-major]
Central Nervous System Neoplasms / complications.
HIV
Infections / physiopathology. Nervous System Diseases / complications
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Neurologic Diseases
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15817957.001).
[ISSN]
0971-5916
[Journal-full-title]
The Indian journal of medical research
[ISO-abbreviation]
Indian J. Med. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
[Publication-country]
India
[Number-of-references]
153
34.
Queiroga EM, Gualco G, Chioato L, Harrington WJ, Araujo I, Weiss LM, Bacchi CE:
Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.
Am J Clin Pathol
; 2008 Aug;130(2):186-92
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Viral studies in burkitt
lymphoma
: association with Epstein-Barr virus but not HHV-8.
Burkitt
lymphoma
(BL) is a highly aggressive non-Hodgkin
lymphoma
, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.
Epstein-Barr virus (EBV) has been
associated
with BL with different frequencies depending on the clinical variant.
Kaposi sarcoma-
associated
herpesvirus, or human herpesvirus 8 (HHV-8), infects a wide range of normal cells, having a well-established role in the pathogenesis of various neoplasms, including Kaposi sarcoma, primary effusion
lymphoma
, multicentric Castleman
disease
(MCD) and MCD-
associated
plasmablastic
lymphoma
.
In secondary immunodeficiencies, such as
HIV
-1 infection and organ transplantation, HHV-8 is considered an opportunistic pathogen linked to the development of
lymphomas
in patients with
AIDS
and
HIV
+ patients.
We found no association of BL with HHV-8 in EBV + BL or in EBV-cases, including the
HIV
+ BL group.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 2005 Aug;19(8):1391-8
[
15973450.001
]
[Cites]
J Exp Med. 2005 Aug 15;202(4):479-84
[
16103407.001
]
[Cites]
Br J Haematol. 2005 Sep;130(5):662-70
[
16115121.001
]
[Cites]
Br J Cancer. 2005 Oct 3;93(7):834-7
[
16136049.001
]
[Cites]
J Clin Pathol. 2005 Oct;58(10):1039-45
[
16189148.001
]
[Cites]
Am J Surg Pathol. 2006 Jan;30(1):123-7
[
16330952.001
]
[Cites]
Hum Pathol. 2006 Jan;37(1):23-31
[
16360412.001
]
[Cites]
J Clin Invest. 2006 Mar;116(3):735-42
[
16498502.001
]
[Cites]
N Engl J Med. 2006 Jun 8;354(23):2419-30
[
16760442.001
]
[Cites]
Br J Haematol. 2006 Aug;134(3):294-301
[
16848772.001
]
[Cites]
Acta Haematol. 2007;117(3):129-31
[
17135725.001
]
[Cites]
Hum Pathol. 2007 Sep;38(9):1293-304
[
17707260.001
]
[Cites]
Br J Haematol. 2008 Jan;140(1):13-24
[
17991301.001
]
[Cites]
Haematologica. 2005 Nov;90 Suppl:ECR35
[
16266926.001
]
[Cites]
Hum Pathol. 1999 Oct;30(10):1269-70
[
10534180.001
]
[Cites]
N Engl J Med. 1999 Nov 11;341(20):1520-9
[
10559454.001
]
[Cites]
Blood. 2000 Feb 15;95(4):1406-12
[
10666218.001
]
[Cites]
Blood. 2001 Apr 1;97(7):2130-6
[
11264181.001
]
[Cites]
Clin Infect Dis. 2002 Feb 15;34(4):559-60
[
11797191.001
]
[Cites]
Blood. 2002 Nov 1;100(9):3415-8
[
12384445.001
]
[Cites]
Br J Haematol. 2003 Feb;120(3):471-7
[
12580962.001
]
[Cites]
Int J Cancer. 2004 Jan 1;108(1):66-70
[
14618617.001
]
[Cites]
Leukemia. 2003 Dec;17(12):2257-317
[
14671650.001
]
[Cites]
Acta Otolaryngol. 2004 Apr;124(3):318-23
[
15141762.001
]
[Cites]
J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62
[
2824665.001
]
[Cites]
Blood. 1992 Jun 15;79(12):3261-6
[
1317726.001
]
[Cites]
Blood. 1995 Mar 1;85(5):1396-403
[
7858270.001
]
[Cites]
Am J Pathol. 1996 Jan;148(1):17-23
[
8546204.001
]
[Cites]
Blood. 1996 Jun 15;87(12):5279-86
[
8652843.001
]
[Cites]
Mod Pathol. 1996 Jan;9(1):63-7
[
8821959.001
]
[Cites]
Leukemia. 1997 May;11(5):743-6
[
9180301.001
]
[Cites]
Histol Histopathol. 1997 Jul;12(3):595-601
[
9225139.001
]
[Cites]
Arch Dermatol. 1998 Jun;134(6):751
[
9645650.001
]
[Cites]
Hum Pathol. 1998 Nov;29(11):1285-9
[
9824108.001
]
[Cites]
J Cutan Pathol. 2005 Jan;32(1):21-7
[
15660651.001
]
[Cites]
J Mol Diagn. 2005 Feb;7(1):17-27
[
15681470.001
]
[Cites]
J Clin Pathol. 2005 Jun;58(6):626-8
[
15917415.001
]
(PMID = 18628086.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Other-IDs]
NLM/ NIHMS125501; NLM/ PMC2718775
35.
Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP:
Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.
J Virol
; 2010 Apr;84(8):3898-908
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--
associated
Herpesvirus
Lymphomas
.
The role of p53 in primary effusion
lymphoma
(PEL) is complicated.
The latency-
associated
nuclear antigen (LANA) of Kaposi's sarcoma-
associated
herpesvirus (KSHV) binds p53.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Med. 2003 Mar;9(3):300-6
[
12592400.001
]
[Cites]
J Virol. 2003 Jun;77(12):7093-100
[
12768028.001
]
[Cites]
Cancer Cell. 2003 Nov;4(5):371-81
[
14667504.001
]
[Cites]
Science. 2004 Feb 6;303(5659):844-8
[
14704432.001
]
[Cites]
Science. 2004 Feb 13;303(5660):1010-4
[
14963330.001
]
[Cites]
Virology. 2004 Feb 20;319(2):225-36
[
14980483.001
]
[Cites]
J Biol Chem. 2004 Apr 16;279(16):16822-31
[
14742422.001
]
[Cites]
J Virol. 2004 Sep;78(18):10074-85
[
15331740.001
]
[Cites]
J Virol. 2004 Oct;78(19):10336-47
[
15367600.001
]
[Cites]
J Virol. 2004 Oct;78(19):10348-59
[
15367601.001
]
[Cites]
J Virol. 2004 Oct;78(20):11121-9
[
15452232.001
]
[Cites]
J Virol. 2004 Nov;78(22):12566-75
[
15507644.001
]
[Cites]
Nature. 1979 Mar 15;278(5701):261-3
[
218111.001
]
[Cites]
Cell. 1979 May;17(1):43-52
[
222475.001
]
[Cites]
Nucleic Acids Res. 1983 Mar 11;11(5):1475-89
[
6828386.001
]
[Cites]
Cell. 1983 Nov;35(1):79-87
[
6313230.001
]
[Cites]
Nature. 1987 Oct 1-7;329(6138):456-8
[
3309672.001
]
[Cites]
Nature. 1987 Oct 1-7;329(6138):458-60
[
2821401.001
]
[Cites]
Science. 1991 Jul 5;253(5015):49-53
[
1905840.001
]
[Cites]
J Virol. 1991 Oct;65(10):5417-24
[
1895390.001
]
[Cites]
Genes Dev. 1991 Dec;5(12B):2375-85
[
1752433.001
]
[Cites]
Virology. 1992 Mar;187(1):343-7
[
1736539.001
]
[Cites]
Cell. 1992 Jun 26;69(7):1237-45
[
1535557.001
]
[Cites]
Genes Dev. 1992 Oct;6(10):1886-98
[
1398068.001
]
[Cites]
Nature. 1993 Apr 29;362(6423):847-9
[
8479522.001
]
[Cites]
Nat Genet. 1993 May;4(1):42-6
[
8099841.001
]
[Cites]
Genes Dev. 1993 Jul;7(7A):1126-32
[
8319905.001
]
[Cites]
FASEB J. 1993 Jul;7(10):951-6
[
8344493.001
]
[Cites]
J Virol. 1994 May;68(5):2869-78
[
8151757.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407-11
[
7753819.001
]
[Cites]
Blood. 1996 Jul 15;88(2):645-56
[
8695812.001
]
[Cites]
EMBO J. 1996 Oct 1;15(19):5349-57
[
8895579.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26
[
8898666.001
]
[Cites]
Science. 1996 Nov 8;274(5289):948-53
[
8875929.001
]
[Cites]
Nature. 1997 May 15;387(6630):296-9
[
9153395.001
]
[Cites]
Nature. 1997 May 15;387(6630):299-303
[
9153396.001
]
[Cites]
J Virol. 1997 Aug;71(8):5915-21
[
9223481.001
]
[Cites]
J Virol. 1999 Dec;73(12):9789-95
[
10559289.001
]
[Cites]
J Clin Invest. 1997 Nov 15;100(10):2606-10
[
9366576.001
]
[Cites]
Oncogene. 1998 Mar;16(11):1429-41
[
9525742.001
]
[Cites]
J Virol. 1998 Jun;72(6):5182-8
[
9573290.001
]
[Cites]
J Virol. 1998 Oct;72(10):8143-9
[
9733855.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3077-80
[
10077639.001
]
[Cites]
J Hum Virol. 1997 Nov-Dec;1(1):19-29
[
10195227.001
]
[Cites]
FEBS Lett. 1999 Mar 19;447(1):5-9
[
10218570.001
]
[Cites]
Science. 1999 Apr 23;284(5414):641-4
[
10213686.001
]
[Cites]
J Virol. 1999 Jun;73(6):5149-55
[
10233979.001
]
[Cites]
J Virol. 2004 Dec;78(24):14033-8
[
15564510.001
]
[Cites]
J Biol Chem. 2005 Feb 4;280(5):3862-74
[
15525642.001
]
[Cites]
J Virol. 2005 Mar;79(6):3468-78
[
15731241.001
]
[Cites]
Blood. 2005 Mar 15;105(6):2510-8
[
15572586.001
]
[Cites]
Oncogene. 2005 Apr 18;24(17):2899-908
[
15838523.001
]
[Cites]
J Virol. 2005 Jun;79(12):7453-65
[
15919901.001
]
[Cites]
J Virol. 2005 Nov;79(21):13618-29
[
16227282.001
]
[Cites]
J Virol. 2005 Nov;79(21):13829-36
[
16227305.001
]
[Cites]
J Virol. 2006 Jan;80(2):697-709
[
16378973.001
]
[Cites]
Science. 2006 Feb 10;311(5762):856-61
[
16469929.001
]
[Cites]
J Virol. 2006 Mar;80(5):2243-56
[
16474132.001
]
[Cites]
J Clin Invest. 2006 Mar;116(3):735-42
[
16498502.001
]
[Cites]
Cancer Res. 2006 Mar 15;66(6):3169-76
[
16540668.001
]
[Cites]
Blood. 2006 May 15;107(10):4122-9
[
16439677.001
]
[Cites]
J Virol. 2006 Jun;80(11):5273-82
[
16699007.001
]
[Cites]
J Clin Invest. 2006 Jul;116(7):1963-73
[
16794734.001
]
[Cites]
J Virol. 2006 Sep;80(18):9017-30
[
16940514.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14554-9
[
16983096.001
]
[Cites]
J Virol. 2006 Nov;80(21):10772-86
[
16928766.001
]
[Cites]
PLoS Pathog. 2006 Oct;2(10):e116
[
17069461.001
]
[Cites]
Virology. 2007 Jan 20;357(2):149-57
[
16979209.001
]
[Cites]
J Virol. 2007 Feb;81(4):1912-22
[
17121789.001
]
[Cites]
J Virol. 2007 Apr;81(8):4348-56
[
17287261.001
]
[Cites]
J Clin Invest. 2007 Apr;117(4):1019-28
[
17364023.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12365-70
[
17640893.001
]
[Cites]
Curr Opin Oncol. 2007 Sep;19(5):452-7
[
17762570.001
]
[Cites]
Blood. 2008 Oct 1;112(7):2886-95
[
18633130.001
]
[Cites]
Blood. 2008 Nov 1;112(9):3827-34
[
18682598.001
]
[Cites]
Virology. 1999 Nov 25;264(2):254-64
[
10562490.001
]
[Cites]
J Gen Virol. 1999 Nov;80 ( Pt 11):2889-900
[
10580050.001
]
[Cites]
J Exp Med. 1999 Dec 20;190(12):1857-68
[
10601360.001
]
[Cites]
Nature. 1999 Dec 23-30;402(6764):889-94
[
10622254.001
]
[Cites]
Mol Cell Biol. 2000 Feb;20(3):1001-7
[
10629057.001
]
[Cites]
J Biol Chem. 2000 Mar 24;275(12):8945-51
[
10722742.001
]
[Cites]
Oncogene. 2000 Mar 9;19(11):1473-6
[
10723139.001
]
[Cites]
J Virol. 2000 Sep;74(18):8532-40
[
10954554.001
]
[Cites]
J Biol Chem. 2000 Sep 8;275(36):28039-44
[
10827196.001
]
[Cites]
Nat Cell Biol. 2000 Sep;2(9):563-8
[
10980695.001
]
[Cites]
J Virol. 2000 Oct;74(20):9637-45
[
11000236.001
]
[Cites]
Nat Med. 2000 Oct;6(10):1121-7
[
11017143.001
]
[Cites]
J Gen Virol. 2000 Nov;81(Pt 11):2645-52
[
11038375.001
]
[Cites]
J Virol. 2001 Jan;75(1):458-68
[
11119614.001
]
[Cites]
J Virol. 2001 Feb;75(4):1798-807
[
11160678.001
]
[Cites]
J Virol. 2001 Apr;75(7):3250-8
[
11238851.001
]
[Cites]
J Biol Chem. 2001 Jun 22;276(25):22971-8
[
11313352.001
]
[Cites]
J Virol. 2001 Sep;75(17):7882-92
[
11483733.001
]
[Cites]
J Biol Chem. 2001 Aug 17;276(33):31016-22
[
11425857.001
]
[Cites]
J Virol. 2001 Sep;75(18):8761-71
[
11507221.001
]
[Cites]
J Virol. 2001 Oct;75(19):9446-57
[
11533207.001
]
[Cites]
Cancer. 2001 Dec 15;92(12):3076-84
[
11753987.001
]
[Cites]
J Gen Virol. 2002 Jan;83(Pt 1):179-88
[
11752715.001
]
[Cites]
Hum Mutat. 2002 Jun;19(6):607-14
[
12007217.001
]
[Cites]
J Biol Chem. 2002 Jul 26;277(30):27401-11
[
12015325.001
]
[Cites]
J Virol. 2002 Nov;76(22):11596-604
[
12388720.001
]
[Cites]
J Virol. 2002 Dec;76(24):12917-24
[
12438617.001
]
(PMID = 20130056.001).
[ISSN]
1098-5514
[Journal-full-title]
Journal of virology
[ISO-abbreviation]
J. Virol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / T32 CA009156; United States / NCI NIH HHS / CA / CA009156; United States / NCI NIH HHS / CA / CA109232-01; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NCI NIH HHS / CA / CA109232-04
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / latency-associated nuclear antigen
[Other-IDs]
NLM/ PMC2849491
36.
Osorio S G, Montenegro U C:
[Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review].
Rev Chilena Infectol
; 2007 Apr;24(2):117-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Lymphomas
and
HIV
infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review].
[Transliterated title]
Linfomas asociados a infección por virus de inmunodeficiencia humana
en
un complejo hospitalario de la Región Metropolitana, Chile: 1990-2002. Reporte de 14 casos y revisión.
The association of
HIV
infection and
lymphoma
in patients attending at the South Health Metropolitan Reference Centre is presented.
RESULTS: 14 cases were detected, 10 non Hodgkin
lymphoma
patients (7 with high malignancy and 50% in stages III-IVB) and 4 with Hodgkin
lymphoma
(3 with mixed cellularity, 2 in stage IVB).
Ten patients were classified under stage C3 of
AIDS
CDC criteria, the mean CD4 count was 139 cells/mm3 and mean CV was 5,32 log.
Eighty six percent of patients presented with unique or multiples lymphonodes, with predominance of advanced
lymphoma
stage.
Conventional CHOP chemotherapy was the treatment for high risk and extended non Hodgkin
lymphomas
and for extended Hodgkin
lymphomas
the ABVD protocol was administered.
Global mortality in this series was 71%, attributable to tumor
disease
per se or to sepsis.
Four patients survived (18 to 50 months) in complete remission, 2 non Hodgkin
lymphomas
and 2 Hodgkin
lymphomas
.
The low incidence of
lymphoma
and
AIDS
association and the high frequency of
lymphomas
with localized or generalized lymphonodes in this series are remarkable.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
.
Lymphoma
, Non-Hodgkin
[MeSH-minor]
Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Chile / epidemiology. Female. Hodgkin
Disease
/ diagnosis. Hodgkin
Disease
/ drug therapy. Hodgkin
Disease
/ epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Viral Load
Genetic Alliance.
consumer health - HIV
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17453069.001).
[ISSN]
0716-1018
[Journal-full-title]
Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
[ISO-abbreviation]
Rev Chilena Infectol
[Language]
spa
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Chile
[Number-of-references]
30
37.
Benicchi T, Ghidini C, Re A, Cattaneo C, Casari S, Caimi L, Rossi G, Imberti L:
T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma.
Transplantation
; 2005 Sep 15;80(5):673-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
T-cell immune reconstitution after hematopoietic stem cell transplantation for
HIV
-
associated
lymphoma
.
BACKGROUND: One of the major concern for high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) for
HIV
-
associated
lymphoma
is that posttransplant immunosuppression might worsen immune defects of
HIV
individuals.
Since the introduction of highly active antiretroviral therapy has made HSCT possible also in these patients, we analyzed whether the immune system already compromised by
HIV
infection might support an efficient T-cell recovery after HSCT.
METHODS: The kinetics and the extent of T-cell reconstitution were investigated before and after HSCT in four patients with
HIV
-
related lymphoma
(one with Hodgkin'
s Disease
and three with non-Hodgkin'
s lymphoma
) by measuring the thymic output, the level of IL-7 and the heterogeneity of T-cell repertoire.
CONCLUSIONS: High-dose therapy and HSCT in
HIV
patients under highly active antiretroviral therapy does not worsen the immune defects.
[MeSH-major]
CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Hematopoietic Stem Cell Transplantation.
Lymphoma
,
AIDS
-
Related
/ immunology.
Lymphoma
,
AIDS
-
Related
/ therapy
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - HIV
.
HIV InSite.
treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Transplantation. 2006 Jun 27;81(12):1752-3
[
16794547.001
]
(PMID = 16177644.001).
[ISSN]
0041-1337
[Journal-full-title]
Transplantation
[ISO-abbreviation]
Transplantation
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, Antigen, T-Cell, alpha-beta
38.
Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups:
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Br J Haematol
; 2008 Feb;140(4):411-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-
associated
diffuse large B-cell
lymphoma
: results of a phase II trial.
Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell
lymphoma
(DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (
HIV
)-
related lymphoma
.
This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with
HIV
-
related
DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact.
Complete response was achieved in 55 (69%) patients, with an estimated 3-year
disease
-free survival of 77% and 3-year overall survival of 56%.
In
HIV
-
related
DLBCL R-CHOP is feasible, safe and effective.
The prognosis depends on
lymphoma
-
related
parameters and on the response to HAART.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / adverse effects.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
, Large B-Cell, Diffuse / drug therapy
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18162120.001).
[ISSN]
1365-2141
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
39.
DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA:
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.
Sci Transl Med
; 2010 Jun 16;2(36):36ra43
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
RNA-based gene therapy for
HIV
with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for
AIDS
-
related lymphoma
.
AIDS
patients who develop
lymphoma
are often treated with transplanted hematopoietic progenitor cells.
As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34(+)) hematopoietic progenitor cells expressing three RNA-based anti-
HIV
moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme).
In vitro estimates of successful expression of the anti-
HIV
moieties were initially as high as 22% but declined to approximately 1% over 4 weeks of culture.
Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no unexpected infusion-
related
toxicities.
These results support the development of an RNA-based cell therapy platform for
HIV
.
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Genes and Gene Therapy
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Biotechnol. 2007 Dec;25(12):1444-54
[
18066041.001
]
[Cites]
Mol Ther. 2007 Jun;15(6):1182-8
[
17406343.001
]
[Cites]
Hum Gene Ther. 2008 Jun;19(6):622-34
[
18533892.001
]
[Cites]
J Gene Med. 2008 Oct;10(10):1059-70
[
18642399.001
]
[Cites]
Gene Ther. 2008 Dec;15(23):1536-49
[
18800151.001
]
[Cites]
N Engl J Med. 2009 Feb 12;360(7):692-8
[
19213682.001
]
[Cites]
Nat Med. 2009 Mar;15(3):285-92
[
19219022.001
]
[Cites]
Science. 2009 Mar 6;323(5919):1304-7
[
19265012.001
]
[Cites]
Mol Ther. 2009 May;17(5):844-50
[
19259065.001
]
[Cites]
Science. 2009 Nov 6;326(5954):818-23
[
19892975.001
]
[Cites]
Gene Ther. 2010 Mar;17(3):389-99
[
19865182.001
]
[Cites]
Blood. 2002 Jan 15;99(2):698-701
[
11781257.001
]
[Cites]
Mol Ther. 2002 Apr;5(4):479-84
[
11945076.001
]
[Cites]
Gene Ther. 2002 Aug;9(16):1055-64
[
12140733.001
]
[Cites]
Gene Ther. 2002 Dec;9(24):1730-4
[
12457288.001
]
[Cites]
Mol Ther. 2003 Mar;7(3):325-33
[
12668128.001
]
[Cites]
Mol Ther. 2003 Jul;8(1):62-71
[
12842429.001
]
[Cites]
Mol Ther. 2003 Aug;8(2):196-206
[
12907142.001
]
[Cites]
Blood. 2004 Feb 1;103(3):796-803
[
12920024.001
]
[Cites]
Hum Gene Ther. 2004 Mar;15(3):251-62
[
15018734.001
]
[Cites]
J Gene Med. 2004 Mar;6(3):268-77
[
15026988.001
]
[Cites]
Nature. 1988 Sep 29;335(6189):395-6
[
3166513.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9870-4
[
1409715.001
]
[Cites]
N Engl J Med. 1993 Sep 30;329(14):987-94
[
8141877.001
]
[Cites]
Blood. 1994 Jul 15;84(2):421-32
[
7517715.001
]
[Cites]
Science. 1996 Apr 12;272(5259):263-7
[
8602510.001
]
[Cites]
Blood. 1996 Jun 1;87(11):4618-28
[
8639830.001
]
[Cites]
Gene Ther. 1996 Aug;3(8):717-24
[
8854097.001
]
[Cites]
J Virol. 1997 Jun;71(6):4707-16
[
9151864.001
]
[Cites]
J Virol. 1999 May;73(5):3649-60
[
10196257.001
]
[Cites]
Blood. 2005 Jan 15;105(2):874-8
[
15388574.001
]
[Cites]
Clin Immunol. 2005 Apr;115(1):26-32
[
15870017.001
]
[Cites]
Mol Ther. 2005 Jul;12(1):77-86
[
15963923.001
]
[Cites]
Mol Ther. 2005 Oct;12(4):697-706
[
16039909.001
]
[Cites]
Mol Ther. 2005 Nov;12(5):900-9
[
16115802.001
]
[Cites]
Mol Ther. 2006 Feb;13(2):366-73
[
16325473.001
]
[Cites]
Blood. 2006 Mar 1;107(5):1751-60
[
16269617.001
]
[Cites]
Clin Infect Dis. 2006 Apr 1;42(7):1003-10
[
16511767.001
]
[Cites]
Mol Ther. 2006 Oct;14(4):494-504
[
16844419.001
]
[Cites]
Blood. 2006 Nov 15;108(10):3305-12
[
16857988.001
]
[Cites]
Mol Ther. 2007 May;15(5):1024-33
[
17356541.001
]
[Cites]
Methods Mol Biol. 2008;434:99-112
[
18470641.001
]
(PMID = 20555022.001).
[ISSN]
1946-6242
[Journal-full-title]
Science translational medicine
[ISO-abbreviation]
Sci Transl Med
[Language]
ENG
[Grant]
United States / NCRR NIH HHS / RR / M01 RR000043-49; United States / NIAID NIH HHS / AI / AI61839; United States / NHLBI NIH HHS / HL / R01 HL074704; United States / NIAID NIH HHS / AI / AI42552; United States / NCI NIH HHS / CA / CA107399-05; United States / NIAID NIH HHS / AI / P01 AI061839-04; United States / NIAID NIH HHS / AI / R37 AI029329; United States / NCRR NIH HHS / RR / RR000043-49; United States / NIAID NIH HHS / AI / AI061839-04; United States / NHLBI NIH HHS / HL / HL07470; United States / NCI NIH HHS / CA / P50 CA107399-05; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCRR NIH HHS / RR / RR025083-01; United States / NCI NIH HHS / CA / P30 CA33572-26; United States / NCRR NIH HHS / RR / S10 RR025083-01; United States / NIAID NIH HHS / AI / AI042552-11; United States / NCI NIH HHS / CA / P30 CA033572-29; United States / NCRR NIH HHS / RR / M01 RR000043; United States / NHLBI NIH HHS / HL / R01 HL074704-07; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NCI NIH HHS / CA / P30 CA033572; United States / NIAID NIH HHS / AI / R01 AI042552; United States / NCRR NIH HHS / RR / S10 RR025083; United States / NIAID NIH HHS / AI / R01 AI042552-11; United States / NCRR NIH HHS / RR / S10RR025083-01; United States / NHLBI NIH HHS / HL / HL074704-07; United States / NCI NIH HHS / CA / P50 CA107399
[Publication-type]
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
63231-63-0 / RNA
[Other-IDs]
NLM/ NIHMS305014; NLM/ PMC3130552
40.
Cobo F, Talavera P, Busquier H, Concha A:
CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS.
Neuropathology
; 2007 Aug;27(4):396-402
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CNK/T-cell brain
lymphoma
associated
with Epstein-Barr virus in a patient with
AIDS
.
We report a case of extranodal NK/T-cell
lymphoma
, nasal type, with exclusive cerebral localization in a patient with
AIDS
.
A diagnosis of extranodal NK/T-cell
lymphoma
was made and the patient died a few days later.
This case represents a very rare example of NK/T-cell
lymphoma
of the brain in a patient with
AIDS
.
The diagnosis of this kind of
lymphomas
requires a multimodality approach correlating clinical, morphological, immunophenotypic and molecular data.
[MeSH-major]
Acquired Immunodeficiency Syndrome / complications. Epstein-Barr Virus Infections / complications. Killer Cells, Natural / pathology.
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
, T-Cell / pathology
[MeSH-minor]
AIDS
-
Related
Opportunistic Infections / pathology. Adult. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Brain Neoplasms / virology. Diagnosis, Differential. Gene Rearrangement, T-Lymphocyte. Hepatitis C / complications. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Polymerase Chain Reaction
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17899696.001).
[ISSN]
0919-6544
[Journal-full-title]
Neuropathology : official journal of the Japanese Society of Neuropathology
[ISO-abbreviation]
Neuropathology
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Australia
41.
Pantanowitz L, Wu Z, Dezube BJ, Pihan G:
Extracavitary primary effusion lymphoma of the anorectum.
Clin Lymphoma Myeloma
; 2005 Sep;6(2):149-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extracavitary primary effusion
lymphoma
of the anorectum.
We report a case of an extracavitary primary effusion
lymphoma
occurring in the anorectum of a patient with advanced acquired immune deficiency syndrome.
The morphology, null cell immunophenotype, and acquisition of plasma cell markers in this case are typical of the so-called solid variant of primary effusion
lymphoma
.
Lymphoma
cells in this case were shown to be co-infected with human herpesvirus-8 and Epstein-Barr virus.
The purpose of this report is to add another case to the emerging literature regarding the heterogeneous category of extraserous human herpesvirus-8-
associated lymphomas
.
[MeSH-major]
Epstein-Barr Virus Infections / pathology.
HIV
Infections / pathology. Herpesvirus 4, Human. Herpesvirus 8, Human.
Lymphoma
,
AIDS
-
Related
/ pathology. Rectal Neoplasms / pathology
Genetic Alliance.
consumer health - Primary effusion lymphoma
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16231856.001).
[ISSN]
1557-9190
[Journal-full-title]
Clinical lymphoma & myeloma
[ISO-abbreviation]
Clin Lymphoma Myeloma
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
42.
Sarek G, Järviluoma A, Ojala PM:
KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas.
Blood
; 2006 Jan 15;107(2):725-32
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion
lymphomas
.
Kaposi sarcoma herpesvirus (KSHV) infection is consistently
associated
with primary effusion
lymphomas
(PELs) that are non-Hodgkin
lymphomas
of B-cell origin.
Here we demonstrate that v-cyclin together with its kinase partner CDK6 phosphorylates the
associated
p27(KIP1) in PEL cells, which represent a biologically relevant model system for KSHV pathobiology.
[MeSH-major]
Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p27 / antagonists & inhibitors. Herpesvirus 8, Human / metabolism.
Lymphoma
,
AIDS
-
Related
/ metabolism. Sarcoma, Kaposi / metabolism. Viral Proteins / pharmacology
MedlinePlus Health Information.
consumer health - Kaposi's Sarcoma
.
Hazardous Substances Data Bank.
L-SERINE
.
Hazardous Substances Data Bank.
L-Threonine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16160006.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cyclins; 0 / HHV8-Vcyc protein, Human herpesvirus 8; 0 / Viral Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
43.
Xu D, Zhao L, Del Valle L, Miklossy J, Zhang L:
Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes.
J Virol
; 2008 Jul;82(13):6251-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Epstein-Barr virus (EBV) infection is
associated
with many human malignancies.
We find that high levels of IRF-4 are
associated
with EBV transformation of human primary B cells in vitro and with EBV type III latency in which LMP-1 is expressed.
Finally, IRF-4 is expressed in significant numbers of specimens of primary central nervous system (CNS)
lymphomas
(12/27 [44.4%]), an EBV-
associated
malignancy.
The association between the expression levels of LMP-1 and IRF-4 is statistically significant (P = 0.011) in these CNS
lymphomas
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
HGNC: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Virol. 2000 Feb;74(3):1061-8
[
10627515.001
]
[Cites]
J Virol. 2000 Apr;74(7):3388-98
[
10708456.001
]
[Cites]
J Exp Med. 2000 Apr 17;191(8):1281-92
[
10770796.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6055-60
[
10811897.001
]
[Cites]
AIDS Read. 2000 Aug;10(8):486-91
[
10967810.001
]
[Cites]
J Clin Oncol. 2000 Oct 1;18(19):3323-4
[
11013270.001
]
[Cites]
J Virol. 2001 Jan;75(1):341-50
[
11119603.001
]
[Cites]
Annu Rev Immunol. 2001;19:623-55
[
11244049.001
]
[Cites]
J Virol. 2001 Dec;75(24):12393-401
[
11711629.001
]
[Cites]
J Gen Virol. 2001 Dec;82(Pt 12):3057-66
[
11714984.001
]
[Cites]
J Interferon Cytokine Res. 2002 Jan;22(1):121-33
[
11846983.001
]
[Cites]
J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
[
11895036.001
]
[Cites]
Oncogene. 2002 Apr 25;21(18):2914-8
[
11973653.001
]
[Cites]
J Immunol. 2002 Sep 15;169(6):3120-30
[
12218129.001
]
[Cites]
J Virol. 2002 Oct;76(20):10427-36
[
12239319.001
]
[Cites]
Genes Dev. 2003 Jul 15;17(14):1703-8
[
12832394.001
]
[Cites]
Nat Cell Biol. 2003 Sep;5(9):834-9
[
12942087.001
]
[Cites]
Cancer Res. 2003 Oct 1;63(19):6424-31
[
14559832.001
]
[Cites]
J Virol. 2004 Apr;78(8):4108-19
[
15047827.001
]
[Cites]
Oncogene. 2004 Apr 12;23(16):2774-84
[
15077141.001
]
[Cites]
Oncogene. 2004 Apr 12;23(16):2797-808
[
15077143.001
]
[Cites]
Oncogene. 2004 Apr 12;23(16):2950-66
[
15077156.001
]
[Cites]
J Natl Cancer Inst. 2004 May 5;96(9):662-72
[
15126603.001
]
[Cites]
J Virol Methods. 2004 Jun 1;118(1):9-13
[
15158063.001
]
[Cites]
Virology. 2004 May 20;323(1):141-52
[
15165826.001
]
[Cites]
J Exp Med. 2004 Jul 19;200(2):247-53
[
15249594.001
]
[Cites]
J Biol Chem. 2004 Oct 29;279(44):46335-42
[
15322136.001
]
[Cites]
Int J Cancer. 1977 Jan;19(1):27-33
[
188769.001
]
[Cites]
Arch Pathol Lab Med. 1997 Dec;121(12):1287-91
[
9431321.001
]
[Cites]
EMBO J. 1998 Mar 16;17(6):1700-9
[
9501091.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3621-6
[
9520415.001
]
[Cites]
Biochimie. 1998 Aug-Sep;80(8-9):651-8
[
9865487.001
]
[Cites]
Mol Cell Biol. 1999 Apr;19(4):3216-23
[
10082588.001
]
[Cites]
Biochem Biophys Res Commun. 1999 Jul 5;260(2):329-31
[
10403770.001
]
[Cites]
J Virol. 2004 Dec;78(23):12987-95
[
15542650.001
]
[Cites]
J Immunol. 2005 Mar 1;174(5):2573-81
[
15728463.001
]
[Cites]
Cancer Res. 2005 Aug 15;65(16):7403-12
[
16103093.001
]
[Cites]
J Biol Chem. 2006 Apr 7;281(14):9163-9
[
16469740.001
]
[Cites]
Expert Rev Anticancer Ther. 2006 May;6(5):775-84
[
16759167.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3402-7
[
17360658.001
]
[Cites]
J Virol. 2007 Jun;81(11):6068-78
[
17376914.001
]
[Cites]
J Virol. 2007 Sep;81(18):9748-58
[
17609264.001
]
[Cites]
J Virol. 1990 May;64(5):2126-34
[
2157875.001
]
[Cites]
Proc Natl Acad Sci U S A. 1983 Apr;80(7):1987-91
[
6300885.001
]
[Cites]
Cell. 1985 Dec;43(3 Pt 2):831-40
[
3000618.001
]
[Cites]
Virology. 1985 Mar;141(2):221-34
[
3002016.001
]
[Cites]
J Virol. 1986 Apr;58(1):233-7
[
3005654.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Nov;84(22):8060-4
[
2825176.001
]
[Cites]
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9558-62
[
2556717.001
]
[Cites]
EMBO J. 1990 Jan;9(1):147-52
[
2153074.001
]
[Cites]
J Virol. 1990 Apr;64(4):1855-8
[
2157069.001
]
[Cites]
J Virol. 1990 May;64(5):2309-18
[
2157887.001
]
[Cites]
J Virol. 1990 Jul;64(7):3407-16
[
2352328.001
]
[Cites]
J Virol. 1991 Jul;65(7):3958-63
[
1645805.001
]
[Cites]
Lancet. 1991 Oct 19;338(8773):969-73
[
1681341.001
]
[Cites]
J Virol. 1991 Dec;65(12):6765-71
[
1658373.001
]
[Cites]
Mol Cell Biol. 1992 Nov;12(11):4930-6
[
1406670.001
]
[Cites]
Cancer Res. 1993 Sep 1;53(17):3976-85
[
8358726.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4
[
8415670.001
]
[Cites]
Cell. 1993 Nov 19;75(4):641-52
[
8242740.001
]
[Cites]
J Virol. 1995 Jul;69(7):4390-8
[
7769701.001
]
[Cites]
Genes Dev. 1995 Jun 1;9(11):1377-87
[
7797077.001
]
[Cites]
J Cancer Res Clin Oncol. 1995;121(9-10):516-20
[
7559730.001
]
[Cites]
J Virol. 1996 Jan;70(1):623-7
[
8523583.001
]
[Cites]
Mol Cell Biol. 1996 Apr;16(4):1283-94
[
8657101.001
]
[Cites]
Clin Neuropathol. 1996 Mar-Apr;15(2):79-86
[
8925601.001
]
[Cites]
Biochem Biophys Res Commun. 1996 Dec 24;229(3):838-44
[
8954981.001
]
[Cites]
J Virol. 1996 Dec;70(12):8653-9
[
8970991.001
]
[Cites]
Science. 1997 Jan 24;275(5299):540-3
[
8999800.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52
[
9037073.001
]
[Cites]
Mol Cell Biol. 1997 Oct;17(10):5748-57
[
9315633.001
]
[Cites]
Nat Genet. 1997 Oct;17(2):226-30
[
9326949.001
]
[Cites]
EMBO J. 1997 Oct 15;16(20):6131-40
[
9359753.001
]
[Cites]
Oncogene. 1997 Oct 16;15(16):1979-85
[
9365244.001
]
[Cites]
Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80
[
10591086.001
]
[Cites]
Oncogene. 1999 Nov 22;18(49):6959-64
[
10602470.001
]
(PMID = 18417578.001).
[ISSN]
1098-5514
[Journal-full-title]
Journal of virology
[ISO-abbreviation]
J. Virol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA108951; United States / NCRR NIH HHS / RR / RR15635; United States / NIAID NIH HHS / AI / R21 AI059132; United States / NCRR NIH HHS / RR / P20 RR015635; United States / NCI NIH HHS / CA / CA108951; United States / NIAID NIH HHS / AI / AI59132
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA Primers; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Interferon Regulatory Factors; 0 / Viral Matrix Proteins; 0 / interferon regulatory factor-4
[Other-IDs]
NLM/ PMC2447047
44.
Singh J, Malani AK, Ganguly S, Kambhampati S:
HAART- and AIDS-related lymphomas.
Blood
; 2006 Nov 15;108(10):3621; author reply 3621-2
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HAART- and
AIDS
-
related
lymphomas
.
[MeSH-major]
Antiretroviral Therapy, Highly Active.
Lymphoma
,
AIDS
-
Related
/ drug therapy
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Blood. 2006 May 15;107(10):3832-40
[
16410446.001
]
(PMID = 17085718.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
45.
Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, De Paoli A, Dal Maso L, Franceschi S, Rezza G:
Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study.
J Acquir Immune Defic Syndr
; 2009 Sep 1;52(1):99-105
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Survival after
AIDS
diagnosis in Italy, 1999-2006: a population-based study.
OBJECTIVES: To provide survival estimates of Italian people with
AIDS
(PWA) in the highly active antiretroviral therapy era and to identify prognostic factors at diagnosis and illnesses present at death.
Non-Hodgkin
lymphoma
at
AIDS
diagnosis was the strongest negative prognostic factor, particularly in the first 12 months after
AIDS
(hazard ratio = 9.2, for primary brain
lymphoma
).
At death, non-
AIDS
-defining illnesses increased from 38.4% in 1999 to 56.9% in 2006, with non-
AIDS
-defining cancers rising from 3.7% to 8.7%.
CONCLUSIONS: Our study documented the prolonged survival of Italian PWA, the strong impact of non-Hodgkin
lymphoma
on mortality, and the increasing frequency of non-
AIDS
-defining illnesses at death.
[MeSH-minor]
Adult. Antiretroviral Therapy, Highly Active / mortality. Female. Humans. Italy / epidemiology. Longitudinal Studies.
Lymphoma
, Non-Hodgkin / etiology.
Lymphoma
, Non-Hodgkin / mortality. Male. Middle Aged. Survival Analysis
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19448558.001).
[ISSN]
1525-4135
[Journal-full-title]
Journal of acquired immune deficiency syndromes (1999)
[ISO-abbreviation]
J. Acquir. Immune Defic. Syndr.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
46.
D'Souza GA, Sunad R, Rajagopalan N, Ananthamurthy A, Murthy KR, Babu K:
NK/T-cell lymphoma in AIDS.
J Assoc Physicians India
; 2006 Nov;54:890-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
NK/T-cell
lymphoma
in
AIDS
.
A 42-year-old man diagnosed to be
HIV
positive and on highly active antiretroviral treatment (HAART), presented with double vision and gradual drooping of the left eyelid.
Further workup showed the mass to be an NK/T cell
lymphoma
.
[MeSH-major]
HIV
Infections / complications.
Lymphoma
,
AIDS
-
Related
/ diagnosis.
Lymphoma
, T-Cell / diagnosis. Nose Neoplasms / diagnosis
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17249261.001).
[ISSN]
0004-5772
[Journal-full-title]
The Journal of the Association of Physicians of India
[ISO-abbreviation]
J Assoc Physicians India
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
India
47.
Ferrazzo KL, Mesquita RA, Aburad AT, Nunes FD, de Sousa SO:
EBV detection in HIV-related oral plasmablastic lymphoma.
Oral Dis
; 2007 Nov;13(6):564-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
EBV detection in
HIV
-
related
oral plasmablastic
lymphoma
.
OBJECTIVES: Plasmablastic
lymphoma
(PBL) of the oral cavity is an aggressive neoplasm derived from B cell, considered to be the second more common among human immunodeficiency virus (
HIV
)-
associated
malignancies.
As Epstein-Barr virus (EBV) infection has been
associated
with this neoplasm, the aim of the present study was to assess the presence of EBV in 11 cases of oral
HIV
-
related
PBL and investigate the controversial issue of the presence of Human herpesvirus-8 (HHV-8) in these tumors.
METHODS: DNA was extracted from nine cases of
HIV
-
associated
oral
lymphomas
, diagnosed as PBL, and genomic material was amplified by polymerase chain reaction to verify the presence of EBV.
CONCLUSION: The presence of EBV in all cases studied favors a direct role of this virus in the development of
HIV
-
related
PBL, and this
finding
could be considered when dealing with
HIV
patients.
[MeSH-major]
DNA, Viral / analysis. Herpesvirus 4, Human / isolation & purification.
Lymphoma
,
AIDS
-
Related
/ virology. Mouth Neoplasms / virology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17944673.001).
[ISSN]
1354-523X
[Journal-full-title]
Oral diseases
[ISO-abbreviation]
Oral Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / DNA, Viral
48.
Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL:
Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm.
Am J Surg Pathol
; 2005 Dec;29(12):1633-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasmablastic
lymphoma
in
HIV
-positive patients: an aggressive Epstein-Barr virus-
associated
extramedullary plasmacytic neoplasm.
AIDS
-
associated
aggressive B-cell
lymphomas
often have plasmacytoid features.
Plasma cell neoplasms in
HIV
patients were commonly described to have atypical morphology and an aggressive clinical course in the literature.
We reviewed 14 cases of neoplasms with marked plasmacytic differentiation in
HIV
-positive patients to determine their clinicopathologic features.
The 14th patient who had a nodal
disease
with more undifferentiated morphology and expression of the HHV8 LNA protein was alive without
disease
at last follow-up (>72 months), probably representing a novel HHV8(+)
lymphoma
.
We conclude that most plasmacytic tumors in
HIV
-positive individuals are extramedullary, clinically aggressive EBV(+) tumors identical to plasmablastic
lymphoma
that does not have the clinical features of plasma cell myeloma.
[MeSH-major]
HIV
Seropositivity. Herpesvirus 4, Human / genetics.
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
,
AIDS
-
Related
/ virology. Multiple Myeloma / pathology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Multiple Myeloma
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Cardiac Cardiac Manifestations of HIV
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16327436.001).
[ISSN]
0147-5185
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / T32CA-09216 D20
[Publication-type]
Case Reports; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / DNA, Viral; EC 3.1.3.48 / Antigens, CD45
49.
Kang KM, Song DS, Park JM, Jung CK, Hong YS, Kang MW, Park CW:
Four cases of non-Hodgkin's lymphoma in AIDS patients.
Korean J Intern Med
; 2006 Dec;21(4):266-74
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Four cases of non-Hodgkin'
s lymphoma
in
AIDS
patients.
The incidence of opportunistic infection has decreased since the introduction of highly active antiretroviral therapy, so
lymphoma
is now far and away the most lethal complication of acquired immunodeficiency syndrome.
We have experienced four cases of NHL in
AIDS
patients.
The first patient was a 37 year old male who presented with left sided hemiplegia due to CNS
lymphoma
.
The second patient was a 40 year old male who was admitted because of jaundice; he was diagnosed as having
lymphoma
that exclusively involved the liver.
The third patient was a 38-year-old male who presented with palpable mass in the left cervical region, which was diagnosed as
lymphoma
.
Above three cases were confirmed as diffuse large B cell
lymphoma
.
The latter case is the first report of NHL involving the chest wall musculature in a Korean
AIDS
patient.
[MeSH-major]
Acquired Immunodeficiency Syndrome / complications.
Lymphoma
, Non-Hodgkin / complications
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30
[
11078759.001
]
[Cites]
Br J Haematol. 2001 Mar;112(4):863-73
[
11298581.001
]
[Cites]
Korean J Intern Med. 2001 Mar;16(1):1-7
[
11417298.001
]
[Cites]
Int J Cancer. 2001 Aug 1;93(3):430-5
[
11433410.001
]
[Cites]
Blood. 2001 Dec 1;98(12):3406-12
[
11719381.001
]
[Cites]
Leuk Lymphoma. 2003 Feb;44(2):349-51
[
12688356.001
]
[Cites]
MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2
[
6265753.001
]
[Cites]
N Engl J Med. 1984 Aug 30;311(9):565-70
[
6611504.001
]
[Cites]
JAMA. 1989 Feb 3;261(5):719-24
[
2536124.001
]
[Cites]
Ann Intern Med. 1990 Aug 15;113(4):276-82
[
1973886.001
]
[Cites]
Lancet. 1991 Apr 6;337(8745):805-9
[
1672911.001
]
[Cites]
N Engl J Med. 1997 Jun 5;336(23):1641-8
[
9171066.001
]
[Cites]
Int J Cancer. 1997 Nov 27;73(5):645-50
[
9398040.001
]
[Cites]
Lancet. 1998 Jun 20;351(9119):1833-9
[
9652666.001
]
[Cites]
Leuk Lymphoma. 1998 Aug;30(5-6):515-24
[
9711914.001
]
[Cites]
Int J Cancer. 1999 Nov 12;83(4):481-5
[
10508483.001
]
[Cites]
CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264
[
16020424.001
]
(PMID = 17249512.001).
[ISSN]
1226-3303
[Journal-full-title]
The Korean journal of internal medicine
[ISO-abbreviation]
Korean J. Intern. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Korea (South)
[Other-IDs]
NLM/ PMC3891035
50.
Trobridge GD, Wu RA, Beard BC, Chiu SY, Muñoz NM, von Laer D, Rossi JJ, Kiem HP:
Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.
PLoS One
; 2009 Nov 02;4(11):e7693
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Protection of stem cell-derived lymphocytes in a primate
AIDS
gene therapy model after in vivo selection.
BACKGROUND: There is currently no effective
AIDS
vaccine, emphasizing the importance of developing alternative therapies.
Recently, a patient was successfully transplanted with allogeneic, naturally resistant CCR5-negative (CCR5Delta32) cells, setting the stage for transplantation of naturally resistant, or genetically modified stem cells as a viable therapy for
AIDS
.
Hematopoietic stem cell (HSC) gene therapy using vectors that express various anti-
HIV
transgenes has also been attempted in clinical trials, but inefficient gene transfer in these studies has severely limited the potential of this approach.
Here we evaluated HSC gene transfer of an anti-
HIV
vector in the pigtailed macaque (Macaca nemestrina) model, which closely models human transplantation.
METHODS AND FINDINGS: We used lentiviral vectors that inhibited both
HIV
-1 and simian immunodeficiency virus (SIV)/
HIV
-1 (SHIV) chimera virus infection, and also expressed a P140K mutant methylguanine methyltransferase (MGMT) transgene to select gene-modified cells by adding chemotherapy drugs.
The high marking levels allowed us to demonstrate protection from SHIV in lymphocytes derived from gene-modified macaque long-term repopulating cells that expressed an
HIV
-1 fusion inhibitor.
We observed a statistically significant 4-fold increase of gene-modified cells after challenge of lymphocytes from one macaque that received stem cells transduced with an anti-
HIV
vector (p<0.02, Student'
s t
-test), but not in lymphocytes from a macaque that received a control vector.
We also established a competitive repopulation assay in a second macaque for preclinical testing of promising anti-
HIV
vectors.
The vectors we used were
HIV
-based and thus efficiently transduce human cells, and the transgenes we used target
HIV
-1 genes that are also in SHIV, so our findings can be rapidly translated to the clinic.
CONCLUSIONS: Here we demonstrate the ability to select protected HSC-derived lymphocytes in vivo in a clinically relevant nonhuman primate model of
HIV
/SHIV infection.
This approach can now be evaluated in human clinical trials in
AIDS
lymphoma
patients.
In this patient setting, chemotherapy would not only kill malignant cells, but would also increase the number of MGMTP140K-expressing
HIV
-resistant cells.
This approach should allow for high levels of
HIV
-protected cells in
AIDS
patients to evaluate
AIDS
gene therapy.
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - Genes and Gene Therapy
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Stem Cells
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
JAMA. 2002 Jul 10;288(2):222-35
[
12095387.001
]
[Cites]
Gene Ther. 2010 Jan;17(1):37-49
[
19741733.001
]
[Cites]
J Med Primatol. 2002 Aug;31(4-5):237-56
[
12390546.001
]
[Cites]
Science. 2003 Jun 13;300(5626):1749-51
[
12805549.001
]
[Cites]
Science. 2003 Jun 27;300(5628):2036-9
[
12829768.001
]
[Cites]
Nat Rev Drug Discov. 2003 Aug;2(8):624-34
[
12904812.001
]
[Cites]
Mol Ther. 2003 Aug;8(2):196-206
[
12907142.001
]
[Cites]
J Clin Invest. 2003 Nov;112(10):1581-8
[
14617759.001
]
[Cites]
J Virol. 2004 Jan;78(2):568-75
[
14694088.001
]
[Cites]
Hum Gene Ther. 2004 Mar;15(3):251-62
[
15018734.001
]
[Cites]
Curr Gene Ther. 2004 Mar;4(1):15-31
[
15032611.001
]
[Cites]
Blood. 2004 May 15;103(10):3710-6
[
14739227.001
]
[Cites]
Blood. 2004 Jun 1;103(11):4062-9
[
14976042.001
]
[Cites]
J Immunol. 1985 Feb;134(2):971-6
[
3871222.001
]
[Cites]
Immunogenetics. 1985;21(3):235-46
[
3872841.001
]
[Cites]
Hum Gene Ther. 1999 Nov 20;10(17):2769-78
[
10584923.001
]
[Cites]
Microbes Infect. 2000 Feb;2(2):223-9
[
10742694.001
]
[Cites]
AIDS. 1999;13 Suppl A:S113-20
[
10885770.001
]
[Cites]
Hum Gene Ther. 2000 Sep 20;11(14):2025-37
[
11020801.001
]
[Cites]
Ann N Y Acad Sci. 2000 Nov;918:318-29
[
11131719.001
]
[Cites]
J Pharmacol Exp Ther. 2001 May;297(2):524-30
[
11303039.001
]
[Cites]
Hum Gene Ther. 2001 Jun 10;12(9):1013-9
[
11399224.001
]
[Cites]
Mol Ther. 2002 Jan;5(1):33-41
[
11786043.001
]
[Cites]
J Virol. 1992 Apr;66(4):2232-9
[
1548759.001
]
[Cites]
J Virol. 1992 Dec;66(12):7517-21
[
1433527.001
]
[Cites]
Cancer Res. 1994 Dec 1;54(23):6221-7
[
7954470.001
]
[Cites]
J Med Primatol. 1996 Jun;25(3):163-74
[
8892037.001
]
[Cites]
J Virol. 1997 May;71(5):3932-9
[
9094670.001
]
[Cites]
Cancer Res. 1998 May 1;58(9):1936-45
[
9581836.001
]
[Cites]
J Virol. 1998 Nov;72(11):8463-71
[
9765382.001
]
[Cites]
Curr Opin Biotechnol. 1998 Oct;9(5):457-63
[
9821272.001
]
[Cites]
Science. 1999 Jan 29;283(5402):682-6
[
9924027.001
]
[Cites]
Blood. 2005 Feb 1;105(3):997-1002
[
15494421.001
]
[Cites]
Methods Mol Biol. 2005;309:261-72
[
15990406.001
]
[Cites]
Hum Gene Ther. 2005 Dec;16(12):1355-66
[
16390267.001
]
[Cites]
Nature. 2006 May 25;441(7092):537-41
[
16724069.001
]
[Cites]
Nat Biotechnol. 2006 Jun;24(6):687-96
[
16732270.001
]
[Cites]
Hum Gene Ther. 2006 Jun;17(6):577-88
[
16776567.001
]
[Cites]
Mol Ther. 2006 Oct;14(4):494-504
[
16844419.001
]
[Cites]
Retrovirology. 2006;3:76
[
17078891.001
]
[Cites]
Mol Ther. 2007 Jan;15(1):76-85
[
17164778.001
]
[Cites]
Blood. 2007 Jan 1;109(1):65-70
[
16968897.001
]
[Cites]
J Virol. 2007 Mar;81(6):2700-12
[
17182671.001
]
[Cites]
PLoS Pathog. 2007 Apr;3(4):e54
[
17432934.001
]
[Cites]
Hum Gene Ther. 2007 May;18(5):451-6
[
17536975.001
]
[Cites]
Exp Hematol. 2007 Jul;35(7):1132-9
[
17588482.001
]
[Cites]
J Virol. 2007 Nov;81(22):12210-7
[
17804491.001
]
[Cites]
Nat Med. 2007 Dec;13(12):1389-90
[
18064013.001
]
[Cites]
Nat Biotechnol. 2007 Dec;25(12):1444-54
[
18066041.001
]
[Cites]
Blood. 2008 Jun 15;111(12):5537-43
[
18388180.001
]
[Cites]
Gene Ther. 2008 Dec;15(23):1536-49
[
18800151.001
]
[Cites]
N Engl J Med. 2009 Feb 12;360(7):692-8
[
19213682.001
]
[Cites]
Nat Med. 2009 Mar;15(3):285-92
[
19219022.001
]
[Cites]
Hum Gene Ther. 2009 Apr;20(4):325-36
[
19267665.001
]
[Cites]
Cell. 2002 Aug 23;110(4):521-9
[
12202041.001
]
(PMID = 19888329.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / P30 DK047754; United States / NIAID NIH HHS / AI / R21 AI063959; United States / NIAID NIH HHS / AI / AI063959; United States / NIAID NIH HHS / AI / AI061839; United States / NHLBI NIH HHS / HL / P01 HL053750; United States / NIDDK NIH HHS / DK / DK056465; United States / NIDDK NIH HHS / DK / DK047754; United States / NIDDK NIH HHS / DK / P30 DK056465; United States / NIAID NIH HHS / AI / R01 AI080326; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NHLBI NIH HHS / HL / HL053750
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / AIDS Vaccines
[Other-IDs]
NLM/ PMC2765621
51.
Madan RA, Chang VT, Dever LL:
An uncommon presentation of HIV-related lymphoma.
AIDS Patient Care STDS
; 2007 Jul;21(7):443-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
An uncommon presentation of
HIV
-
related lymphoma
.
Although highly active antiretroviral therapy has improved the clinical course of patients with
HIV
, this population remains at a significantly increased risk for non-Hodgkin'
s lymphoma
(NHL).
We encountered a patient with
HIV
-
related
NHL who presented with a thoracic spinal cord compression and had a complicated clinical course as a result of the atypical presentation.
[MeSH-major]
HIV
Infections / complications.
Lymphoma
,
AIDS
-
Related
/ complications.
Lymphoma
, Non-Hodgkin / virology. Spinal Cord Compression / etiology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17651024.001).
[ISSN]
1087-2914
[Journal-full-title]
AIDS patient care and STDs
[ISO-abbreviation]
AIDS Patient Care STDS
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
52.
Levine AM:
Management of AIDS-related lymphoma.
Curr Opin Oncol
; 2008 Sep;20(5):522-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management of
AIDS
-
related lymphoma
.
PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of
AIDS
-
lymphoma
has changed, and prognosis has improved.
Although the incidence of
AIDS
-
lymphoma
has decreased, the incidence of
HIV
-
associated
Hodgkin'
s lymphoma
has increased; mechanisms for these changes in epidemiology will be discussed.
RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in
HIV
-negative patients.
The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is
associated
with improved outcome; the increased risk of infectious death has not been confirmed.
The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is
associated
with excellent results.
High-dose chemotherapy with autologous stem cell transplant is
associated
with long-term,
disease
-free survival in approximately 50-80% of patients with relapsed/refractory
AIDS
-
lymphoma
.
Addition of rituximab is
associated
with improved response rates, without an increase in infections.
Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is
associated
with excellent results among patients with either diffuse large B cell
lymphoma
or Burkitt'
s lymphoma
.
Optimal therapy for patients with
HIV
-Hodgkin'
s lymphoma
has not yet been defined.
[MeSH-major]
Antineoplastic Agents / therapeutic use.
Lymphoma
,
AIDS
-
Related
/ drug therapy
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19106654.001).
[ISSN]
1531-703X
[Journal-full-title]
Current opinion in oncology
[ISO-abbreviation]
Curr Opin Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
48
53.
Goldstein MA, Naidich TP, Silverman ME:
Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS.
BMJ Case Rep
; 2009;2009
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical importance of delayed MRI contrast enhancement of primary central nervous system
lymphoma
in
AIDS
.
Accurately distinguishing between cerebral toxoplasmosis and primary central nervous system
lymphoma
(PCNSL), still the most common secondary CNS mass lesion complications of
AIDS
, has long represented a diagnostic challenge in those with
HIV
.
A young adult male with
AIDS
presented with evolving ophthalmoplegias, Parinaud's syndrome and gait dysfunction.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
AJNR Am J Neuroradiol. 2003 Apr;24(4):554-5
[
12695179.001
]
[Cites]
Neurology. 1998 Jan;50(1):21-6
[
9443452.001
]
(PMID = 21686485.001).
[ISSN]
1757-790X
[Journal-full-title]
BMJ case reports
[ISO-abbreviation]
BMJ Case Rep
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC3027744
54.
Rühl H, Bein G, Sachs UJ:
Transfusion-associated graft-versus-host disease.
Transfus Med Rev
; 2009 Jan;23(1):62-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transfusion-
associated
graft-versus-host
disease
.
Transfusion-
associated
graft-versus-host
disease
(TA-GvHD) is a rare complication of blood transfusion that has a fatal outcome in most patients.
Among the potential risk factors that have been discussed to date, a definite hazard for developing TA-GvHD has been recognized for HLA-matched transfusions or transfusions from blood relatives, intrauterine and exchange transfusions, patients with congenital immunodeficiency syndromes, bone marrow transplantation, stem cell transplantation, or
lymphomas
.
Although postulated, an increased risk for term or preterm newborns and patients with
HIV
/
AIDS
has not thus far been demonstrated.
[MeSH-major]
Blood Donors. Blood Transfusion. Graft vs Host
Disease
/ diagnosis. Graft vs Host
Disease
/ prevention & control. Graft vs Host
Disease
/ therapy. HLA Antigens. T-Lymphocytes
MedlinePlus Health Information.
consumer health - Blood Transfusion and Donation
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19056035.001).
[ISSN]
1532-9496
[Journal-full-title]
Transfusion medicine reviews
[ISO-abbreviation]
Transfus Med Rev
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / HLA Antigens
[Number-of-references]
137
55.
Pérez GR, Taborda MA, Toffi A, Palonsky M, Pagotto M, Gardiol DN, Giri AA:
[Development of slides for Epstein-Barr virus diagnosis by indirect immunofluorescence].
Medicina (B Aires)
; 2005;65(4):315-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Desarrollo de improntas para
el
diagnóstico del virus Epstein-Barr por inmunofluorescencia indirecta.
Moreover, high titles of anti-VCA antibodies are observed in EBV-
associated
neoplasic disorders, such as
lymphomas
in
AIDS
patients.
In conclusion, the slides here presented can be a useful instrument for acute EBV infection diagnosis and for the serologic detection of IgG anti-VCA antibodies in EBV-
associated
neoplastic disorders.
[MeSH-minor]
Adult. Antigens, Viral / analysis. Antigens, Viral / immunology. Burkitt
Lymphoma
/ immunology. Capsid Proteins / analysis. Capsid Proteins / immunology. Equipment Design. Fluorescent Antibody Technique, Indirect. Humans. Sensitivity and Specificity
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16193709.001).
[ISSN]
0025-7680
[Journal-full-title]
Medicina
[ISO-abbreviation]
Medicina (B Aires)
[Language]
spa
[Grant]
United States / FIC NIH HHS / TW / 5 D43 TW001037
[Publication-type]
Comparative Study; English Abstract; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
Argentina
[Chemical-registry-number]
0 / Antigens, Viral; 0 / Capsid Proteins; 0 / Epstein-Barr viral capsid antigen
56.
Dunleavy K, Wilson WH, Kaplan LD:
The case for rituximab in AIDS-related lymphoma.
Blood
; 2006 Apr 1;107(7):3014-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The case for rituximab in
AIDS
-
related lymphoma
.
[MeSH-major]
Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
,
AIDS
-
Related
/ drug therapy
[MeSH-minor]
Antibodies, Monoclonal, Murine-Derived. Humans.
Lymphoma
, Non-Hodgkin / drug therapy. Rituximab. Treatment Outcome
Genetic Alliance.
consumer health - AIDS-HIV
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Blood. 2005 Sep 1;106(5):1538-43
[
15914552.001
]
(PMID = 16554492.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
57.
Du MQ, Bacon CM, Isaacson PG:
Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.
J Clin Pathol
; 2007 Dec;60(12):1350-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Kaposi sarcoma-
associated
herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.
Kaposi sarcoma-
associated
herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), is a recent addition to the list of human viruses that are directly
associated
with lymphoproliferative disorders.
KSHV was first shown to be involved in multicentric Castleman
disease
and primary effusion
lymphoma
(PEL).
Subsequently, the virus was identified in solid
lymphomas
, often of extranodal sites, with morphological and immunophenotypic characteristics similar to those of PEL, and in other lymphoproliferative disorders with heterogeneous clinicopathological presentations.
The recent advances in our understanding of the histology, immunophenotype and pathogenesis of these KSHV-
associated
lymphoproliferative disorders are reviewed.
[MeSH-minor]
Cell Transformation, Neoplastic. Cell Transformation, Viral. Giant Lymph Node Hyperplasia / pathology. Giant Lymph Node Hyperplasia / virology. Humans.
Lymphoma
, Primary Effusion / pathology.
Lymphoma
, Primary Effusion / virology. Viral Proteins / physiology
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2002 Nov 1;100(9):3415-8
[
12384445.001
]
[Cites]
Blood. 2003 May 15;101(10):4115-21
[
12531789.001
]
[Cites]
J Virol. 2006 Jan;80(2):697-709
[
16378973.001
]
[Cites]
Blood. 2006 Jan 15;107(2):725-32
[
16160006.001
]
[Cites]
J Clin Invest. 2006 Mar;116(3):735-42
[
16498502.001
]
[Cites]
Blood. 2006 Apr 15;107(8):3295-302
[
16380446.001
]
[Cites]
Diagn Cytopathol. 2006 May;34(5):335-47
[
16604559.001
]
[Cites]
J Exp Med. 2006 May 15;203(5):1295-305
[
16682493.001
]
[Cites]
Curr Top Microbiol Immunol. 2007;312:101-36
[
17089795.001
]
[Cites]
Curr Top Microbiol Immunol. 2007;312:157-83
[
17089797.001
]
[Cites]
J Clin Invest. 2007 Apr;117(4):1019-28
[
17364023.001
]
[Cites]
Oncogene. 2007 Jul 26;26(34):4979-86
[
17310999.001
]
[Cites]
Am J Surg Pathol. 1997 Jun;21(6):719-24
[
9199651.001
]
[Cites]
Am J Surg Pathol. 1999 Nov;23(11):1393-400
[
10555008.001
]
[Cites]
Hum Immunol. 1999 Oct;60(10):921-7
[
10566591.001
]
[Cites]
Eur Cytokine Netw. 1999 Dec;10(4):501-8
[
10586116.001
]
[Cites]
Blood. 1999 Dec 15;94(12):4247-54
[
10590069.001
]
[Cites]
Nature. 1999 Dec 23-30;402(6764):889-94
[
10622254.001
]
[Cites]
Mod Pathol. 2000 Jan;13(1):77-85
[
10658913.001
]
[Cites]
Blood. 2000 Feb 15;95(4):1406-12
[
10666218.001
]
[Cites]
Leukemia. 2000 Feb;14(2):271-7
[
10673744.001
]
[Cites]
Am J Pathol. 2000 Mar;156(3):743-9
[
10702388.001
]
[Cites]
Clin Cancer Res. 2000 Mar;6(3):1180-9
[
10741750.001
]
[Cites]
J Clin Virol. 2000 May;16(3):215-24
[
10738140.001
]
[Cites]
Am J Pathol. 2000 Apr;156(4):1209-15
[
10751346.001
]
[Cites]
J Natl Cancer Inst. 2000 May 3;92(9):729-36
[
10793109.001
]
[Cites]
Blood. 2000 Aug 15;96(4):1599-601
[
10942415.001
]
[Cites]
Blood. 2000 Sep 15;96(6):2069-73
[
10979949.001
]
[Cites]
Blood. 2000 Oct 1;96(7):2537-42
[
11001908.001
]
[Cites]
Nat Med. 2000 Oct;6(10):1121-7
[
11017143.001
]
[Cites]
Br J Haematol. 2000 Oct;111(1):247-57
[
11091208.001
]
[Cites]
J Virol. 2001 Jan;75(1):429-38
[
11119611.001
]
[Cites]
J Virol. 2001 Mar;75(6):2938-45
[
11222719.001
]
[Cites]
Blood. 2001 Apr 1;97(7):2130-6
[
11264181.001
]
[Cites]
Blood. 2001 Apr 1;97(7):2173-6
[
11264189.001
]
[Cites]
Leukemia. 1999 Jul;13(7):1093-9
[
10400426.001
]
[Cites]
J Med Virol. 1999 Aug;58(4):394-401
[
10421407.001
]
[Cites]
Blood. 1999 Oct 15;94(8):2871-9
[
10515891.001
]
[Cites]
Blood. 1999 Oct 15;94(8):2931-3
[
10515899.001
]
[Cites]
Cancer Genet Cytogenet. 2005 Jan 1;156(1):49-53
[
15588855.001
]
[Cites]
J Virol. 2005 Jan;79(2):1244-51
[
15613351.001
]
[Cites]
J Mol Diagn. 2005 Feb;7(1):17-27
[
15681470.001
]
[Cites]
Blood. 2005 Mar 15;105(6):2510-8
[
15572586.001
]
[Cites]
Am J Surg Pathol. 2005 May;29(5):647-52
[
15832089.001
]
[Cites]
Leukemia. 2005 May;19(5):851-5
[
15744337.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206
[
16037778.001
]
[Cites]
Mod Pathol. 2003 May;16(5):424-9
[
12748248.001
]
[Cites]
Oncogene. 2003 May 29;22(22):3371-85
[
12776188.001
]
[Cites]
Hum Pathol. 2003 Jun;34(6):630
[
12827623.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404
[
12925741.001
]
[Cites]
Clin Transplant. 2003 Oct;17(5):451-4
[
14703929.001
]
[Cites]
Am J Surg Pathol. 2004 Jan;28(1):41-6
[
14707862.001
]
[Cites]
Cancer Res. 2004 Jan 15;64(2):581-9
[
14744772.001
]
[Cites]
J Biol Chem. 2004 Feb 27;279(9):7643-54
[
14668346.001
]
[Cites]
J Mol Med (Berl). 2004 Apr;82(4):223-31
[
14991150.001
]
[Cites]
J Exp Med. 2004 Apr 5;199(7):993-1003
[
15067035.001
]
[Cites]
Am J Surg Pathol. 2004 May;28(5):693-7
[
15105661.001
]
[Cites]
Leuk Res. 2004 Apr;28(4):333-8
[
15109530.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404
[
15190178.001
]
[Cites]
Am J Surg Pathol. 2004 Nov;28(11):1401-16
[
15489644.001
]
[Cites]
Am J Surg Pathol. 2004 Nov;28(11):1538-40; author reply 1540
[
15489661.001
]
[Cites]
Semin Oncol. 1993 Dec;20(6):636-47
[
8296200.001
]
[Cites]
Science. 1994 Dec 16;266(5192):1865-9
[
7997879.001
]
[Cites]
N Engl J Med. 1995 May 4;332(18):1186-91
[
7700311.001
]
[Cites]
Blood. 1995 Aug 15;86(4):1276-80
[
7632932.001
]
[Cites]
Blood. 1996 May 1;87(9):3903-9
[
8611719.001
]
[Cites]
AIDS. 1996 Jan;10(1):61-7
[
8924253.001
]
[Cites]
Blood. 1996 Jul 15;88(2):645-56
[
8695812.001
]
[Cites]
Leukemia. 1996 Aug;10(8):1358-62
[
8709643.001
]
[Cites]
Br J Haematol. 1996 Sep;94(3):533-43
[
8790156.001
]
[Cites]
Science. 1996 Dec 6;274(5293):1739-44
[
8939871.001
]
[Cites]
Blood. 1997 Feb 15;89(4):1413-20
[
9028965.001
]
[Cites]
J Virol. 1997 Mar;71(3):1984-91
[
9032330.001
]
[Cites]
Nat Med. 1997 Mar;3(3):287-92
[
9055855.001
]
[Cites]
J Clin Pathol. 2005 Oct;58(10):1039-45
[
16189148.001
]
[Cites]
Am J Surg Pathol. 2005 Dec;29(12):1633-41
[
16327436.001
]
[Cites]
Am J Surg Pathol. 2006 Jan;30(1):123-7
[
16330952.001
]
[Cites]
Blood. 2001 Apr 15;97(8):2526-7
[
11307774.001
]
[Cites]
Br J Haematol. 2001 May;113(2):425-8
[
11380409.001
]
[Cites]
J Virol. 2001 Nov;75(22):10933-40
[
11602733.001
]
[Cites]
Cell Immunol. 2001 Sep 15;212(2):118-25
[
11748928.001
]
[Cites]
Blood. 2002 Jan 15;99(2):649-54
[
11781250.001
]
[Cites]
Br J Haematol. 2002 Jan;116(1):113-21
[
11841403.001
]
[Cites]
J Biol Chem. 2002 Apr 19;277(16):13745-51
[
11830587.001
]
[Cites]
AIDS Patient Care STDS. 2002 Apr;16(4):139-45
[
12015867.001
]
[Cites]
Hum Pathol. 2002 Aug;33(8):846-9
[
12203218.001
]
[Cites]
Cancer Cell. 2002 Sep;2(3):229-41
[
12242155.001
]
[Cites]
J Infect Dis. 1997 May;175(5):1198-201
[
9129085.001
]
[Cites]
J Virol. 1997 Jun;71(6):4193-8
[
9151805.001
]
[Cites]
J Biol Chem. 1997 Aug 1;272(31):19625-31
[
9235971.001
]
[Cites]
Blood. 1997 Aug 1;90(3):1186-91
[
9242551.001
]
[Cites]
Cancer. 1997 Aug 15;80(4):788-97
[
9264363.001
]
[Cites]
Immunol Rev. 1997 Apr;156:111-26
[
9280752.001
]
[Cites]
Int J Cancer. 1997 Oct 9;73(2):303-4
[
9335459.001
]
[Cites]
Blood. 1997 Dec 15;90(12):4894-900
[
9389706.001
]
[Cites]
Bull Acad Natl Med. 1997 Jun-Jul;181(6):1023-34
[
9453829.001
]
[Cites]
Blood. 1998 Mar 15;91(6):1858-63
[
9490667.001
]
[Cites]
J Gen Virol. 1998 Jun;79 ( Pt 6):1445-52
[
9634087.001
]
[Cites]
Br J Haematol. 1998 Sep;102(4):1081-9
[
9734661.001
]
[Cites]
J Virol. 1998 Oct;72(10):8309-15
[
9733875.001
]
[Cites]
Am J Pathol. 1998 Nov;153(5):1609-14
[
9811353.001
]
[Cites]
Am J Surg Pathol. 1998 Dec;22(12):1528-37
[
9850179.001
]
[Cites]
Lab Invest. 1998 Dec;78(12):1637-42
[
9881964.001
]
[Cites]
Genes Chromosomes Cancer. 1999 Jan;24(1):16-23
[
9892104.001
]
[Cites]
Arch Pathol Lab Med. 1999 Mar;123(3):257-60
[
10086517.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51
[
10200299.001
]
[Cites]
Leukemia. 1999 Apr;13(4):634-40
[
10214873.001
]
[Cites]
Blood. 1999 Jun 15;93(12):4034-43
[
10361100.001
]
[Cites]
J Exp Med. 2005 Aug 15;202(4):479-84
[
16103407.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12885-90
[
16120683.001
]
(PMID = 18042691.001).
[ISSN]
1472-4146
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Viral Proteins
[Number-of-references]
114
[Other-IDs]
NLM/ PMC2095558
58.
Mwakigonja AR, Kaaya EE, Heiden T, Wannhoff G, Castro J, Pak F, Porwit A, Biberfeld P:
Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association.
BMC Cancer
; 2010;10:344
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tanzanian malignant
lymphomas
: WHO classification, presentation, ploidy, proliferation and
HIV
/EBV association.
BACKGROUND: In Tanzania, the International Working Formulation [WF] rather than the WHO Classification is still being used in diagnosing malignant
lymphomas
(ML) and the biological characterization including the
HIV
/EBV association is sketchy, thus restraining comparison, prognostication and application of established therapeutic protocols.
METHODS: Archival, diagnostic ML biopsies (N = 336), available sera (N = 35) screened by ELISA for
HIV
antibodies and corresponding clinical/histological reports at Muhimbili National Hospital (MNH) in Tanzania between 1996 and 2006 were retrieved and evaluated.
RESULTS: A third (38.8%, 109/281) of the ML patients with available clinical information had extranodal
disease
presentation.
8%, 134/158) non-Hodgkin
lymphoma
(NHL).
Most (83.6%, 112/134) of NHL were B-cell
lymphomas
(BCL) (CD20+), of which 50.9%, (57/112) were diffuse large B-cell (DLBCL).
Out of the 158 confirmed MLs, 22 (13.9%) were T-cell [CD3+]
lymphomas
(TCL) and 24 (15.2%) were Hodgkin
lymphomas
(HL) [CD30+].
The majority (51.4%, 19/37) of EBER ISH analyzed
lymphoma
biopsies were positive.
Of the serologically tested MLs, 40.0% (14/35) were
HIV
positive, mostly with high (> or =40.0%) Ki-67 reactivity.
Extranodal presentation was common among MNH
lymphoma
patients who also showed high aneuploidy, tumor proliferation (KI-67) and EBER positivity.
HIV
was apparently
associated
with high ML cell proliferation but extended studies are needed to clarify this.
[MeSH-major]
Cell Proliferation. Epstein-Barr Virus Infections / virology.
HIV
Infections / virology.
Lymphoma
, B-Cell / etiology.
Lymphoma
, B-Cell / pathology.
Lymphoma
, T-Cell / etiology.
Lymphoma
, T-Cell / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry.
HIV
/ pathogenicity. Herpesvirus 4, Human / pathogenicity. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. Ploidies. Tanzania. World Health Organization. Young Adult
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
AIDS. 1999 Dec 24;13(18):2583-8
[
10630528.001
]
[Cites]
Ann Oncol. 2008 Nov;19(11):1941-6
[
18647967.001
]
[Cites]
Cancer. 2000 Jul 1;89(1):12-20
[
10896995.001
]
[Cites]
Lab Invest. 2000 Aug;80(8):1207-13
[
10950111.001
]
[Cites]
Curr Opin Oncol. 2000 Sep;12(5):383-94
[
10975544.001
]
[Cites]
Hematol Oncol. 2001 Dec;19(4):129-50
[
11754390.001
]
[Cites]
AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):383-90
[
11897040.001
]
[Cites]
Pathol Int. 2002 Jan;52(1):1-12
[
11940200.001
]
[Cites]
Anal Quant Cytol Histol. 2003 Feb;25(1):31-8
[
12630080.001
]
[Cites]
Blood. 2003 Apr 15;101(8):3109-17
[
12406872.001
]
[Cites]
Blood. 2004 Jan 1;103(1):275-82
[
14504078.001
]
[Cites]
Acta Cytol. 2004 Mar-Apr;48(2):269-72
[
15085766.001
]
[Cites]
Curr HIV Res. 2004 Jul;2(3):215-21
[
15279585.001
]
[Cites]
Cancer Res. 1966 Jun;26(6):1063-83
[
5947336.001
]
[Cites]
Acta Pathol Microbiol Scand A. 1981 Nov;89(6):417-24
[
6278823.001
]
[Cites]
Acta Radiol Oncol. 1985 Mar-Apr;24(2):159-65
[
2988279.001
]
[Cites]
Cancer. 1986 Sep 15;58(6):1295-304
[
3742454.001
]
[Cites]
Leuk Res. 1989;13(4):307-14
[
2716347.001
]
[Cites]
J Clin Oncol. 1991 Aug;9(8):1334-40
[
1677032.001
]
[Cites]
Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;61(1):29-38
[
1683061.001
]
[Cites]
APMIS. 1994 Nov;102(11):865-73
[
7833007.001
]
[Cites]
Mod Pathol. 1995 Jan;8(1):51-8
[
7731942.001
]
[Cites]
Cytometry. 1998 Aug 15;34(4):187-97
[
9725459.001
]
[Cites]
CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
[
10200776.001
]
[Cites]
Cytopathology. 1999 Apr;10(2):87-96
[
10211614.001
]
[Cites]
J Cutan Pathol. 2005 Jan;32(1):21-7
[
15660651.001
]
[Cites]
J Mol Diagn. 2005 Feb;7(1):17-27
[
15681470.001
]
[Cites]
Zhonghua Bing Li Xue Za Zhi. 2005 Jan;34(1):22-7
[
15796877.001
]
[Cites]
Mod Pathol. 2005 Aug;18(8):1113-20
[
15920553.001
]
[Cites]
Clin Lab Haematol. 2005 Oct;27(5):302-6
[
16178909.001
]
[Cites]
J Pathol. 2006 Apr;208(5):714-23
[
16400625.001
]
[Cites]
Br J Cancer. 2006 May 22;94(10):1504-9
[
16705315.001
]
[Cites]
Afr Health Sci. 2006 Jun;6(2):69-75
[
16916294.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3786-91
[
16917006.001
]
[Cites]
Oncol Rep. 2007 Jun;17(6):1291-9
[
17487381.001
]
[Cites]
South Med J. 2007 May;100(5):549-50
[
17534105.001
]
[Cites]
Ann Oncol. 2007 Aug;18(8):1382-7
[
17693651.001
]
[Cites]
Zhonghua Bing Li Xue Za Zhi. 2007 Jul;36(7):470-3
[
17845761.001
]
[Cites]
Am J Hematol. 2007 Oct;82(10):893-7
[
17573693.001
]
[Cites]
Pathologe. 2007 Feb;28(1):29-35
[
17211671.001
]
[Cites]
Pediatr Blood Cancer. 2008 Feb;50(2):280-3
[
17417795.001
]
[Cites]
Pediatr Dev Pathol. 2009 May-Jun;12(3):195-9
[
18442302.001
]
[Cites]
Arch Pathol Lab Med. 2008 Mar;132(3):441-61
[
18318586.001
]
[Cites]
J Exp Clin Cancer Res. 2008;27:9
[
18577266.001
]
[Cites]
Ann Oncol. 2008 Aug;19(8):1477-84
[
18385201.001
]
[Cites]
Int J Hematol. 2008 Sep;88(2):202-5
[
18654739.001
]
[Cites]
Mod Pathol. 2000 Jan;13(1):77-85
[
10658913.001
]
(PMID = 20591198.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC2909982
59.
Verma N, Chaudhary UB, Costa LJ, Gudena V, Lazarchick J:
Primary testicular lymphoma and AIDS.
Ann Clin Lab Sci
; 2010;40(1):75-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary testicular
lymphoma
and
AIDS
.
Immunosuppressed patients have an increased risk for developing extranodal
lymphoma
, including testicular
lymphoma
.
In
AIDS
patients, primary testicular
lymphoma
has been reported as an initial manifestation of the
disease
.
These patients typically present at an early age; their
lymphomas
usually have aggressive histologic appearance and are
associated
with poor prognosis.
We report a testicular
lymphoma
consistent with diffuse large B-cell
lymphoma
(DLBCL) in an
AIDS
patient and we review the literature on primary testicular
lymphoma
in
AIDS
patients.
[MeSH-major]
Acquired Immunodeficiency Syndrome / pathology.
Lymphoma
,
AIDS
-
Related
/ pathology.
Lymphoma
, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Testicular Cancer
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20124334.001).
[ISSN]
1550-8080
[Journal-full-title]
Annals of clinical and laboratory science
[ISO-abbreviation]
Ann. Clin. Lab. Sci.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
60.
Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, Serraino D, Rezza G, Suligoi B:
[AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era].
Epidemiol Prev
; 2009 Jul-Oct;33(4-5):184-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
AIDS
and injecting drug use: survival determinants in the highly active antiretroviral therapy era].
[Transliterated title]
AIDS
e tossicodipendenza: determinanti della sopravvivenza nell'era delle terapie antiretrovirali altamente efficaci.
OBJECTIVES: to estimate survival, after
AIDS
diagnosis, in people who got infected with
HIV
through injecting drug use (IDUs), to identify among variables collected at
AIDS
diagnosis those which were
associated
to prognosis and to assess the frequency of morbid conditions at death.
SETTING AND PARTICIPANTS: 4,040 IDUs diagnosed with
AIDS
in Italy between 1999 and 2005.
RESULTS: the 2-year and 5-year survival probabilities after
AIDS
diagnosis of IDUs were 72% and 60%, respectively.
Elevated risks of death emerged for IDUs with older ages (HR=2.0 95% CI 1.6-2.4 for>45 years old vs.<35 years old), lower education (HR=1.4 95% CI 1.2-1.7 for elementary school vs. high school/university), longer time span between first
HIV
positive test and
AIDS
diagnosis (HR=1.6 95% CI 1.4-1.9 for > 6 months vs. < 6 months), and lower CD4 cell count at diagnosis (HR=1.5 95% CI 1.3-1.7 for <50 cells/mm3 vs. > 200 cells/mm3).
Compared to Pneumocystis carinii pneumonia, non-Hodgkin
lymphomas
were the worst prognostic factors, particularly primary brain
lymphoma
(HR=7.2, 95% CI 4.4-11.8).
52% of cases reported no
AIDS
-defining illnesses: 64 (4%) violent causes, 94 (6%) cancers, and 656 (42%) only non neoplastic illnesses, among which 415 (27%) liver diseases.
CONCLUSION: the results of this population-based study showed that, in the highly active antiretroviral therapy era, survival of IDUs with
AIDS
was still lower compared to that of
HIV
sexual transmission groups.
The presence at death, in 52% of cases, of non
AIDS
-defining illnesses indicates the important role on mortality of co-morbidities, including liver diseases and violent causes.
[MeSH-major]
Acquired Immunodeficiency Syndrome / mortality. Anti-
HIV
Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Substance Abuse, Intravenous / epidemiology
[MeSH-minor]
AIDS
-
Related
Opportunistic Infections / mortality. Age Factors. Comorbidity. Death Certificates. Educational Status. Equipment Contamination.
HIV
Infections / transmission. Homicide / statistics & numerical data. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Liver Diseases / mortality.
Lymphoma
,
AIDS
-
Related
/ mortality. Medical Record Linkage. Needles. Proportional Hazards Models. Registries. Retrospective Studies. Risk. Sexual Behavior
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20124634.001).
[ISSN]
1120-9763
[Journal-full-title]
Epidemiologia e prevenzione
[ISO-abbreviation]
Epidemiol Prev
[Language]
ita
[Publication-type]
Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
0 / Anti-HIV Agents
61.
Bedoya F, Medveczky MM, Lund TC, Perl A, Horvath J, Jett SD, Medveczky PG:
Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines.
Leuk Res
; 2009 Nov;33(11):1499-504
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of mitochondrial genome concatemers in
AIDS
-
associated lymphomas
and lymphoid cell lines.
Since most oncogenic viruses persist as extrachromosomal covalently closed circular DNA (cccDNA) in tumor cells, we developed an assay to visualize and identify cccDNA in primary
lymphomas
.
One
AIDS
-
associated
lymphoma
(
EL
) was further studied in detail as its mitochondrial genome consisted of tandem head-to-tail duplications.
Insertion of C-residues was noted near the origin of replication of
EL
mtDNA.
EL
cells responded weakly to Fas-apoptotic stimulus, displayed reduced mitochondrial activity and mass, and produced higher levels of reactive oxygen intermediates.
Screening of several
AIDS
-
associated lymphomas
and established lymphoid cell lines also revealed the presence of mitochondrial genome concatemers consisting of interlinked monomer molecules.
Taken together, our results suggest that formation of mtDNA concatemers is
associated
with oncogenic transformation in lymphoid cells.
Genetic Alliance.
consumer health - AIDS-HIV
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Semin Oncol. 2000 Aug;27(4):390-401
[
10950365.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14453-8
[
18796602.001
]
[Cites]
Cancer Res. 2001 Oct 1;61(19):7015-9
[
11585726.001
]
[Cites]
J Clin Pathol. 2003 Mar;56(3):188-92
[
12610094.001
]
[Cites]
Bone Marrow Transplant. 2003 Feb;31(3):145-55
[
12621474.001
]
[Cites]
Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820
[
12852656.001
]
[Cites]
IUBMB Life. 2003 Apr-May;55(4-5):213-7
[
12880201.001
]
[Cites]
Mol Genet Genomics. 2003 Jul;269(4):454-63
[
12768414.001
]
[Cites]
Science. 2004 May 14;304(5673):981
[
15143273.001
]
[Cites]
Biopolymers. 1970;9(3):373-9
[
5417647.001
]
[Cites]
J Virol. 1984 Apr;50(1):248-54
[
6321792.001
]
[Cites]
J Virol. 1989 Sep;63(9):3601-11
[
2547988.001
]
[Cites]
Antimicrob Agents Chemother. 1994 Dec;38(12):2743-9
[
7695256.001
]
[Cites]
Nucleic Acids Res. 1996 Oct 15;24(20):4084-91
[
8918816.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1172-6
[
9037025.001
]
[Cites]
Nature. 1997 Apr 3;386(6624):517-21
[
9087414.001
]
[Cites]
Nucleic Acids Res. 1998 Feb 15;26(4):967-73
[
9461455.001
]
[Cites]
Biochem Z. 1962;336:281-98
[
14003030.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24
[
15647368.001
]
[Cites]
Br J Haematol. 2005 Sep;130(5):662-70
[
16115121.001
]
[Cites]
Biochim Biophys Acta. 2006 May-Jun;1757(5-6):700-7
[
16782042.001
]
[Cites]
Cold Spring Harb Symp Quant Biol. 2005;70:363-74
[
16869773.001
]
[Cites]
Oncogene. 2006 Aug 7;25(34):4647-62
[
16892079.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3786-91
[
16917006.001
]
[Cites]
J Infect Dis. 2007 May 15;195(10):1419-25
[
17436221.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 May 22;104(21):9001-6
[
17517629.001
]
[Cites]
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4331-5
[
17671113.001
]
[Cites]
J Clin Pathol. 2007 Dec;60(12):1365-72
[
18042692.001
]
[Cites]
Methods Mol Biol. 2007;372:153-66
[
18314724.001
]
[Cites]
Cancer Lett. 2008 Jul 18;266(1):30-6
[
18372105.001
]
[Cites]
Cancer Lett. 2008 Jul 18;266(1):21-9
[
18374479.001
]
[Cites]
Nature. 2000 Oct 12;407(6805):789-95
[
11048730.001
]
(PMID = 19362738.001).
[ISSN]
1873-5835
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA111196-04; United States / NCI NIH HHS / CA / CA111196-02; United States / NCI NIH HHS / CA / R01CA111196; United States / NCI NIH HHS / CA / R01 CA111196-01A2; United States / NCI NIH HHS / CA / CA111196-03; United States / NCI NIH HHS / CA / R01 CA111196-03; United States / NCI NIH HHS / CA / CA111196-04; United States / NCI NIH HHS / CA / R01 CA111196; United States / NCI NIH HHS / CA / R01 CA111196-02; United States / NCI NIH HHS / CA / CA111196-01A2
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / DNA Primers; 0 / DNA, Mitochondrial
[Other-IDs]
NLM/ NIHMS103972; NLM/ PMC2730422
62.
Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K:
HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition.
Blood
; 2005 Dec 15;106(13):4294-302
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
One in 20 carriers of human T-cell leukemia virus type 1 (HTLV-1) will develop adult T-cell leukemia/
lymphoma
(ATL),
a disease
frequently
associated
with hypercalcemia, bone destruction, and a fatal course refractory to current therapies.
Overexpression of the HTLV-1-encoded Tax oncoprotein under the human granzyme B promoter causes large granular lymphocytic leukemia/
lymphomas
in mice.
Mice doubly transgenic for Tax and the osteoclast inhibitory factor, osteoprotegerin, were protected from osteolytic bone
disease
and developed fewer soft-tissue tumors.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
COS Scholar Universe.
author profiles
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell. 1997 Apr 18;89(2):309-19
[
9108485.001
]
[Cites]
Annu Rev Immunol. 1997;15:15-37
[
9143680.001
]
[Cites]
Cancer. 1997 Oct 15;80(8 Suppl):1557-63
[
9362422.001
]
[Cites]
J Clin Oncol. 1998 Feb;16(2):593-602
[
9469347.001
]
[Cites]
Methods. 1998 Sep;16(1):83-94
[
9774518.001
]
[Cites]
Front Biosci. 2005 Jan 1;10:919-30
[
15569630.001
]
[Cites]
J Bone Miner Res. 2005 Jan;20(1):58-66
[
15619670.001
]
[Cites]
Skeletal Radiol. 1985;14(3):194-7
[
2997937.001
]
[Cites]
J Clin Invest. 1987 Sep;80(3):911-6
[
2887587.001
]
[Cites]
J Clin Invest. 1999 Jan;103(2):197-206
[
9916131.001
]
[Cites]
Blood. 2004 Nov 15;104(10):3305-11
[
15292059.001
]
[Cites]
Cancer Cell. 2004 Aug;6(2):185-95
[
15324701.001
]
[Cites]
Front Biosci. 2004 Sep 1;9:2852-9
[
15353320.001
]
[Cites]
Calcif Tissue Int. 2004 Jul;75(1):71-7
[
15037971.001
]
[Cites]
Am J Pathol. 1988 Sep;132(3):593-7
[
3414786.001
]
[Cites]
J Bone Miner Res. 1987 Dec;2(6):595-610
[
3455637.001
]
[Cites]
Cancer Res. 1988 Dec 1;48(23):6876-81
[
3180096.001
]
[Cites]
Endocrinology. 1989 Oct;125(4):1805-13
[
2676473.001
]
[Cites]
Trans R Soc Trop Med Hyg. 1989 Nov-Dec;83(6):729-31
[
2617642.001
]
[Cites]
J Exp Med. 1990 Sep 1;172(3):759-65
[
2388034.001
]
[Cites]
Blood. 1991 Jun 1;77(11):2451-5
[
2039827.001
]
[Cites]
Science. 1991 Aug 30;253(5023):1026-8
[
1887217.001
]
[Cites]
J Virol. 1991 Oct;65(10):5471-6
[
1895396.001
]
[Cites]
Virology. 1993 Nov;197(1):196-204
[
8212554.001
]
[Cites]
Blood. 1994 Nov 1;84(9):2904-11
[
7949164.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61
[
7862633.001
]
[Cites]
Baillieres Clin Haematol. 1995 Mar;8(1):131-48
[
7663044.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S162-9
[
8797719.001
]
[Cites]
J Clin Invest. 1996 Oct 1;98(7):1544-9
[
8833902.001
]
[Cites]
Oncogene. 2005 Jan 20;24(4):525-40
[
15580311.001
]
[Cites]
Cancer Res. 2005 Feb 15;65(4):1129-35
[
15734993.001
]
[Cites]
Leukemia. 2005 Apr;19(4):664-70
[
15744346.001
]
[Cites]
Retrovirology. 2004;1:20
[
15310405.001
]
[Cites]
Cancer. 2000 Mar 1;88(5):1082-90
[
10699899.001
]
[Cites]
Blood. 2000 Jul 1;96(1):275-81
[
10891462.001
]
[Cites]
Cancer. 2000 Jun 15;88(12 Suppl):2961-78
[
10898340.001
]
[Cites]
Cancer. 2000 Jun 15;88(12 Suppl):2979-88
[
10898341.001
]
[Cites]
J Virol. 2000 Dec;74(23):11394-7
[
11070040.001
]
[Cites]
AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1677-81
[
11080809.001
]
[Cites]
J Clin Invest. 2000 Dec;106(12):1481-8
[
11120755.001
]
[Cites]
J Virol. 2001 Mar;75(5):2185-93
[
11160722.001
]
[Cites]
Blood. 2002 Jan 1;99(1):88-94
[
11756157.001
]
[Cites]
Blood. 2002 Jan 15;99(2):634-40
[
11781248.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Jan 18;290(2):650-5
[
11785948.001
]
[Cites]
Leuk Res. 2002 Jun;26(6):561-7
[
12007504.001
]
[Cites]
J Clin Oncol. 2002 Aug 1;20(15):3219-24
[
12149294.001
]
[Cites]
Nat Rev Cancer. 2002 Aug;2(8):584-93
[
12154351.001
]
[Cites]
J Dermatol. 2002 Oct;29(10):644-7
[
12432996.001
]
[Cites]
J Clin Invest. 2002 Nov;110(10):1559-72
[
12438453.001
]
[Cites]
J Exp Med. 2003 Jan 20;197(2):163-8
[
12538656.001
]
[Cites]
Cancer. 2003 Feb 1;97(3 Suppl):748-57
[
12548572.001
]
[Cites]
Semin Oncol. 2002 Dec;29(6 Suppl 21):19-27
[
12584691.001
]
[Cites]
Curr Rheumatol Rep. 2003 Feb;5(1):65-74
[
12590887.001
]
[Cites]
J Bone Miner Res. 2003 Mar;18(3):482-92
[
12619933.001
]
[Cites]
Blood. 2003 Jul 1;102(1):200-6
[
12623838.001
]
[Cites]
Cancer Cell. 2003 Jun;3(6):537-49
[
12842083.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9506-11
[
12881486.001
]
[Cites]
Prostate Cancer Prostatic Dis. 2003;6(3):204-11
[
12970722.001
]
[Cites]
Ann Oncol. 2003 Oct;14(10):1468-76
[
14504045.001
]
[Cites]
Cancer Res. 2003 Oct 1;63(19):6170-3
[
14559799.001
]
[Cites]
Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S19-31
[
14600589.001
]
[Cites]
Breast. 2003 Aug;12 Suppl 2:S22-9
[
14659140.001
]
[Cites]
J Bone Miner Res. 2004 Feb;19(2):278-88
[
14969398.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1655-64
[
15084698.001
]
[Cites]
J Bone Miner Res. 2004 Jul;19(7):1105-11
[
15176993.001
]
[Cites]
Blood. 2004 Aug 1;104(3):802-9
[
15090453.001
]
[Cites]
Br J Haematol. 2004 Aug;126(4):583-92
[
15287953.001
]
[Cites]
Jpn J Cancer Res. 1996 Sep;87(9):887-92
[
8878449.001
]
[Cites]
N Engl J Med. 1996 Dec 12;335(24):1785-91
[
8965890.001
]
[Cites]
J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8
[
8931609.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):272-80
[
9117461.001
]
(PMID = 16118323.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA100730; United States / NIDDK NIH HHS / DK / P30 DK056341; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P30 CA091842; United States / NIDDK NIH HHS / DK / DK56341
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Gene Products, tax; 0 / Interleukin-6; 0 / Lymphokines; 0 / Organophosphonates; 64060-24-8 / osteoclast activating factor
[Other-IDs]
NLM/ PMC1895233
63.
Tschudin S, Sponagel L, Flückiger U:
[Dangerous fever].
Ther Umsch
; 2006 Oct;63(10):651-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Additionally, fever is a frequent symptom in non-infectious diseases, e.g. autoimmune diseases or
lymphomas
.
The term dangerous fever describes febrile conditions which are
associated
with high mortality and, in most cases, mandate hospitalization, and even monitoring in an intensive care unit.
[MeSH-minor]
AIDS
-
Related
Opportunistic Infections / diagnosis. Adult. Bacterial Infections / diagnosis. Diagnosis, Differential. Humans. Male. Opportunistic Infections / diagnosis. Prognosis. Shock, Septic / diagnosis. Systemic Inflammatory Response Syndrome / diagnosis
MedlinePlus Health Information.
consumer health - Critical Care
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17048184.001).
[ISSN]
0040-5930
[Journal-full-title]
Therapeutische Umschau. Revue thérapeutique
[ISO-abbreviation]
Ther Umsch
[Language]
ger
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Switzerland
64.
Castillo J, Hansen C, Mega A, Tashima K:
AIDS-related lymphomas: the Rhode Island experience.
Med Health R I
; 2008 Nov;91(11):332-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AIDS
-
related
lymphomas
: the Rhode Island experience.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
Genetic Alliance.
consumer health - AIDS-HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19093379.001).
[ISSN]
1086-5462
[Journal-full-title]
Medicine and health, Rhode Island
[ISO-abbreviation]
Med Health R I
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
65.
Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ:
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas.
Blood
; 2005 Jan 15;105(2):874-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Durable remissions with autologous stem cell transplantation for high-risk
HIV
-
associated lymphomas
.
The treatment of
HIV
-
associated
lymphoma
has changed since the widespread use of highly active antiretroviral therapy.
HIV
-infected individuals can tolerate more intensive chemotherapy, as they have better hematologic reserves and fewer infections.
This has led to higher response rates in patients with
HIV
-
associated
Hodgkin
disease
(HD) or non-Hodgkin
lymphoma
(NHL) treated with chemotherapy in conjunction with antiretroviral therapy.
However, for patients with refractory or relapsed
disease
, salvage chemotherapy still offers little chance of long-term survival.
In the non-
HIV
setting, patients with relapsed Hodgkin
disease
(HD) or non-Hodgkin
lymphoma
(NHL) have a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue (ASCT) compared with conventional salvage chemotherapy.
In a prior report we demonstrated that this approach is well tolerated in patients with underlying immunodeficiency from
HIV
infection.
Furthermore, similar engraftment to the non-
HIV
setting and low infectious risks have been observed.
With long-term follow-up we demonstrate that ASCT can lead to an 85% progression-free survival, which suggests that this approach may be potentially curative in select patients with relapsed
HIV
-
associated
HD or NHL.
[MeSH-major]
Lymphoma
,
AIDS
-
Related
/ therapy. Stem Cell Transplantation
[MeSH-minor]
Adolescent. Adult. Aged. CD4 Lymphocyte Count. Child.
Disease
-Free Survival. Follow-Up Studies. Humans. Middle Aged. Recurrence. Remission Induction. Risk Factors. Transplantation, Autologous
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - HIV
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15388574.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Grant]
United States / NIAID NIH HHS / AI / AI38592; United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / CA33572
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
66.
Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ:
Multicentric Castleman's disease masquerading as HIV-related lymphoma.
Am J Med Sci
; 2007 Oct;334(4):317-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Multicentric Castleman'
s disease
masquerading as
HIV
-
related lymphoma
.
Patients with human immunodeficiency virus (
HIV
) infection are at increased risk for developing lymphoproliferative disorders.
Multicentric Castleman'
s disease
should always be kept in the differential diagnosis of
HIV
-positive patients suspected of having
lymphoma
to avoid misdiagnosis.
We report the case of a 40-year-old
HIV
-positive homosexual man who presented with lower back pain and features highly suggestive of
lymphoma
including lymphadenopathy, elevated lactic dehydrogenase, and splenomegaly.
The patient's plasma was positive by polymerase chain reaction for Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/ HHV8), and a lymph node biopsy revealed Multicentric Castleman'
s disease
.
Albeit a rare condition, Castleman'
s disease
should always be considered in immunocompromised patients suspected of having
lymphoma
.
[MeSH-major]
Giant Lymph Node Hyperplasia / diagnosis.
Lymphoma
,
AIDS
-
Related
/ diagnosis
Genetic Alliance.
consumer health - Castleman's Disease
.
Genetic Alliance.
consumer health - Multicentric Castleman's Disease
.
Genetic Alliance.
consumer health - HIV
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18030193.001).
[ISSN]
0002-9629
[Journal-full-title]
The American journal of the medical sciences
[ISO-abbreviation]
Am. J. Med. Sci.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
67.
Qin Z, Kearney P, Plaisance K, Parsons CH:
Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.
J Leukoc Biol
; 2010 Jan;87(1):25-34
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pivotal advance: Kaposi's sarcoma-
associated
herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.
KSHV is the causative agent of KS and
lymphomas
preferentially arising in immuno compromised patients, and specific cytokines, including IL-6 and IL-10, have been implicated in KSHV-
associated
cancer pathogenesis.
However, the contribution of KSHV-infected macrophages to the cytokine milieu within KSHV-
related
tumors is unclear.
In addition,RNA interference specifically targeting LIP induced basal secretion of IL-6 and IL-10 by macrophages.Taken together, these data support a role for KSHV miRNA in the programming of macrophage cytokine responses in favor of KSHV-
related
tumor progression.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 1998 Feb 1;91(3):968-76
[
9446658.001
]
[Cites]
Annu Rev Immunol. 2001;19:683-765
[
11244051.001
]
[Cites]
Blood. 2000 Aug 15;96(4):1599-601
[
10942415.001
]
[Cites]
Blood. 2000 Sep 15;96(6):2069-73
[
10979949.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51
[
10200299.001
]
[Cites]
Leukemia. 1999 Apr;13(4):634-40
[
10214873.001
]
[Cites]
Blood. 1999 Oct 15;94(8):2871-9
[
10515891.001
]
[Cites]
J Invest Dermatol. 2004 Dec;123(6):1169-75
[
15610530.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5
[
15800047.001
]
[Cites]
Nat Methods. 2005 Apr;2(4):269-76
[
15782219.001
]
[Cites]
Clin Exp Allergy. 2005 Jun;35(6):782-9
[
15969670.001
]
[Cites]
AIDS. 2005 Jul 22;19(11):1229-31
[
15990578.001
]
[Cites]
J Virol. 2005 Jul;79(14):9301-5
[
15994824.001
]
[Cites]
Mol Cell. 2005 Oct 7;20(1):3-7
[
16209940.001
]
[Cites]
AIDS. 2005 Nov 4;19(16):1907-10
[
16227799.001
]
[Cites]
J Immunol. 2001 Apr 1;166(7):4312-8
[
11254683.001
]
[Cites]
J Virol. 2002 May;76(10):4688-98
[
11967286.001
]
[Cites]
Biochem J. 2002 Aug 1;365(Pt 3):561-75
[
12006103.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8
[
12145325.001
]
[Cites]
Science. 2002 Nov 15;298(5597):1432-5
[
12434062.001
]
[Cites]
Cytokine. 2003 Mar 7;21(5):242-7
[
12824009.001
]
[Cites]
J Immunol. 2003 Jul 15;171(2):821-8
[
12847250.001
]
[Cites]
J Virol. 2003 Aug;77(16):8893-914
[
12885907.001
]
[Cites]
J Biomed Sci. 2004 Jul-Aug;11(4):517-27
[
15153787.001
]
[Cites]
Cancer. 2004 Jul 15;101(2):317-24
[
15241829.001
]
[Cites]
Science. 1989 Nov 17;246(4932):911-6
[
2683088.001
]
[Cites]
Cell. 1991 Nov 1;67(3):569-79
[
1934061.001
]
[Cites]
Adv Immunol. 1994;56:1-26
[
8073945.001
]
[Cites]
N Engl J Med. 1995 May 4;332(18):1186-91
[
7700311.001
]
[Cites]
Blood. 1995 Aug 15;86(4):1276-80
[
7632932.001
]
[Cites]
J Virol. 1997 Oct;71(10):7963-8
[
9311888.001
]
[Cites]
Ann Diagn Pathol. 1999 Dec;3(6):357-63
[
10594287.001
]
[Cites]
Cancer Res. 2005 Dec 1;65(23):10794-800
[
16322225.001
]
[Cites]
Nat Immunol. 2006 Feb;7(2):131-7
[
16424890.001
]
[Cites]
J Clin Invest. 2006 Jul;116(7):1963-73
[
16794734.001
]
[Cites]
Cell Signal. 2006 Nov;18(11):1865-75
[
16600570.001
]
[Cites]
J Virol. 2006 Nov;80(21):10874-8
[
16956953.001
]
[Cites]
J Virol. 2006 Dec;80(24):12171-86
[
17020951.001
]
[Cites]
J Leukoc Biol. 2007 Jan;81(1):221-8
[
17023556.001
]
[Cites]
J Interferon Cytokine Res. 2006 Dec;26(12):893-900
[
17238832.001
]
[Cites]
J Infect Dis. 2007 Mar 1;195(5):645-59
[
17262705.001
]
[Cites]
J Biochem. 2007 Feb;141(2):137-45
[
17190786.001
]
[Cites]
J Virol. 2007 May;81(10):5079-90
[
17329329.001
]
[Cites]
PLoS Pathog. 2007 May 11;3(5):e65
[
17500590.001
]
[Cites]
Immunol Cell Biol. 2007 Aug-Sep;85(6):420-4
[
17637696.001
]
[Cites]
Blood. 2007 Oct 1;110(7):2685-95
[
17525287.001
]
[Cites]
Eur J Immunol. 2007 Oct;37(10):2900-11
[
17899538.001
]
[Cites]
J Virol. 2007 Dec;81(23):12836-45
[
17881434.001
]
[Cites]
Cancer Cell. 2008 Mar;13(3):272-86
[
18328430.001
]
[Cites]
J Biol Chem. 2008 Mar 14;283(11):6843-53
[
18195020.001
]
[Cites]
J Immunol. 2008 Apr 15;180(8):5689-98
[
18390754.001
]
[Cites]
Int J Cancer. 2008 Jul 1;123(1):187-94
[
18435450.001
]
[Cites]
J Virol. 2008 Jun;82(11):5440-9
[
18367536.001
]
[Cites]
Immunol Lett. 2008 Oct 30;120(1-2):37-41
[
18680763.001
]
[Cites]
Cytokine. 2008 Sep;43(3):391-4
[
18701320.001
]
[Cites]
Cell Host Microbe. 2008 Nov 13;4(5):470-83
[
18996347.001
]
[Cites]
J Immunol. 2009 Feb 15;182(4):2258-68
[
19201880.001
]
[Cites]
J Cell Physiol. 2009 Jun;219(3):698-706
[
19229882.001
]
[CommentIn]
J Leukoc Biol. 2010 Jan;87(1):9-12
[
20047884.001
]
(PMID = 20052801.001).
[ISSN]
1938-3673
[Journal-full-title]
Journal of leukocyte biology
[ISO-abbreviation]
J. Leukoc. Biol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA142362; United States / NCRR NIH HHS / RR / P20-RR-017696; United States / NCI NIH HHS / CA / K08 CA103858-05; United States / NCI NIH HHS / CA / CA103858-05; United States / NCRR NIH HHS / RR / P20 RR017696-085957; United States / NCI NIH HHS / CA / P30 CA138313; United States / NCI NIH HHS / CA / K08-1CA103858; United States / NCRR NIH HHS / RR / RR017696-085957; United States / NCI NIH HHS / CA / K08 CA103858; United States / NCRR NIH HHS / RR / P20 RR017696; United States / NCI NIH HHS / CA / P30-CA-138313
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / 3' Untranslated Regions; 0 / CCAAT-Enhancer-Binding Protein-beta; 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-6; 0 / MicroRNAs; 0 / Protein Isoforms; 0 / RNA, Viral; 130068-27-8 / Interleukin-10
[Other-IDs]
NLM/ PMC2801620
68.
Das DK:
Serous effusions in malignant lymphomas: a review.
Diagn Cytopathol
; 2006 May;34(5):335-47
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Serous effusions in malignant
lymphomas
: a review.
Serous effusions are a common complication of
lymphomas
.
Although the frequency of pleural effusion is 20-30% in non-Hodgkin'
s lymphoma
(NHL) and Hodgkin'
s disease
(HD), the involvement of peritoneal and pericardial cavities is uncommon.
Among
lymphoma
subtypes, T-cell neoplasms, especially the lymphoblastic
lymphomas
, more frequently involve the serous fluids.
Cytologic features of specific
lymphoma
subtypes such as lymphoblastic
lymphoma
, follicular center cell
lymphoma
, including Burkitt-type
lymphoma
, marginal zone
lymphoma
, MALT
lymphoma
, and anaplastic large-cell
lymphoma
, etc., have been described in the literature.
The differential diagnostic problems of
lymphomas
in serous effusions include reactive lymphocytoses, early involvement by lymphomatous process, small round-cell tumors (SRCT), and presence of look-alike of Reed-Sternberg cells.
ICC not only distinguishes
lymphomas
from reactive lymphocytoses and SRCTs, it significantly modifies the morphologic diagnosis to achieve a better classification of
lymphomas
.
Morphometry also distinguishes reactive lymphocytoses from malignant
lymphoma
with a high degree of sensitivity (>85%) and specificity (>95%).
Although
lymphomas
rarely present as serous effusions without the involvement of other thoracic and extrathoracic sites, a small group of
lymphomas
called primary effusion
lymphomas
(PEL) exhibit exclusive or dominant involvement of serous cavities, without a detectable solid tumor mass.
This body cavity based
lymphoma
(BCBL) is a distinct clinicopathologic entity and is found predominantly in
AIDS
patients with preexisting Kaposi sarcoma.
Cytomorphologically, PEL is usually a large-cell
lymphoma
, which appears to bridge features of large-cell immunoblastic and anaplastic large-cell
lymphoma
(ALCL).
Most of these cases comprise a unique subgroup of B-cell
lymphoma
, with features of both high-grade anaplastic and B-immunoblastic
lymphoma
, but T-cell and/or natural killer cell immunophenotypes are described.
Pleural effusion due to
lymphomas
, either primary or otherwise, is considered as one of the factors adversely influencing overall survival.
The presence of pleural effusion at the time of presentation is not only
associated
with extremely poor outcome of
lymphomas
, it is also a predictor of
disease
relapse after chemotherapy and decreased survival.
In such situations, cytology along with ancillary studies not only gives a quick diagnosis of
lymphoma
, but also offers prognostically significant information such as classification of
lymphomas
, its grade and immunophenotype, and presence/absence of viral DNAs and tumor lysis syndrome.
[MeSH-major]
Cytodiagnosis / methods.
Lymphoma
/ complications. Pleural Effusion, Malignant / etiology
[MeSH-minor]
Ascitic Fluid / pathology. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Female. Hodgkin
Disease
/ pathology. Humans. Immunophenotyping. Lymphocytosis / pathology. Male. Pericardial Effusion / etiology. Pericardial Effusion / pathology. Reed-Sternberg Cells / pathology
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16604559.001).
[ISSN]
8755-1039
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
136
69.
Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU:
Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
Leuk Lymphoma
; 2005 Feb;46(2):207-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Changing incidence and prognostic factors of survival in
AIDS
-
related
non-Hodgkin'
s lymphoma
in the era of highly active antiretroviral therapy (HAART).
Non-Hodgkin'
s lymphoma
is an
AIDS
-defining
disease
.
We collected data of 214 cases of
AIDS
-
related Lymphoma
(ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.
The incidence of
AIDS
-
related
primary CNS
lymphomas
(PCNSL) took a comparable, yet more pronounced development.
Using the univariate Kaplan-Meier analysis prolonged survival was significantly
associated
with the achievement of a complete remission as well as with a favourable virological response to HAART.
[MeSH-major]
Antiretroviral Therapy, Highly Active.
Lymphoma
,
AIDS
-
Related
/ drug therapy.
Lymphoma
,
AIDS
-
Related
/ epidemiology
Genetic Alliance.
consumer health - AIDS-HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15621803.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antiviral Agents
70.
Camilleri-Broët S, Raphaël M:
[Physiopathogenic aspects of HIV-associated primary brain lymphomas].
Rev Neurol (Paris)
; 2006 Jan;162(1):57-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Physiopathogenic aspects of
HIV
-
associated
primary brain
lymphomas
].
[Transliterated title]
Les lymphomes cérébraux primitifs associés
au SIDA
: aspects physiopathogéniques.
HIV
-
associated
Primary brain
lymphomas
(PBLs) are usually diffuse, large B-cell
lymphomas
(DLBCLs).
In contrast to those occurring in immunocompetent patients, nearly all
HIV
-
associated
PBLs are
associated
with Epstein-Barr virus (EBV).
Since viral latency proteins are target antigens for anti-viral cytotoxic T lymphocytes, the double immunodeficiency (
HIV
infection, central nervous system microenvironment) favors the expression of viral latency proteins (LMP-1, EBNA2).
[MeSH-major]
Brain Neoplasms / physiopathology.
Lymphoma
,
AIDS
-
Related
/ physiopathology
[MeSH-minor]
B-Lymphocytes / pathology. B-Lymphocytes / virology. Biopsy. Brain / pathology. Brain / virology. Cerebrospinal Fluid / immunology. Epstein-Barr Virus Infections / complications.
HIV
/ physiology. Herpesvirus 4, Human / isolation & purification. Humans.
Lymphoma
, Large B-Cell, Diffuse / cerebrospinal fluid.
Lymphoma
, Large B-Cell, Diffuse / etiology.
Lymphoma
, Large B-Cell, Diffuse / genetics.
Lymphoma
, Large B-Cell, Diffuse / pathology.
Lymphoma
, Large B-Cell, Diffuse / physiopathology.
Lymphoma
, Large B-Cell, Diffuse / virology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16446623.001).
[ISSN]
0035-3787
[Journal-full-title]
Revue neurologique
[ISO-abbreviation]
Rev. Neurol. (Paris)
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Number-of-references]
25
71.
Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL:
Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection.
Lancet Infect Dis
; 2008 Apr;8(4):261-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasmablastic
lymphoma
of the oral cavity: a rapidly progressive
lymphoma
associated
with
HIV
infection.
Plasmablastic
lymphoma
of the oral cavity is a form of non-Hodgkin
lymphoma
(NHL) and was first described in 1997.
We describe a case of plasmablastic
lymphoma
in an
HIV
-infected patient who presented with an expanding oral lesion and symptoms of a toothache.
We review all cases of plasmablastic
lymphoma
that have been reported in the literature.
Plasmablastic
lymphoma
is strongly
associated
with immunodeficiency, and most particularly, with
HIV
infection.
The pathophysiological origin of plasmablastic
lymphoma
has not been fully characterised, but the presence of Epstein-Barr virus (EBV) has often been documented in biopsy specimens, supporting a role for EBV in the pathogenesis of this
lymphoma
.
Infectious
disease
clinicians should be aware of this newly described and increasingly encountered
lymphoma
, since it is prominently
associated
with immunosuppression and may be mistaken for other entities.
[MeSH-major]
HIV
Infections / complications.
Lymphoma
,
AIDS
-
Related
/ diagnosis. Mouth / pathology. Mouth Neoplasms / diagnosis
[MeSH-minor]
Adult. Anti-
HIV
Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Head / radiography. Humans. Male. Tomography, X-Ray Computed. Toothache / etiology
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Lancet Infect Dis. 2010 Apr;10(4):226
(PMID = 18353267.001).
[ISSN]
1473-3099
[Journal-full-title]
The Lancet. Infectious diseases
[ISO-abbreviation]
Lancet Infect Dis
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-HIV Agents; 0 / Antineoplastic Agents
72.
Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G:
High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
Blood
; 2009 Aug 13;114(7):1306-13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for
AIDS
-
related lymphoma
: long-term results of the Italian Cooperative Group on
AIDS
and Tumors (GICAT) study with analysis of prognostic factors.
After the introduction of highly active antiretroviral therapy (HAART), intensive treatment, including high-dose therapy (HDT) and peripheral blood stem cell transplantation (PBSCT), has become feasible in
HIV
-positive patients with Hodgkin (HL) and non-Hodgkin (NHL)
lymphoma
.
Herein, we report the long-term results, on an intention-to-treat basis, of a prospective study on HDT and PBSCT in 50
HIV
-positive HAART-responding patients with refractory/relapsed
lymphoma
.
After debulking therapy, 2 patients had early toxic deaths, 10 had chemoresistant
disease
, 6 failed stem cell mobilization, 1 refused collection, and 4 progressed soon after PBSC harvest.
Twenty-one patients are alive and
disease
-free after a median follow-up of 44 months (OS, 74.6%; PFS, 75.9%).
Only
lymphoma
response significantly affected OS after transplantation.
In multivariate analyses both
lymphoma
stage and low CD4 count negatively influenced the possibility to receive transplant.
PBSCT is a highly effective salvage treatment for chemosensitive
AIDS
-
related lymphoma
.
It seems rational to explore its use earlier during the course of
lymphoma
to increase the proportion of patients who can actually receive transplant.
[MeSH-major]
Acquired Immunodeficiency Syndrome / therapy. Antiretroviral Therapy, Highly Active. Hodgkin
Disease
/ therapy.
Lymphoma
, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
[MeSH-minor]
Adult. CD4 Lymphocyte Count.
Disease
-Free Survival. Female. Follow-Up Studies. Humans. Italy. Male. Middle Aged. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Blood. 2009 Aug 13;114(7):1284-5
[
19679696.001
]
(PMID = 19451551.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
73.
Martí-Carvajal AJ, Cardona AF, Lawrence A:
Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.
Cochrane Database Syst Rev
; 2009;(3):CD005419
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Interventions for previously untreated patients with
AIDS
-
associated
non-Hodgkin'
s lymphoma
.
BACKGROUND: Human immunodeficiency virus (
HIV
) infection is known to be
associated
with an increased risk of non-Hodgkin'
s lymphoma
(NHL).
The majority of
lymphomas
(>80%) occurring during immunosuppression are aggressive B-cell in origin and have a high-to-intermediate histology grade.
OBJECTIVES: To assess the clinical effectiveness and safety of single agent or combination chemotherapy with or without immunochemotherapy (rituximab) and with or without highly active antiretroviral therapy (HAART) on overall survival (OS) and
disease
-free survival (DFS) for previously untreated patients with
AIDS
-
related
NHL.
For additional information see the Cochrane
HIV
/
AIDS
Group search strategy.
SELECTION CRITERIA: Randomized controlled trials (RCTs) assessing the effectiveness of systemic treatments for previously untreated
AIDS
-
related
NHL.
Disease
free survival (DFS) was reported in two of the four RCTs, but it was not statistically significant between treatment groups.
AUTHORS' CONCLUSIONS: We found no evidence that the systemic interventions for untreated patients with
AIDS
-
related
NHL provide superior clinical effectiveness for improving OS, DSF, and tumour response rate; however, this conclusion is based on four RCTs with limited sample size and variable quality.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
,
AIDS
-
Related
/ drug therapy
[MeSH-minor]
Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage.
Disease
-Free Survival. Doxorubicin / administration & dosage. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Randomized Controlled Trials as Topic. Rituximab. Vincristine / administration & dosage. Vindesine / administration & dosage
Genetic Alliance.
consumer health - AIDS-HIV
.
HIV InSite.
treatment guidelines - Pneumocystosis and HIV
.
Hazardous Substances Data Bank.
BLEOMYCIN
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISOLONE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINDESINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
Hazardous Substances Data Bank.
METHOTREXATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19588373.001).
[ISSN]
1469-493X
[Journal-full-title]
The Cochrane database of systematic reviews
[ISO-abbreviation]
Cochrane Database Syst Rev
[Language]
eng
[Publication-type]
Journal Article; Meta-Analysis; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q573I9DVLP / Leucovorin; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol; M-BACOD protocol; VAP-cyclo protocol
[Number-of-references]
112
74.
Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A, European Group for Blood and Marrow Transplantation Lymphoma Working Party:
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.
Blood
; 2009 Jun 4;113(23):6011-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparable survival between
HIV
+ and
HIV
- non-Hodgkin and Hodgkin
lymphoma
patients undergoing autologous peripheral blood stem cell transplantation.
Autologous stem cell transplantation (ASCT) has been successfully used in
HIV
-
related lymphoma
(
HIV
-Ly) patients on highly active antiretroviral therapy.
We report the first comparative analysis between
HIV
-Ly and a matched cohort of
HIV
(-)
lymphoma
patients.
This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin
lymphoma
) within each cohort.
Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin
lymphoma
and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the
HIV
-Ly cohort.
A higher nonrelapse mortality within the first year after ASCT was observed in the
HIV
-Ly group (8% vs 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival.
Thus, within the highly active antiretroviral therapy era,
HIV
patients should be considered for ASCT according to the same criteria adopted for
HIV
(-)
lymphoma
patients.
[MeSH-major]
HIV
Infections / surgery. Hodgkin
Disease
/ surgery. Peripheral Blood Stem Cell Transplantation
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19307667.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
75.
Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC:
Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study.
Cancer Causes Control
; 2009 Jul;20(5):517-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Vaccination history and risk of non-Hodgkin
lymphoma
: a population-based, case-control study.
OBJECTIVE: As factors that alter the immune system have been implicated in non-Hodgkin
lymphoma
(NHL) etiology, it is of interest to explore the association between vaccination and risk of NHL.
RESULTS: We found that NHL risk was inversely
associated
with ever receiving a polio (OR = 0.59, CI = 0.40-0.87) or smallpox (OR = 0.71, CI = 0.51-0.98) vaccination, and positively
associated
with influenza vaccination (OR = 1.53, CI = 1.14-2.06).
Analysis by histologic subtypes showed that polio vaccination was
associated
with a lower risk of follicular (OR = 0.54, CI = 0.31-0.92) and chronic lymphocytic leukemia/small lymphocytic
lymphomas
(OR = 0.29, CI = 0.12-0.69) and smallpox vaccination was
associated
with a lower risk of marginal zone
lymphoma
(OR = 0.41, CI = 0.19-0.88).
In contrast, ever receiving an influenza vaccination was
associated
with a higher risk of follicular (OR = 1.98, CI = 1.23-3.18) and diffuse large B cell
lymphomas
(OR = 1.88, CI = 1.13-3.12).
CONCLUSION: Risk of NHL is inversely
associated
with polio and smallpox vaccination and positively
associated
with influenza vaccination.
[MeSH-major]
Lymphoma
, Non-Hodgkin / epidemiology. Vaccination / adverse effects
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
MedlinePlus Health Information.
consumer health - Immunization
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur J Cancer Prev. 2000 Feb;9(1):59-64
[
10777011.001
]
[Cites]
Semin Oncol. 2000 Aug;27(4):390-401
[
10950365.001
]
[Cites]
Science. 2002 Apr 19;296(5567):490-4
[
11964470.001
]
[Cites]
Vaccine. 2003 Jan 17;21(5-6):419-30
[
12531640.001
]
[Cites]
Am J Epidemiol. 2003 Aug 15;158(4):316-27
[
12915497.001
]
[Cites]
Clin Lymphoma. 2003 Dec;4(3):161-8
[
14715098.001
]
[Cites]
Eur J Haematol. 2004 May;72(5):336-41
[
15059068.001
]
[Cites]
J Natl Cancer Inst. 2004 Apr 21;96(8):571-3
[
15100327.001
]
[Cites]
Cancer Res. 1992 Oct 1;52(19 Suppl):5465s-5467s
[
1327508.001
]
[Cites]
Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s
[
1394165.001
]
[Cites]
Am J Epidemiol. 1993 Dec 1;138(11):923-36
[
8256780.001
]
[Cites]
Blood. 1994 Nov 1;84(9):3047-53
[
7949176.001
]
[Cites]
Am J Prev Med. 1999 Apr;16(3):173-7
[
10198654.001
]
[Cites]
Am J Epidemiol. 1999 Aug 15;150(4):375-89
[
10453814.001
]
[Cites]
Eur J Cancer. 2005 Jan;41(1):133-42
[
15617998.001
]
[Cites]
Vaccine. 2005 Jan 11;23(8):1015-20
[
15620474.001
]
[Cites]
Br J Haematol. 2005 Mar;128(5):610-5
[
15725081.001
]
[Cites]
Arch Intern Med. 2005 Nov 14;165(20):2337-44
[
16287762.001
]
[Cites]
Blood. 2006 Apr 15;107(8):3034-44
[
16397126.001
]
[Cites]
Acta Oncol. 2006;45(3):258-71
[
16644568.001
]
[Cites]
Immunity. 2006 Jun;24(6):663-6
[
16782020.001
]
[Cites]
AIDS. 2006 Aug 1;20(12):1645-54
[
16868446.001
]
[Cites]
Curr Opin Oncol. 2006 Sep;18(5):417-24
[
16894287.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8
[
17337643.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4
[
17337646.001
]
[Cites]
Vaccine. 2007 Jun 15;25(25):4775-83
[
17499402.001
]
[Cites]
Cancer Causes Control. 2007 Aug;18(6):677-85
[
17484069.001
]
[Cites]
Cancer Causes Control. 2007 Oct;18(8):821-31
[
17588155.001
]
[Cites]
Immunity. 2007 Nov;27(5):687-90
[
18031690.001
]
(PMID = 19011978.001).
[ISSN]
1573-7225
[Journal-full-title]
Cancer causes & control : CCC
[ISO-abbreviation]
Cancer Causes Control
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / R25 CA100600; United States / NCI NIH HHS / CA / R25 CA100600
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Other-IDs]
NLM/ NIHMS399830; NLM/ PMC3446202
76.
Pagès F, Galon J, Karaschuk G, Dudziak D, Camus M, Lazar V, Camilleri-Broët S, Lagorce-Pagès C, Lebel-Binay S, Laux G, Fridman WH, Henglein B:
Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells.
Blood
; 2005 Feb 15;105(4):1632-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We show here that the EBV nuclear antigen EBNA2 induces expression of the 2 chains of the interleukin-18 receptor (IL-18R) in Burkitt
lymphoma
(BL) cell lines and in nontransformed B cells.
We report that EBNA2 expression is
associated
with IL-18R expression in vivo in EBV-positive B-
lymphomas
from
AIDS
patients.
[MeSH-minor]
Burkitt
Lymphoma
/ immunology. Burkitt
Lymphoma
/ metabolism. Burkitt
Lymphoma
/ virology. Cell Line, Transformed. Cell Line, Tumor. Gene Expression Regulation, Viral / immunology. Genes, Viral. Herpesvirus 4, Human / genetics. Humans. Interleukin-18 Receptor alpha Subunit.
Lymphoma
,
AIDS
-
Related
/ immunology.
Lymphoma
,
AIDS
-
Related
/ metabolism.
Lymphoma
,
AIDS
-
Related
/ virology.
Lymphoma
, Large B-Cell, Diffuse / immunology.
Lymphoma
, Large B-Cell, Diffuse / metabolism.
Lymphoma
, Large B-Cell, Diffuse / virology. Protein Subunits / biosynthesis. Protein Subunits / metabolism. Receptors, Interleukin-18. Viral Proteins. Viral Structural Proteins / genetics
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15498855.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / EBNA-2 protein, Human herpesvirus 4; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / IL18R1 protein, human; 0 / Interleukin-18 Receptor alpha Subunit; 0 / Protein Subunits; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-18; 0 / Viral Proteins; 0 / Viral Structural Proteins
77.
Wong KH, Lee SS, Chan KC:
Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong.
Hong Kong Med J
; 2006 Apr;12(2):133-40
[Fulltext service]
Download
fulltext PDF
of
this article and